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Abstract
Human Cytomegalovirus (CMV) is a common herpesvirus found in 60% of 
the population. Normally, it poses no risk, however it can have consequences 
for unborn babies. This is of concern when donor sperm is used in assisted 
conception, as CMV is present in semen. The risk of transmission from a 
positive donor is unclear, as it is not known if sperm can act as a vector for 
transmission. Additionally, this raises questions about whether CMV might 
affect sperm function. The hypothesis for this study is that CMV will interact 
with human sperm and alter sperm function and that sperm will act as a 
vector for viral transmission.
A survey was conducted to examine how fertility clinics were screening for 
CMV in sperm donors. This survey found that the majority of UK clinics are 
screening for CMV in sperm donors in the manner recommended by current 
guidelines but that the requirement to screen for CMV is causing problems in 
clinics with regards to sperm donor supply. Fortunately, this thesis has 
shown that sperm washing by density gradient centrifugation is mostly 
effective at removing CMV from semen samples infected in vitro, with CMV 
(AD169) grown in the laboratory, and in naturally infected samples. This 
presents a possible approach for alleviating some of the problems relating to 
CMV infection in sperm donors in UK fertility clinics. However, co-incubation 
with CMV has no effect on any of the sperm function parameters tested in 
this thesis, including, motility, viability, acrosome reaction, tyrosine 
phosphorylation and levels of DNA damage. 
In conclusion, this thesis has highlighted problems with the current approach 
to screening and managing CMV infection in sperm donors but has provided 
evidence to show that there could be a simple solution to the problem. No 
effect on sperm function was observed, but this does not rule out a direct 
interaction between CMV and sperm. Overall, this thesis shows that fertility 
clinics should be concerned about CMV infection in sperm donors, but that 
simple steps could be taken to alleviate the current problems clinics are 
experiencing.
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Chapter 1
Introduction & Literature Review
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1.1 Introduction
It is estimated that 1 in 7 heterosexual couples in the UK will experience 
problems conceiving a child (National Institute for Clinical Excellence, 2013). 
For these couples, the advent of innovative assisted conception technologies
(Edwards and Steptoe, 1983) has provided many new options to achieve this 
goal. Fertility treatment is now a central part of medical technology and in 
2013, 64,600 cycles of in vitro fertilisation (IVF) or intracytoplasmic sperm 
injection (ICSI) were performed in the UK (HFEA, 2013a). In heterosexual 
couples where male factor fertility issues are unresolved, a sperm donor 
might be used. In 2013, 4,611 cycles of donor insemination were carried out 
on 2,379 women (HFEA, 2013a). The number of cycles requiring donor 
sperm is increasing, with the number of donor insemination cycles in 2013 
rising by 3.6% from 2012 and the number of cycles of IVF using donor sperm 
rising by 6.5% (HFEA, 2013a). Part of the rise in numbers of women 
undergoing donor insemination is a shift towards single women and same 
sex couples choosing this treatment (Baetens and Brewaeys, 2001; Leiblum 
et al., 1995), a trend that continues to increase year on year (HFEA, 2014). 
The increasing number of cycles using donor sperm creates problems due to 
the lack of availability of sperm donors. In 2013, there were 586 new sperm 
donor registrations, with a third being imported from overseas (HFEA, 
2013b). This is a decrease from the previous year, when there were 631 new 
registrants (HFEA, 2013b) and falls short of the current demand for the UK 
(Hamilton et al., 2008). 
A further complication to the availability of donors is the strict criteria under 
which a sperm donor is able to donate sperm for treatment (Association of 
Biomedical Andrologists et al., 2008). A study from 2003 showed that of the 
1,101 men that applied to be a sperm donor over a 9-year period, only 40 
were released as sperm donors, a rate of 3.63% (Paul et al., 2003). One 
limiting factor in the release of sperm donors for treatment is the requirement 
to go through a strict screening process for genetic and infectious diseases. 
The list of diseases screened for is not exhaustive and there are often 
debates surrounding what should and should not be included in this
-23-
screening process. One such argument is the requirement to screen for 
human Cytomegalovirus (CMV), a highly prevalent Herpesvirus infection. 
CMV is present in 60% of the population and usually presents as an 
asymptomatic infection in healthy individuals. However, for those with 
compromised immune systems, such as transplant patients or those 
suffering from Acquired Immune Deficiency Syndrome (AIDS), infection with 
CMV can have severe health implications (Griffiths, 2002a). Neonates can 
also be severely affected by CMV infection, if acquired in utero, due to an 
immature immune system (Griffiths, 2002a). Known as congenital CMV, this 
type of infection can lead to the development of severe illnesses, including 
hearing loss and a range of neurological disorders (Griffiths, 2002b). 
Given the potential severe health consequences to the neonate, and the 
evidence that CMV is present in semen cryopreserved for donor insemination 
(Mansat et al., 1997), the requirement to screen for CMV is apparent. 
However, the risk of transmission of CMV from a semen sample to a female 
recipient and onto a child is a highly debated subject. Part of the reason 
behind this is the little scientific evidence surrounding the relationship 
between CMV and sperm. A better understanding of this relationship and 
how CMV is transmitted through semen would allow the risk of transmission 
from sperm donors to be better assessed. Little is known about this aspect of 
CMV transmission, compared to other pathogens such as Human 
Immunodeficiency Virus (HIV) and Chlamydia trachomatis. For these 
pathogens, developments have been made in understanding how they 
interact with sperm, leading to increased knowledge and changes to clinical 
practice, making assisted conception both available and safer for patients. 
The same is not true of CMV, which by comparison has been poorly studied. 
There is a need to address this deficit and better understand if and how CMV 
might interact with sperm. This is the primary focus of this thesis. 
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1.2 Literature Review
This literature review will encompass the background to sperm, male fertility
and CMV before considering the implications of CMV infection within the 
assisted conception field. Subsequently, evidence surrounding the 
interactions between other pathogens, such as bacteria and viruses, and 
sperm will be detailed as a basis for understanding the relationship between 
CMV and sperm. 
1.2.1 The spermatozoon
Human spermatozoa are highly specialised haploid cells (Fawcett, 1975)
evolved for the purpose of delivering the male genome to the oocyte (Suarez 
and Pacey, 2006). In order to do this, sperm have a highly specialised 
structure, which is created through the complex process of spermatogenesis.
All features of the sperm are specialised for the journey of traversing the 
female reproductive tract (Suarez and Pacey, 2006) and penetrating the 
oocyte, in order to pass the male genetic information onto the next 
generation. Spermatogenesis occurs in the testicles and is responsible for 
producing millions of fully differentiated sperm every day (Bronson, 2011). 
1.2.1.1 The spermatozoon structure
A spermatozoon consists of three major parts, the sperm head, mid-piece
and the tail. The major components of the sperm head are the nucleus and 
the acrosome. The sperm tail can be further divided into four sections, which 
are connected by the same internal structure. First of all, the connecting 
piece containing the sperm centriole, the mid-piece containing the 
mitochondria, the source of ATP required for sperm motility, the principal
piece and the end piece (Figure 1.1a). 
The nucleus contains the male DNA in a highly condensed and quiescent 
form (Brewer et al., 2002; Dadoune, 2003). During spermiogenesis, the 
histones bound to DNA are replaced by protamines, making the DNA 
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Figure 1.1: The overall structure of the human spermatozoa is represented in 
diagram (a). The head contains the acrosome and the condensed male DNA in the 
nucleus. The head is connected to the tail via the mid (connecting) piece containing 
the centriole and the mitochondria, wrapped around the axial filament which runs 
throughout the entire sperm tail (Fawcett, 1975). Diagram (b) shows the axial 
filament is comprised of the microtubule axoneme, which is essential for motility of 
the sperm tail. Nine outer doublets, connected by radial spokes, surround a central 
doublet of microtubules. Nine outer dense fibres surround the outer doublets and 
provide rigidity for the sperm tail (Fawcett, 1975; Porter and Sale, 2000).
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inaccessible to enzymes, serving to protect the male genetic information. It is 
thought that sperm are unable to repair their own DNA (Matsuda et al., 
1985); therefore once spermatogenesis is complete the DNA needs to be 
protected from any damage, which might compromise its integrity. The 
condensation of the male DNA is also thought to serve in aiding the transit 
through the female reproductive tract and penetration of the oocyte outer 
layers (Dadoune, 2003). The condensed nature of sperm DNA makes it 
inaccessible to enzymes and therefore it is thought that transcriptional 
activity and de novo gene expression is unlikely to occur (Kierszenbaum and 
Tres, 1975). However, evidence pertaining to sperm genomics and 
proteomics questions this accepted theory, which will be discussed in detail 
in a Section 1.2.1.2.
The sperm head also contains the acrosome, a Golgi-derived vesicle, 
containing hydrolytic enzymes and receptors (Yoshinaga and Toshimori, 
2003) required for interaction and penetration of the oocyte zona pellucida
(ZP) (Osman et al., 1989). Interaction with a ZP glycoprotein, ZP3, initiates 
an exocytotic reaction, resulting in the release of the acrosomal components 
and digestion of the ZP, allowing the sperm to penetrate this layer (Brewis et 
al., 1996). After penetration of the ZP, sperm enter the perivitelline space and 
are able to bind to the oolemma (Figure 1.2). After the acrosome reaction 
occurs, receptors present on the inner acrosomal membrane and at the 
equatorial segment (ES) are unveiled. Receptors located at the ES, such as 
Fertilin-β were thought to be involved in the fusion with the oolemma (Cho et 
al., 1998). However, it is now thought that a member of a major 
immunoglobulin family, Izumo1, is the main receptor (Inoue et al., 2005) 
involved with fusion to the putative egg receptor, Juno (Bianchi et al., 2014). 
The remainder of the sperm head is composed of the perinuclear theca (PT),
a matrix of structural proteins that provides support and confers head shape. 
PT proteins located in the posterior part of the sperm head, the post-
acrosomal segment, are thought to function in signalling during early 
embryogenesis once the PT is dissolved in the oocyte cytoplasm (Sutovsky 
et al., 1997). 
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Figure 1.2: Diagrammatic representation of four key steps of fertilisation: (1) sperm 
bind to the zona pellucida (ZP) initiating an exocytotic reaction, which (2) 
subsequently releases the contents of the acrosome. Step (3) shows digestive 
enzymes from the acrosome penetrating the ZP and (4) shows the entry of the 
sperm to the perivitelline space. Once in this space, the sperm binds to the egg 
membrane (oolemma), and the sperm nucleus containing the paternal genome is 
delivered to the oocyte.
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The sperm tail provides the motile force for sperm to travel through the 
female reproductive tract. At the centre of the sperm tail is the microtubule 
axoneme (Figure 1.1b). This is composed of a 9+2 arrangement of 
microtubule doublets, with 9 symmetrically arranged outer doublets 
connected to the two central doublets by radial spokes (Fawcett, 1975). The 
outer doublets are connected by dynein arms, which are the motor proteins 
responsible for the creation of mechanical energy from ATP (Turner, 2003).
Coordinated asynchronous movement of dynein arms at each microtubule 
doublet allows for bending of the axoneme and subsequent flagella 
movement (Burgess et al., 2003; Turner, 2003). Surrounding the outer 
doublets are 9 outer dense fibres that provide flexibility and support during 
movement of the flagellum (Figure 1.1b). The sperm tail can be divided into 
three major sections in addition to the end piece (Figure 1.1a). The 
connecting piece contains the remaining proximal centriole, leftover from 
spermatogenesis (Sutovsky and Manandhar, 2006). The mid-piece contains 
approximately 75-100 mitochondria, arranged helically around the central 
axoneme (Sutovsky and Manandhar, 2006). The mitochondria supply ATP to 
the axoneme for conversion into mechanical energy, required for the 
movement of the flagellum (Piomboni et al., 2012). The principal piece has 
the addition of a fibrous sheath, which is thought to provide support. It is 
thought that the fibrous sheath is involved in particular steps during 
capacitation and hyperactivation (Eddy et al., 2003). 
1.2.1.2 Sperm transcriptome and proteome
It was traditionally thought that the spermatozoon only contributed the male 
DNA to the resulting zygote, however research into the sperm transcriptome 
is highlighting that sperm probably contribute more than just the paternal 
genome. It is now known that sperm contain a population of RNAs (Miller et 
al., 1999), including microRNAs (Ostermeier et al., 2005a). It is thought that 
this RNA is leftover from spermatogenesis, however there is an apparent 
selection process regarding which RNAs to keep, as the mature 
spermatozoon RNA population is significantly different from the testis-specific 
cell transcripts (Miller et al., 1999). This suggests that the presence of a 
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population of RNA is important to the function of the spermatozoon. One 
potential function is the de novo synthesis of proteins.  Despite typically 
being thought of as a translationally inert cell, there is evidence to suggest 
that sperm are able to translate these mRNAs into protein using 
mitochondrial ribosomes (Gur and Breitbart, 2006). Other roles for the 
presence of spermatozoal RNA include a role in early embryonic 
development (Herrada and Wolgemouth, 1997; Ostermeier et al., 2004), 
epigenetic regulation of genes (Gapp et al., 2014), or a structural role within 
the sperm itself (Miller and Ostermeier, 2006). 
The presence of an RNA population within a spermatozoon is also believed 
to be of importance to male factor infertility. Variation of the RNA present in 
individual men was reported (Ostermeier et al., 2002) and is thought to 
contribute to infertility, as when certain elements are missing, the ability to
achieve a natural pregnancy is compromised (Jodar et al., 2015). 
Interestingly, when assisted reproductive techniques (ART) were used, the 
absence of certain sperm RNA elements did not affect the outcome of these
procedures. This suggests a role for these RNAs in the potential of the 
spermatozoon to reach and fertilise the egg, rather than an inability to initiate 
embryonic development. Investigation into whether differences in the RNA 
carriage of fertile and infertile men can be used as markers for infertility is 
now being explored (Ostermeier et al., 2005b).  
Another interesting observation in relation to the sperm genome is the ability 
to modify histone-bound DNA. Around 15% of human sperm DNA remains 
associated with histones, rather than protamines (Tanphaichitr et al., 1978). 
This histone bound DNA is therefore still vulnerable to modification by 
enzymes and studies have shown that sperm are able to digest a portion of 
their histone bound DNA when challenged with exogenous DNA (Maione et 
al., 1997; Sotolongo et al., 2003). Also, sperm are able to uptake exogenous 
DNA into their nucleus (Francolini et al., 1993). It is clear from this evidence 
that sperm are not as silent and inert as previously thought and are able to 
respond to environmental triggers. 
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What is also clear from this evidence is that sperm contain a host of proteins, 
which regulate these processes. The ability to digest DNA upon exposure to 
exogenous DNA requires the function of endogenous nucleases, which have 
been shown to be present in sperm (Maione et al., 1997). In addition, whilst 
the ability for mature sperm to undergo apoptosis is a controversial point, 
sperm do possess proteins involved in the apoptotic pathway, including 
caspase-3 (Weng et al., 2002). In addition to these unexpected proteomic 
findings, sperm also contain proteins involved in the fundamental processes 
of sperm hyperactivation and capacitation, such as AKAP4 (Miki and Eddy, 
1998) and the CatSper channels (Ren et al., 2001). Sperm also contain 
numerous receptors involved in egg recognition and penetration, including 
Izumo1 (Inoue et al., 2005) and Fertilin-β (Cho et al., 1998). Other receptors 
have shown to be present on the spermatozoon, including epidermal growth 
factor (EGFR) (Jaldety et al., 2012), fibroblast growth factors (FGFR) 
(Saucedo et al., 2015), heparin sulphate proteoglycans (Foresta et al., 
2011a), Toll-like receptor (TLR)-2 (Saeidi et al., 2014), lactoferrin receptor 
(Wang et al., 2011a), as well as receptors for binding progesterone 
(Tantibhedhyangkul et al., 2014) and oestrogen (Rago et al., 2014). These 
receptors serve different functions to the spermatozoon, from acquisition of 
motility, ability to undergo the acrosome reaction and defence against
exposure of pathogens.  It is clear that we are only just beginning to realise 
the true complexity of the sperm, both inside and out. 
1.2.1.3 Spermatogenesis
Functional mature spermatozoa are made through the process of 
spermatogenesis, occurring in the seminiferous tubules, situated in the testes 
(Figure 1.3). This process produces millions of fully differentiated sperm 
everyday (Sutovsky & Manandhar, 2006). The first stage of spermatogenesis 
involves the mitotic division of non-proliferative type A spermatogonia into 
type B spermatogonia, which are ready to enter meiosis (Phillips et al., 
2010). Type A spermatogonia can either commit to differentiate, or self-
renew, a step required in order to maintain a population of progenitor cells.
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Figure 1.3: Anatomical diagram of the male reproductive tract. Human 
spermatozoa are produced through the process of spermatogenesis, which occurs 
in the lining of the seminiferous tubule, located in the testis. Fully differentiated 
spermatozoa travel through the lumen of the seminiferous tubule to the rete testis. 
From the rete testis, the spermatozoa travel through the epididymis, undergoing 
further maturation steps before being stored in the tail of the epididymis. During 
ejaculation, spermatozoa travel up the vas deferens, joined by seminal plasma from
the seminal vesicle before exiting through the urethra. Reprinted with permission 
from Cambridge University Press and taken from (Mason, 2010).
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Figure 1.4: Cellular differentiation during spermatogenesis begins with Type A 
spermatogonia either committing to differentiate into Type B spermatogonia or self-
renewal. Type B spermatogonia then further differentiate into primary spermatocytes 
which are in prophase of meiosis I, consisting of a duplicated complement of DNA, 
2n, 4c. In primary spermatocytes, homologous chromosomes line up along the 
metaphase plate, which allows for homologous recombination, before entering 
meiosis I and dividing into secondary spermatocytes, which have a haploid 
complement of chromosomes with sisters chromatids still bound together (1n, 2c). 
Meiosis I is known as a reductional division as the chromosomal complement has 
halved to haploid.  Secondary spermatocytes then progress through meiosis II to 
form four round spermatids with one set of chromosomes (1n, 1c). During the final 
step, spermiogenesis, the round spermatids further differentiate into the specialised 
form that is required for a functional sperm. 
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Type B cells then differentiate into primary spermatocytes, which then 
progress through meiosis I to half their chromosomal complement and form 
haploid secondary spermatocytes. The final step of spermatogenesis 
involves a meiosis II division forming haploid round spermatids (Figure 1.4) 
(reviewed in Wistuba et al., 2007). Round spermatids then go through a 
series of morphological changes during the second stage of this process, 
known as spermiogenesis. During this stage, many spermatid organelles are 
remodelled or degraded by ubiquitin-dependent proteolysis (Bedard et al., 
2011), in order to form a functional sperm with the correct accessory 
structures. The Golgi apparatus is remodelled to form the acrosomal cap
(Moreno et al., 2000) and the cytosol becomes the perinuclear theca (Oko, 
1995). It is during this step of spermatogenesis that the sperm DNA is 
remodelled into a more condensed structure more suitable to the function of 
the spermatozoon (Meistrich et al., 2003). Other features of the spermatid 
are removed, including half of the mitochondrial load and the nuclear pore 
complexes, involved in mRNA transport (Sutovsky & Manandhar, 2006).
Once the round spermatid is remodelled into an elongated form, the process 
of sperm production is concluded by the release of the sperm cell from the 
tight associations with Sertoli cells. This last step is known as spermiation.
The elongated spermatid is released into the lumen of the seminiferous 
tubule where the sperm travel to the rete testis and continue their 
developmental journey through the male reproductive tract (Bronson, 2011).
The architecture of the testis is a complex of looped seminiferous tubules, 
which end in the rete testis. Spermatogenesis occurs in the epithelium of the 
seminiferous tubules, which is solely populated by spermatogonial and 
Sertoli cells (Griswold, 1995). The Sertoli cells surround the germ cells, 
providing nutrients and are also involved in the hormonal regulation of 
spermatogenesis (Griswold, 1998). Sertoli cells form tight junctional 
complexes between each cell, creating a blood-testis barrier which divides 
the seminiferous epithelium into two compartments: the basal and adluminal 
compartments (Griswold, 1995). Spermatogenesis and spermiogenesis 
occur whilst the spermatogonial cells are in close contact with the Sertoli 
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cells in the basal compartment of the tubule (Griswold, 1995). The final step 
of the process, spermiation, involves the release of the differentiated 
spermatid from the close connections with the Sertoli cells into the immune-
privileged lumen of the seminiferous tubule. 
The process of spermatogenesis is regulated by a complex endocrine 
feedback loop (reviewed in Holdcraft & Braun, 2004). Gonadotropin releasing 
hormones (GnRH) secreted from the hypothalamus act on the pituitary gland. 
Subsequently, Follicle-Stimulating Hormone (FSH) is released, which acts 
upon Sertoli cells. The pituitary gland also releases Lutenising Hormone
(LH), which acts upon Leydig cells. Leydig cells are located in the interstitial 
space between seminiferous tubules, and upon activation with LH these cells 
release testosterone. Testosterone then acts upon Sertoli cells, which are
involved in the differentiation of spermatogonial stem cells into the 
spermatozoon. 
1.2.1.4 Sperm transit through male reproductive tract
After release into the lumen of the seminiferous tubule and passing through 
the rete testis, sperm enter the epididymis. At this point, they are incapable of 
fertilising an egg, as they are biologically immature. Further maturation 
occurs during transport through the epididymis where spermatozoa acquire 
fertilisation capability (Moore, 1998). Under the influence of epididymal 
secretory proteins (Brown et al., 1983), spermatozoa acquire the ability to 
recognise and bind to the oocyte (Hinrichsen and Blaquier, 1980). They also
acquire progressive motility (Dacheux et al., 1987), through activation of 
tyrosine phosphorylation signalling pathways (Lin et al., 2006). Upon 
reaching the tail (cauda) of the epididymis, the final storage place before 
ejaculation (Robaire and Viger, 1995), spermatozoa have acquired the ability 
to fertilise an egg. In comparison, samples taken from the head (caput) of the 
epididymis are still biologically immature (Dacheux et al., 1987; Hinrichsen 
and Blaquier, 1980). During ejaculation, mature spermatozoa are transported 
through the vas deferens to the urethra, accompanied by secretions from the 
seminal vesicles and prostate gland, which constitute the seminal fluid 
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(Nojimoto et al., 2009). The accessory proteins present in the seminal fluid 
contribute to the protection of sperm throughout its transport through the 
female reproductive tract. An alkaline pH serves to neutralise the acidic pH of 
vaginal secretions (TeviBenissan et al., 1997) and protection from the female 
immune system through the presence of immune evasion factors such as 
TGF-β (Lokeshwar and Block, 1992; Robertson et al., 2002). 
1.2.1.5 Further changes in preparation for fertilisation
Whilst travelling through the female reproductive tract, sperm undergo two 
further changes in preparation for fertilisation: capacitation and 
hyperactivation (De Jonge, 2005). During this process, sperm undergo 
multiple membrane changes, such as cholesterol removal (Zarintash and 
Cross, 1996) and binding of a calcium binding glycoprotein, SABP (Banerjee 
and Chowdhury, 1995), to the sperm head (Banerjee and Chowdhury, 1994). 
These changes constitute the molecular processes of capacitation and cause 
the sperm head membrane to be more fluid (De Jonge, 2005) and more 
permeable to Ca2+ (Banerjee and Chowdhury, 1995). Binding to ZP3, 
induces further calcium influxes within the sperm, resulting in initiation of the 
acrosome reaction (O'Toole et al., 2000). This process is enabled by the 
changes to the plasma membrane during capacitation. Hyperactivation is 
also induced by changes in membrane permeability and subsequent calcium 
influxes. This is a change in the beating of the sperm tail, imparting thrust 
upon the sperm, necessary for penetration of the ZP (Stauss et al., 1995)
and release from storage in the tubual isthmus (Pacey et al., 1995). This is 
thought to occur as a result of increased intracellular calcium (Suarez et al., 
1993), which has been linked (Harayama et al., 2012) to the additional 
increase in levels of cAMP (Calogero et al., 1998) involved in increased 
tyrosine phosphorylation, known to be responsible for acquisition of motility 
(Lin et al., 2006).
Before considering how CMV could affect sperm function and assisted 
conception, it is necessary to discuss the biology and pathogenesis of CMV.
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1.2.2 “The stealth virus’” human Cytomegalovirus (CMV)
Cytomegalovirus (CMV) is a member of the Herpesviridae family, a group of 
double-stranded DNA viruses capable of establishing a latent infection in the 
host, resulting in a lifelong infection with periods of reactivation (Slonczewski 
and Foster, 2008). There are different types of CMV, specific to different 
species. There are eight different strains known to infect humans, with over 
150 known to infect many other species (Lou & Zhou, 2007).
The prototypical herpesvirus structure (Figure 1.5) consists of a lipid bilayer 
envelope, derived from cellular internal membranous structures, containing 
multiple different types of glycoprotein, essential for entry into the host cell. 
Inside the virion, the double stranded DNA genome is enclosed in a 
protective protein capsid, known as the nucleocapsid. This is surrounded by 
the tegument, which contains proteins needed for survival of the virus, 
including those that support viral gene expression and mechanisms for 
evading the host response (Lou & Zhou, 2007). 
1.2.2.1 Lytic life cycle in susceptible cells
CMV has a broad cell tropism, enabling the infection of multiple different cell 
types in vivo. Among the types of cells CMV can infect are fibroblasts, 
endothelial, epithelial, monocytes and hepatocytes (Sinzger et al., 1995). The 
ability to infect multiple cell types is thought to be due to a complex 
mechanism of binding to broadly expressed cellular receptors in conjunction 
with cell-specific receptors (Compton & Feire, 2007). Upon infection of a cell, 
a characteristic cytopathic effect is observed. Cells become enlarged and 
undergo rounding, as a direct result of the formation of intracellular and 
intranuclear exclusion bodies (Rowe et al., 1956).
Binding and entry of CMV to a cell is a complex pathway of multiple binding 
events via the three different glycoprotein complexes, gCI, gCII and gCIII. 
Complex gCI, containing a homodimer of glycoprotein B (Cranage et al., 
1986), is thought to be responsible for the initial binding step (Figure 1.6), 
involving interaction with a broadly expressed type of receptor, heparin 
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Figure 1.5: The prototypical structure of a herpesvirus virion. The lipid bilayer, 
derived from the host cell inner membranous structures, contains multiple types of 
glycoprotein (Emery and Griffiths, 2000), including glycoprotein B and H. Viral 
glycoproteins are essential for entry into a host cell by binding with putative 
receptors. The ~250kB double stranded DNA genome is enclosed inside the 
nucleocapsid which delivers the DNA to the host cell nucleus (Slonczewski and
Foster, 2008). The nucleocapsid is surrounded by the tegument, which contains 
proteins essential for viral survival inside the host cell (Griffiths and Grundy, 1987).
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Figure 1.6: Diagrammatic representation of the CMV lytic life cycle. CMV binds to 
a susceptible host cell via initial interaction between gB and HSPGs. Further 
interactions with other glycoproteins are also involved which serve to stabilise the 
interaction and initiate viral and cell membrane fusion. (1) Binding of CMV activates 
cellular transcription factors necessary for expression of the IE genes. (2) Upon 
entry to the cell, the nucleocapsid is transported to the nucleus where the viral DNA 
is delivered. It is thought that CMV also contains mRNAs, which function to translate 
proteins in the absence of translation of viral DNA (Bresnahan and Shenk, 2000). 
(3) The replicated viral DNA and translated tegument proteins are packaged into the 
virion, assembled from newly translated structural proteins. (4) The virus is released 
from the nucleus where multiple steps of envelopment and de-envelopment result in 
the virus obtaining its lipid bilayer. During transit through the cytoplasm and the 
various trafficking vehicles the cell employs, the virion acquires the remaining 
elements of the viral envelope and is ultimately released from the cell. Adapted with 
permission from Nature Publishing Group from (Huang and Johnson, 2000).
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sulphate proteoglycan (HSPG) (Carlson et al., 1997; Compton et al., 1993). 
The second complex, gCII, containing glycoproteins gM and gN, is also 
involved in this interaction, by binding to HSPGs (Kari & Gehrz, 1992). gCII 
potentially also aids gB in binding to a secondary receptor and stabilising the 
interaction (Boyle & Compton, 1998). The third glycoprotein complex, gCIII, 
is a heterodimer containing gH and gL, complexed with either gO or an 
unknown product of a particular region of the CMV genome, the UL128 locus
(Huber & Compton, 1997; Ryckman et al., 2008) This complex is thought to 
be involved with the fusion of virus and host membranes, allowing entry of 
the virus to the host cell (Topilko and Michelson, 1994; Compton et al., 
1992). Whilst fusion of the virus and host cell membranes is thought to be the 
main route of entry to a cell, pathways that employ endocytosis-mediated 
entry are also thought to play a role in the entry of CMV to certain cell types 
(Ryckman et al., 2006; Wang et al., 2007). 
Upon entry to the cell, the nucleocapsid is delivered to the nucleus (Figure 
1.6), facilitated by the capsid and tegument components, in a process known 
as uncoating (Compton & Feire, 2007). Once the viral DNA is delivered to the 
nucleus, the viral genes are expressed in a temporal cascade (Sinclair & 
Sissons, 2006). Gene expression begins with the immediate early (IE) genes, 
which does not require de novo protein synthesis to occur prior to 
expression. These genes are responsible for controlling viral and cellular 
gene expression in order to optimise the cellular environment for production 
of daughter progeny (Sinclair and Sissons, 2006). The expression of IE 
genes is essential for the production of viral progeny as they are involved in 
activating the expression of the early (E) genes which function in the 
replication of the viral DNA (Emery & Griffiths, 1990). Finally, the late (L) 
genes are expressed once DNA replication is complete (Emery & Griffiths, 
1990). The L genes are mainly structural proteins, such as those required for 
the nucleocapsid. Upon entry to a host cell, expression of IE genes also 
serves to promote survival in the cell by hijacking the host cell DNA synthesis 
and cell cycle pathways, as well as encoding mechanisms for avoiding 
cellular defence mechanisms (reviewed in Fortunato et al., 2000). 
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Viral assembly begins in the nucleus, where the newly replicated DNA is 
packaged into the nucleocapsid (Griffiths and Grundy, 1987). The capsid 
then acquires its tegument proteins and through a process of repeated steps 
of envelopment and de-envelopment, the virion acquires its lipid bilayer 
(Skepper et al., 2001). The mature virion is then transported to the host cell 
membrane where it is released into the extracellular environment via 
exocytosis (Das et al., 2014) (Figure 1.6). 
The activation of the IE genes is thought to be the event that commits CMV 
to a productive (lytic) life cycle. However, in addition to undergoing a 
productive life cycle, CMV is also able to undergo a latent cycle, enabling the 
virus to remain hidden from the cellular immune response (Sinclair and 
Sissons, 2006). 
1.2.2.2 Sites of CMV latency and persistence
All members of the Herpesviridae family are able to establish sites of latency 
within the host. This serves as a mechanism to ensure the continued survival 
of the virus through multiple opportunities to infect other hosts during 
repeated bouts of reactivation. Sites of latency are regions of specific cellular 
sub-types where the viral genome is present, but there is no production of 
infectious virus (Sinclair, 2008). Unlike other viruses which establish 
persistent or latent infections, such as HIV or EBV, the CMV genome is not 
thought to integrate into the genome of the host cell, rather it remains in an 
episomal form, similar to a circular plasmid, in the nucleus of the cell 
(Bolovan-Fritts et al., 1999). 
Different herpesviruses use different cell types as sites of latency and CMV 
utilises myeloid progenitor cells (Mendelson et al., 1996). When these 
progenitor cells undergo differentiation into monocytes and ultimately 
macrophages/dendritic cells, CMV is reactivated (Taylor-Wiedeman et al., 
1994), allowing the virus to re-enter the lytic life cycle, resulting in secretion 
of infectious virus by the host (Figure 1.7). Due to this unique method of 
reactivation, CMV has been described as a persistent infection in the cell 
populations where it remains latent (Seckert et al., 2012). 
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Figure 1.7: A model of reactivation from latency upon progenitor cell differentiation into macrophages. One of the sub-types of cell CMV is 
able to establish sites of latency in are the CD34+ progenitor cell type, which gives rise to monocytes and macrophages/dendritic cells upon 
differentiation. In the progenitor cells, CMV can be detected by PCR but no expression of CMV IE genes is detected, showing no viral gene 
expression is occurring, supporting the presence of CMV in these cells in a latent form. The same situation is found upon differentiation into 
monocytes but upon terminal differentiation into macrophages or dendritic cells, expression of CMV IE genes is found, supporting the ability for 
CMV to reactivate and enter a lytic life cycle in this cell type. Also, prior to this point, the progenitor cells are not permissive to exogenous CMV 
infection, further supporting the presence of CMV in these cells in a latent form only. Reprinted from (Sinclair and Sissons, 2006) with permission from 
the Microbiology Society.
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Constant reactivation of the virus due to monocyte differentiation modulates 
the immune system as more cytotoxic T lymphocytes (CTL) become 
dedicated to stopping dissemination of the virus during reactivation episodes 
(White et al., 2012). This can leave the host vulnerable to other infections in 
a process called immunosenescence. Normally, the immune system is able 
to control the reactivation of CMV, but in those with compromised immune 
systems, reactivation of CMV from latency can result in a systemic infection 
that can be life threatening (Smyth et al., 1991). Reactivation from latency is 
dependent upon the expression of the IE genes (Sinclair and Sissons, 2006), 
which are repressed during latency. This is achieved by modulation of the 
chromatin surrounding the promotor regions of these genes, making the DNA 
inaccessible to transcription factors, conferring transcriptional silence and a 
state of latency (Reeves et al., 2005a). During differentiation of the progenitor 
cells into macrophages and dendritic cells, this repressive chromatin is 
remodelled again and transcription of viral IE genes is initiated (Reeves et 
al., 2005b). The mechanism that modulates this chromatin remodelling is not 
fully understood in CMV, however it is known that HSV utilises latency 
associated transcripts (LATs) to achieve this. These genes are expressed 
during latency to maintain a state of repressed chromatin surrounding the 
promotor regions of IE genes (Wang et al., 2005). CMV is known to express 
similar transcripts, known as cytomegalovirus latency transcripts (CLTs) 
(Lunetta and Wiedeman, 2000), but their function in maintaining latency in 
CMV is not clear.
1.2.2.3 CMV virulence vs host immune response
A productive life cycle for CMV is a delicate balance between promoting viral 
replication and growth whilst down regulating cellular growth and promoting 
cell survival (Sinclair and Sissons, 2006). In addition, the ability to establish a 
latent infection and remain persistent within a population of cells relies on the 
ability to effectively evade the host immune response. CMV has developed 
many intelligent mechanisms for continued survival within a host (reviewed in 
Miller-Kittrell and Sparer, 2009). The majority of CMV gene products are 
thought to be involved in modulation of the host response to CMV, as they 
-43-
are not essential for viral growth in culture (Dunn et al., 2003; Yu et al., 
2003). This section will cover a few of these mechanisms in order to 
understand how the pathogenesis of CMV has evolved.
Initial interaction of the virus with the host cell initiates an innate immune 
response, thought to be through the Toll-Like Receptor 2 (TLR2) (Compton 
et al., 2003). This response results in the activation of several transcription 
factors, including NF-κB and SP1, which has an effect on cell gene 
expression (Yurochko et al., 1995). Initial activation of these transcription 
factors is thought to serve to enable the transcription of IE genes. However, 
in addition to initiating viral gene transcription, virally encoded proteins act to 
shut down cellular gene expression, allowing for all resources to be diverted 
to the transcription of viral genes only (Castillo & Kowalik, 2002). CMV also 
acts to stop the cell cycle progressing, further acting to focus cellular
resources on viral reproduction, as opposed to cellular growth and division 
(reviewed in Fortunato et al., 2000). 
After infection with CMV, a peak in the activation of p53, a gene responsible
for growth arrest and activation of apoptosis, is observed (Muganda et al., 
1994). Whilst activation of cell cycle arrest is beneficial to CMV, induction of 
apoptosis is not. Despite employing these mechanisms to promote viral 
replication over cellular replication, the host immune response deployed 
upon activation of such mechanisms is not beneficial for the continued 
replication and dissemination of CMV. As such, CMV has developed 
mechanisms to evade these innate responses. Whilst p53 is activated, CMV 
is able to repress apoptosis through the action of two viral genes, which
prevents the cell from dying. One viral gene inhibits caspase-8 (Skaletskaya 
et al., 2001), a key component in the initiation of apoptosis. The second gene 
prevents cytochrome C release from mitochondria, which is an intermediary 
step in the pathway of mitochondrion mediated apoptosis (Goldmacher et al., 
1999; Roberedo et al., 2004). 
Similarly, infection with CMV results in the activation of NF-κB, which is 
required to induce viral replication (Yurochko et al., 1995), but this also 
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results in the activation of cytokines and interferon (Boehme et al., 2004). 
Activation of this signalling pathway acts to induce an inflammatory 
response, resulting in the recruitment of cells involved in the innate immune 
reaction to the site of infection. Whilst this might at first appear 
disadvantageous for CMV, it actually serves as an opportunity for further 
dissemination. The cells of the innate immune response, such as 
macrophages, are permissive to CMV infection and therefore present as 
additional sources for its continued productive infection (Castillo & Kowalik, 
2002). 
It is clear that during the initial stages of CMV replication, there is a fine 
balance between activating pathways that allow CMV to replicate whilst also 
down regulating cell death pathways. However, the immune system is
generally able to eventually control the productive infection, but not before 
CMV is able to establish sites of latency within some cells. During periods of 
reactivation, the cell-mediated immunity, primarily CD8+ lymphocytes, will 
continue to fight the productive infection and keep the infection below a level 
at which disease is manifested (Griffiths and Grundy, 1987). However, CMV 
has developed ways to evade these mechanisms, in order to promote its 
spread from one person to another. In individuals experiencing a reactivation, 
symptoms of CMV might not be present, but CMV will be shed in the bodily 
fluids of the individual, making them infectious to others (Ling et al., 2003; 
Cannon et al., 2010).
One major mechanism CMV has evolved to avoid detection by cytotoxic T-
lymphocytes (CTL) is to downregulate the presentation of viral antigens on 
the surface of the cell. Major histocompatability complex (MHC) class I 
molecules are responsible for presenting viral antigens to CTLs, which act to 
destroy the cell and subsequently destroy the virus (Slonczewski and Foster, 
2008). CMV prevents this response from occurring by initiating the 
degradation of MHC class I molecules (Jones et al., 1995). CMV also 
produces a MHC class I homologue which inhibits destruction of the infected 
cell by Natural Killer (NK) cells (Reyburn et al., 1997). Similarly, CMV 
controls cellular production of cytokines in response to infection, by 
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sequestering a certain type of cytokine and removing it from the extracellular 
environment, preventing the recruitment of NK and CTL cells to the site of 
the infection (Bodaghi et al., 1998). 
These are only a few of many mechanisms in place to evade the human 
immune response. Over many years of co-evolving with the mammalian 
immune system, CMV has developed many more mechanisms to evade this 
response. Effective evasion of attack from the immune system allows 
promotion of virus survival, explaining why CMV is so successful at persisting 
in the human population. If these immune evasion mechanisms were not in 
place, the virus would be destroyed before it was able to establish sites of 
latency within the host. Conversely, in the immunocompromised individual, 
these mechanisms of immune evasion are redundant as there is no immune 
system for CMV to fight against, allowing the virus to become widely 
disseminated in the body and cause serious damage to the infected organs. 
At this point, the symptoms of CMV pathogenesis become apparent and the 
virus becomes life threatening to the host. 
1.2.2.4 CMV pathogenesis
Infection with CMV can be grouped into three different types: (i) primary 
infection, where CMV is contracted for the first time; (ii) re-infection, with a 
different strain of CMV; and (iii) reactivation of the individual’s own latent 
virus. Each type of infection can result in the same disease manifestation, 
dependent on the integrity of the immune system of the individual.
Infection with CMV can occur at any age and can be contracted through 
contact with any bodily fluid from an infected individual, including saliva, 
urine, breast milk (Hamprecht et al., 2001) and through sexual secretions 
(Chandler et al., 1985; Handsfield et al., 1985; Staras et al., 2008). Infected 
children are thought to be a large contributor to the transmission of CMV 
(Cannon et al., 2011), and are a particular risk factor to pregnant women 
(Pass et al., 1986), due to the continued secretion of CMV during the first few 
years of life (Stagno et al., 1975) and the frequent transmission between 
children (Adler et al., 1985). Infection with CMV is normally asymptomatic in a 
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healthy individual, although occasionally it can result in CMV mononucleosis 
(Manfredi et al., 2006), similar to the symptoms of Epstein-Barr virus (EBV). 
Infection can also result in CMV hepatitis in both healthy individuals, and as 
an added complication in immunocompromised patients (Castiglione et al., 
2000). 
Primary infection or reactivation of latent virus in immunocompromised
individuals can lead to a host of diseases through direct and indirect effects 
(Freeman, 2009). In AIDS patients, CMV is a common opportunistic 
pathogen resulting in progressive blindness due to inflammation of the retina 
(Sugar et al., 2012). However, with the advent of effective antiretroviral 
therapy against HIV, the incidence of CMV-induced retinitis has decreased 
(Sugar et al., 2012). CMV is also thought to drive the pathogenicity of HIV by 
acting as a co-factor to the retrovirus (Griffiths, 2006).
Prior to the advent of antiviral drugs, CMV was a major concern to organ 
transplant patients due to the risk of transmission of CMV via an organ from 
a seropositive donor (Grundy et al., 1988). This is of most risk to 
seronegative recipients, but is also of concern to seropositive recipients due 
to the risk of reactivation and re-infection (Smyth et al., 1991). A further 
complication in this scenario is the immunosuppressed nature of the patient, 
necessary during transplant surgery to prevent rejection of the organ. 
Systemic CMV infection in a transplant patient can result in a range of direct 
and indirect effects, including pneumonitis (de Maar et al., 1998), hepatitis, 
retinitis and death (Rubin, 1989). 
The elderly are also vulnerable to the effects of CMV due to the biological 
phenomena of immunosenescence. As the host experiences continued bouts 
of CMV reactivation, an increasing number of cytotoxic T lymphocytes (CTL) 
become dedicated to killing CMV infected cells. This leaves the host 
vulnerable to new infections, such as the seasonal influenza virus, due to a 
lack of naive T cells available to fight the new infection (Khan et al., 2002). 
If acquired in utero, CMV can have severe health consequences for the 
neonate, ranging from progressive bilateral sensorineural hearing loss 
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(Grosse et al., 2008) to severe neurological disorders (Preece et al., 1983).
Clinically recognised as congenital CMV, the effect CMV has on neonates is 
of primary concern for the objectives of this thesis and will be discussed in 
more detail in Section 1.2.2.6. 
Pathogenesis associated with CMV infection correlates with the viral load of 
CMV in the blood of a patient in a non-linear relationship (reviewed in 
Griffiths et al., 2012). This is known as the ‘threshold effect’, in which the 
chance of developing symptoms and the severity of those symptoms 
increases once the viral load passes a threshold value (Emery et al., 2000). 
In transplant patients, the chance of developing viraemia, and subsequent 
end-organ disease increases greatly after passing this threshold value 
(Figure 1.8a) (Cope et al., 1997a,b). A similar relationship between viral load 
and severity of sensorineural hearing loss is observed in congenital CMV 
infection (Figure 1.8b) (Walter et al., 2008). In transplant patients, pre-
emptive treatment given before the level of CMV reaches this critical 
threshold value has proven effective at reducing the incidence of CMV 
related disease in these patients (Mattes et al., 2004). This type of treatment 
relies on the ability to detect CMV accurately at low levels, in order to monitor 
the progression of the viral load. This is now possible due to the development 
of DNA technologies. Prior to this, different methods of diagnosis and 
treatment were employed to try and control the development and progression 
of CMV related disease in infected individuals. 
1.2.2.5 Diagnosis and treatment
Diagnosis of CMV infection can only be determined by detecting the virus in 
a biological specimen from the infected individual. Prior to the advent of DNA 
technologies, using cell culture methods to detect CMV was the only method 
of diagnosis. This involved exposing permissive cells to patient swabs and 
waiting until the typical CPE developed. The time taken for CPE to develop is 
typically two to three weeks, therefore this method was hindered by the long 
lead time on test results (Griffiths et al., 1984). In the early 1980’s scientists
searched for a faster method of diagnosis, and a technique was developed 
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Figure 1.8: Graphs depicting the ‘threshold model’ of infection for CMV-related 
disease. Graph (a) depicts the increase of disease risk in transplant patients once 
the viral load passes a certain ‘threshold’ level. Pre-emptive treatment prior to this 
point helps to protect the patient from systemic disease (Cope et al., 1997a,b). 
Graph (b) displays a similar relationship between viral load and the severity of 
hearing loss in neonates (Walter et al., 2008). Reprinted from (Griffiths et al., 2012) with 
permission from Elsevier. Originally published in (Cope et al., 1997b) and (Walter et al., 
2008) and permission was granted for re-use from the Journal of Medical Virology and BMI 
Publishing Group Ltd, respectively.
a
b
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utilising a monoclonal antibody against proteins found to be present in 
cultures within hours of inoculation with CMV (Stinski et al., 1982). By using 
indirect immunofluorescence, the detection of early antigen fluorescent foci 
(DEAFF) test was proven effective at rapidly detecting the presence of CMV, 
however it was ineffective at detecting low viral titres, which were often found 
in blood (Griffiths et al., 1984). Another early test for determining CMV 
infection was the pp65 antigenemia test. This method utilises a monoclonal 
antibody to detect a viral structural late protein, pp65, which is expressed in 
blood leukocytes (Van der Bij et al., 1988).
The methods described above are able to provide information on whether 
infectious CMV is present, but they are both labour intensive and insensitive 
(Ross et al., 2011). Another method of diagnosing CMV that has been used 
for many years is the detection of CMV specific IgG and IgM antibodies via 
serology testing. Whilst this technique is retrospective and is not able to give 
an accurate picture on the presence of infectious virus in an individual, it is 
able to show if a person has previously been infected with CMV and 
therefore harbouring a latent infection. 
The detection of CMV IgM is thought to be indicative of a primary infection, 
which is known to cause more severe symptoms if contracted in the neonate 
from the mother (Fowler et al., 1992). However, the presence of IgM 
antibodies has also been shown to be present in re-infection and reactivation 
(GrangeotKeros et al., 1997), which causes less severe symptoms in the 
neonate (Fowler et al., 1992). These discrepancies presented problems 
when counselling expectant mothers on the risk of transmission to their fetus, 
as the three different types of infection carry significantly different risks of 
symptomatic infection in the neonate. Due to this, a different test, which was 
able to better quantify the risk of symptomatic congenital CMV, was required. 
In an attempt to fulfil this diagnostic requirement, the IgG avidity test was 
developed, aimed at testing the strength of binding between antigen and 
antibody. A strong avidity was thought to be indicative of a re-infection or 
reactivation whereas a weak avidity indicated a primary infection 
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(GrangeotKeros et al., 1997). This technique was first used for CMV infection 
in the early 1990’s (Boppana and Britt, 1995) and was able to give mothers 
more accurate information on the risk of having a baby born with congenital 
CMV, through a more accurate understanding of the type of infection the 
mother was experiencing.
In more recent years, more sophisticated techniques for detecting CMV at 
even low titres were developed upon the advent of DNA technologies, most 
importantly, the discovery of polymerase chain reaction (PCR) (Saiki et al., 
1988). PCR detection of CMV DNA in liver transplant patients showed that 
the presence of viral DNA was associated with the development of CMV 
related diseases and rejection of the organ (Lao et al., 1997). This evidence 
showed that detection of CMV could predict disease progression in the 
patient. Subsequently, quantitative PCR (qPCR) assays were developed 
which allowed virologists to accurately quantify the levels of CMV DNA in the 
blood of a patient. Through this, it is now possible to use pre-emptive 
treatment, preventing the viral load reaching the critical threshold value and 
the onset of symptoms (Mattes et al., 2004).
The first antiviral drug targeted to CMV was ganciclovir, which acts by 
disrupting viral DNA synthesis. This drug was shown to be effective in the 
prevention of CMV pneumonitis in bone marrow transplant patients (Schmidt 
et al., 1991), also showing that pre-emptive therapy was an effective 
treatment plan in preventing disease onset after organ transplantation 
(Rubin, 1991). In addition, ganciclovir was also effective in protecting the 
hearing of neonates born with symptomatic congenital CMV through an 
intensive six-week course given after birth (Kimberlin et al., 2003). 
Subsequently, an oral version of the drug, valganciclovir was developed to 
treat neonates born without symptoms (Kimberlin et al., 2008), previously 
excluded from treatment due to the toxic side effects of ganciclovir (Schmidt 
et al., 1991). 
Attempts to develop a vaccine for CMV have been underway for many years 
and multiple phase I and II clinical trials have been carried out (reviewed in 
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Reider & Steininger, 2014). Whilst there have been multiple vaccine 
candidates trialled, the development of a vaccine against CMV was hindered 
by evidence suggesting that prior immunity to CMV did not confer protection 
against the virus. Cases of seropositive mothers having babies born with 
congenital CMV fuelled this argument (Fowler et al., 1992). Fortunately, this 
discrepancy was explained by further discoveries showing that prior immunity 
only failed to confer protection against a different strain of CMV (Boppana et 
al., 2001). 
Most of the current vaccine candidates are targeted toward CMV gB, and a 
vaccine containing recombinant gB was shown to reduce the transmission of 
CMV and decrease death rate in guinea pigs (Schleiss et al., 2004). Whilst 
these findings may not be translatable to humans, a phase II clinical trial 
using CMV gB in combination with a water emulsion adjuvant, MF59, was 
found to be safe and effective at reducing the length of viraemia in post 
transplant patients. Whilst this trial did not demonstrate complete immunity to 
CMV, the levels of CMV antibodies were increased in those treated with the 
vaccine over 6 months, in comparison to a placebo (Griffiths et al., 2011). 
Furthermore, in seronegative patients who received an organ from a 
seropositive donor, the number of days treated with ganciclovir was reduced 
(Griffiths et al., 2011). These findings are promising for the future of CMV 
vaccines, in particularly for transplant patients in reducing post surgery 
complications related to CMV. However, the development of a CMV vaccine 
is also thought to provide hope for preventing the transmission of CMV from 
mother to fetus (Griffiths, 2012). 
1.2.2.6 Congenital CMV infection
Congenital CMV infection is the leading cause of sensorineural hearing loss 
in neonates along with neurological problems such as cognitive impairment, 
visual impairment and cerebral palsy (Fowler et al., 2003). A seronegative 
woman has a 32% chance (Kenneson and Cannon, 2007) of transmitting the 
virus to the fetus through infection of the placenta (Hemmings et al., 1998). It 
is estimated that the overall birth prevalence of CMV is 0.7% (Dollard et al., 
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2007). Most babies born with the virus will remain asymptomatic, however a 
small proportion ~13.5% (Dollard et al., 2007) will develop symptoms within 
the first year of life and ~12% will be born with symptoms at birth (Dollard et 
al., 2007; Preece et al., 1983).
It is estimated that between 40-58% of symptomatic infants will develop 
permanent severe symptoms of CMV infection (Dollard et al., 2007). The 
severity of any symptoms is proportional to the viral load, which was first 
observed by detecting the amount of excreted virus in the urine of infants 
(Stagno et al., 1975). Those born with symptoms had greater quantities of 
virus in their urine than those who were born without symptoms (Stagno et
al., 1975). Progressive hearing loss of babies born with no symptoms during 
the first year of life was explained due to the continual excretion of virus in 
the urine some time after birth, indicating a continual productive infection 
(Stagno et al., 1975).
The onset of symptoms due to a high viral load is a direct result of maternal 
antibody status (Fowler et al., 1992). In women with a primary infection, the 
virus is able to establish viraemia and infect the layers of the placenta and 
pass onto the fetus (Hemmings et al., 1998). In mothers with prior immunity, 
the virus is managed by the immune system, keeping the viral load low and 
preventing, or limiting, placental transfer (Fowler et al., 1992).
The three types of infection, primary, re-infection and reactivation, can be 
ranked with regards to the risk of transmission of CMV to a neonate and the 
severity of any subsequent symptoms. Primary infection during pregnancy 
poses more risk to the neonate, due to a high viral load in the mother, 
increasing the chance of transmission and onset/severity of symptoms. In 
women experiencing a recurrent infection (reactivation or reinfection), the 
rate of transmission of CMV is ~1.4%, in comparison to 32% in women 
experiencing a primary infection (Kenneson and Cannon, 2007). Additionally, 
in mothers experiencing a primary infection, symptoms of congenital CMV 
are more likely to occur and the severity of the symptoms is likely to be 
higher (Fowler et al., 1992). According to a meta-analysis of the risk of 
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hearing loss, the risk was slightly greater in babies born to mothers with a 
primary infection (13%), than a non-primary infection (11%) (de Vries et al., 
2013). 
Despite these statistics that show a higher risk of vertical transmission in 
seronegative mothers, it is estimated that the majority of babies born with 
CMV are from seropositive mothers that have experienced a recurrent 
infection (de Vries et al., 2013). Approximately 8% of pregnancies in 
seropositive women result in a re-infection with an exogenous strain of CMV 
(Yamamoto et al., 2010). This evidence appears to contradict the evidence 
that a primary infection poses a greater risk of transmission to a fetus and the 
onset of symptoms. However, it is thought that this epidemiological finding is 
due to the evidence that “the risk of re-infection among seropositive women 
outweighs the combined risks of both acquisition and maternal-to-fetal 
transmission among seronegative women” (de Vries et al., 2013). Therefore, 
whilst the greatest risk of a baby being born with congenital CMV is a woman 
experiencing a primary infection during pregnancy, the role of seropositive 
women in contributing to the rates of congenital CMV infection should not be 
underestimated. 
Whilst the main source of infection to both seronegative and seropositive 
expectant mothers is thought to be infected children (Cannon et al., 2011; 
Pass et al., 1986), sexual transmission of CMV does occur, and can also be 
thought of as a risk factor for pregnant women (Chandler et al., 1985; 
Handsfield et al., 1985; Staras et al., 2008). Furthermore, the evidence that 
CMV is able to survive the cryopreservation process of sperm (Mansat et al., 
1997), presents a dilemma to the assisted conception field when using donor 
sperm from CMV positive men. 
1.2.3 Male infertility and the implications of CMV in assisted 
reproduction
Before considering the role CMV plays in donor insemination, it is important 
to consider the wider context of assisted reproduction, including the 
techniques available and the reasons for requiring intervention. As previously 
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stated, one in seven heterosexual couples will experience fertility problems; 
defined as the failure to conceive after 2 years of unprotected sexual 
intercourse. According to the 2013 National Institute for Clinical Excellence 
(NICE) fertility assessment guidelines, fertility problems can be divided into 3 
categories. Female factors, including tubal damage (20%), ovulatory 
disorders (25%) or uterine/peritoneal disorders (10%), a further 25% can be 
attributed to unexplained fertility in either party (male or female) and the final 
30% constitutes issues surrounding male factor infertility (NICE, 2013). 
1.2.3.1 Male factor infertility
The majority of male infertility is of an unknown cause (idiopathic), however 
there are some known medical problems associated with fertility issues in the 
male, including varicocele, accessory gland infection (Irvine, 1998) or the 
absence of a vas deferens which is often found in cystic fibrosis sufferers 
(Chillon et al., 1995).  
Aside from issues that affect the male reproductive tract, male infertility can 
arise from problems with the spermatozoa themselves. A complete lack of 
production of any sperm is known as azoospermia, which can be divided into 
non-obstructive and obstructive causes. Alternatively, sperm may be 
produced, but in small numbers (oligozoospermia), or defective due to 
problems with sperm production or maturation, resulting in reduced motility 
(asthenozoospermia), or have an abnormal morphology (teratozoospermia) 
(World Health Organisation, 2010).  Defective sperm are unable to cope with 
the female reproductive environment and get filtered out, resulting in only the 
normal sperm reaching the Fallopian tubes and potentially fertilising the egg 
(Suarez and Pacey, 2006). Subsequently, this reduces the reproductive
potential of an individual. Defects in sperm production or sperm function can 
be caused by genetic mutations, lifestyle or occupational factors or due to
infection. 
Non-obstructive azoospermia can be caused by a number of genetic 
mutations, including microdeletions in the azoospermia factor (AZF) region of 
the Y chromosome, which deletes genes involved in spermatogenesis (Oates 
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et al., 2002). Similarly, mutations in genes involved in the endocrine 
regulation of spermatogenesis can result in an inability to produce sperm, 
such as hypogonadotropic hypogonadism (Bhagavath et al., 2006).
Obstructive azoospermia, where sperm are produced but unable to be 
ejaculated due to blockages in the reproductive tract (Seshagiri, 2001), is 
often caused by a reproductive tract infection. 
An infection in the reproductive tract can also have a direct effect on sperm. 
Infection leads to inflammation, which results in the production of reactive 
oxygen species (ROS). ROS can be produced by sperm themselves prior to 
ejaculation, or by seminal leukocytes, which would affect sperm during 
ejaculation and after ejaculation, and would result in sperm membrane lipid 
peroxidation (Aitken et al., 1989). This changes the composition of the sperm 
membrane and can impair sperm function, including the ability to fuse to the 
oocyte. Infection with certain pathogens, such as Chlamydia trachomatis can 
also result in direct damage to the spermatozoon, either through exposure 
prior to ejaculation, during storage in the epididymis for example, or after 
ejaculation either through exposure during the ejaculatory process, or 
exposure from pathogens present in the female reproductive tract. In vitro
incubation of sperm with C. trachomatis leads to decreased motility and 
increased sperm death (Hosseinzadeh et al., 2003), thought to be due to a 
receptor mediated interaction between the bacterium and sperm. 
Whilst the reasons for male factor infertility are able to be diagnosed in many 
cases, the underlying cause is often not known. The presence of common 
pathogens, such as CMV, in the semen of men, might indicate an infection 
throughout the reproductive tract with a pathogen that has the potential to 
affect sperm function, and therefore might provide an explanation for 
infertility in men that present without an obvious cause.  
1.2.3.2 Assisted conception 
Different assisted conception treatment options are available for infertile 
couples based on the medical cause of their fertility issues, including 
intrauterine insemination (IUI) (Guzick et al., 1999), IVF (Edwards and 
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Steptoe, 1983) and ICSI (Palermo et al., 1992). When infertility is attributed 
to a male factor cause, such as oligozoospermia or asthenozoospermia, ICSI 
is the most common form of assisted reproduction technology employed in 
the UK, with over half of fresh IVF cycles in 2013 using ICSI to achieve a 
pregnancy (HFEA, 2013b). In cases of azoospermia, some couples may 
consider the use of a sperm donor, and in other instances of unresolved 
infertility issues, donor eggs or embryos might be used. Treatment using 
donor gametes is not only available for infertile heterosexual couples but also 
to same-sex couples (Baetens and Brewaeys, 2001) and single women 
(Leiblum et al., 1995) who are considered to suffer ‘social infertility’ and need 
medical intervention to reproduce (Pacey, 2010).
1.2.3.1 Donor conception
Donor conception using donor sperm (Clarke et al., 1997a), eggs (Wiggins 
and Main, 2005) or embryos (Devroey et al., 1989) was carried out in 1 in 10 
fresh IVF cycles in 2013 (HFEA, 2013a). The number of donor insemination 
and IVF cycles using donor sperm rose in 2013 from 2012 by 3.6% and 6.5% 
respectively, highlighting the increasing demand for this type of treatment. 
The ability to use donor gametes in assisted conception has been facilitated 
by the advent of freezing gametes and embryos in liquid nitrogen. The 
discovery of cryogenic properties of agents such as dimethyl sulphoxide 
(DMSO) (Chen, 1986) and glycerol (Paz et al., 1991) revolutionised this field 
as it allowed freezing of gametes with limited damage. Cryopreservation of 
eggs, sperm and embryos is now routinely used in both donor and non-donor 
assisted conception procedures. Donor conception poses a variety of health 
and ethical risks to the mother and unborn child. Not only is there a risk of 
transferring genetically inherited diseases (Gebhardt, 2002), there is also the 
risk of both horizontal and vertical transmission of infections, such as HIV 
(Wortley et al., 1998). 
In the UK, these risks have been identified and screening guidelines for the 
donation of gametes and embryos have been in place for a number of years. 
Screening for sperm donors was first suggested in Barton et al., (1945) and 
-57-
the British Andrology Society (BAS) formally recommended screening in 
1993 (Barratt et al., 1993) and later revised their guidelines in 1999 (British 
Andrology Society, 1999). A further updated version of the guidelines was 
published in 2008 as a collaborative effort between all professional bodies in 
the field. The aim was to update and consolidate all the guidelines across the 
field for sperm, egg and embryo donation, in order to increase safety and 
consistency (Association of Biomedical Andrologists, Association of Clinial 
Embryologists., British Andrology Society, British Fertility Society and Royal 
College of Obstetricians and Gynaecologists., 2008). 
1.2.3.2 General UK screening guidelines
UK screening guidelines for all donors currently recommend an initial clinical 
assessment of the potential donor to assess age and basic medical history
(Association of Biomedical Andrologists et al., 2008). Further to this, an 
extensive genetic history and exhaustive genetic tests, including karyotyping, 
are carried out to rule out any obvious inheritable diseases.
Potential donors are also screened for the presence of sexually transmitted 
infections (STIs) such as Neisseria gonorrhoea and C. trachomatis in 
addition to viral infections, including HIV, Hepatitis B and C (Association of 
Biomedical Andrologists et al., 2008). The 2008 guidelines also advise on 
quarantine procedures, which differ between sperm and eggs due to different 
success rates in cryopreservation procedures. The current guidelines 
stipulate that donor sperm should be quarantined for >180 days, to allow for 
detection of any seroconversion events, which may take place in the case of 
a recent infection. These guidelines are very similar to those published by the 
American Society for Reproductive Medicine (ASRM, 2013). 
In addition to the viral infections mentioned above, CMV infection is also 
tested for as part of the sperm donor screening process. Although it is not 
solely transmitted through sexual contact, and the risk of transmission is 
unknown, it is included in the screening process, as the guidelines state; “it is 
clear that the risk to the neonate of a maternal CMV infection during 
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pregnancy can be significant and should be avoided if at all possible” 
(Association of Biomedical Andrologists et al., 2008). 
1.2.3.3 CMV specific UK screening guidelines 
In 1993, the BAS advised that serum IgG antibody testing for CMV should be 
carried out on all donors (Barratt et al., 1993). Further advice stated that if a 
donor was seropositive for CMV, that donor must only be used on 
seropositive recipients. In response to the evidence that CMV is present in 
cryopreserved semen samples (Mansat et al., 1997; Prior et al., 1994), the 
BAS revised their guidelines regarding CMV screening in 1999, 
controversially recommending that only seronegative donors be recruited 
(British Andrology Society, 1999). The revised 1999 guidelines also 
recommended IgM antibody testing. The recommendation to recruit only 
CMV negative donors was a highly debated subject and in response to this, 
the guidance for CMV screening was further revised in 2008. A summary 
flowchart of how the current screening process should occur, as 
recommended by the current 2008 guidelines can be found in Figure 1.9. 
These guidelines recommend that IgG and IgM testing be carried out on all 
sperm donors. If found to be IgM positive before or after the quarantine 
period, the donor should be deferred from use, as this serology result is 
indicative of a current infection (Ljungman, 2007). However, these guidelines 
state that where possible, CMV negative donors should be used, but IgG 
positive (IgM negative) donors can be used for seropositive recipients, if 
required, “at the clinicians discretion”.
Whilst the current UK guidelines are taking measures to diagnose an active 
infection in the form of IgM testing, there are other indicators of active CMV 
infection that are not currently tested for. For example, the standards for 
screening in the UK fall short of those in the USA. More thorough tests are 
performed in the US to detect an active infection, including urine or throat 
cultures, in addition to detecting changes in the antibody titre levels (ASRM, 
2013). Both a positive culture and an increase in antibody titre levels 
(including IgG) are indicators of a current active infection in a sperm donor, 
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Figure 1.9: A flowchart summarising the screening process for CMV in sperm 
donors and those undergoing donor insemination. Briefly, current guidelines state all 
sperm donors should be screened for CMV by serum antibody testing. IgM positive 
donors should be deferred from donating, but seronegative and IgG positive donors 
are allowed to be used, dependent upon continued IgM negative results after a 
quarantine period. Donors and recipients should be matched based on their CMV 
serostatus and CMV IgG positive donors should only be given to seropositive 
recipients.
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and therefore, the ASRM recommend that a donor with such positive test 
results should be excluded from use. A primary or reactivation infection 
poses a greater risk as it has been shown that in these instances the level of 
viral secretion, detected by PCR, can be up to 100 fold higher than IgG 
positive patients (Bresson et al., 2003). These cases represent an active 
infection with the potential to infect the recipient, in comparison to IgG 
positive donors, which represent a past infection and may no longer be 
infectious. 
1.2.3.4 Risk of CMV transmission via donor conception
Although all sperm donors are screened for the presence of CMV, there is no 
evidence to suggest that there is a risk of CMV transmission via egg or 
embryo donation (Witz et al., 1999) compared to sperm donation. During 
non-donor assisted conception, the transmission of CMV is not problematic 
as the female is in regular contact with her partner’s bodily secretions, 
suggesting prior contact with CMV infected secretions and existing immunity 
to the virus. However, in donor conception, a seronegative female could 
potentially contract CMV from a positive donor, which could lead to a primary 
infection. This leaves the neonate vulnerable to congenital CMV, as there is 
no maternal immunity protecting from placental transfer (Hemmings et al., 
1998). The risk of transmission through donor conception is not known and 
any incidences of congenital CMV infection through donor conception are 
likely to go unreported. These epidemiological factors make it difficult to 
assess the true risk of CMV transmission through assisted conception. 
1.2.3.5 Consequences for donor conception
The recommendation for exclusion of all CMV seropositive donors from the 
BAS in 1999 sparked huge controversy and debate about the feasibility of 
such an exclusive recruitment strategy (Liesnard et al., 1998; Matson, 2001). 
Arguments were made that this decision would drastically impact upon the 
number of available donors, a realistic consequence as approximately 60% 
of the population will have encountered CMV in their lifetime and would 
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present as seropositive for the virus. It has been shown that the number of 
available sperm donors is significantly below what is needed to meet the 
demand of couples waiting for donor fertility treatment (Hamilton et al., 2008). 
This is potentially exacerbated further by the removal of donor anonymity by 
the Department of Health in 2005 (Burr, 2010). In turn, this ultimately 
increases the length of waiting lists and pressure on the NHS (Pacey, 2010; 
Gudipati et al., 2013), in addition to causing an increase in the number of 
couples seeking donors from abroad and from the internet (Hudson et al., 
2011), which can be time consuming and may increase unnecessary risks for 
these couples. 
1.2.3.6 Solutions to the problem
Ultimately, the availability of sperm donors for women waiting for fertility 
treatment needs to be increased. The current guidelines recommend that IgG 
seropositive samples can be used on IgG seropositive recipients 
(Association of Biomedical Andrologists et al., 2008). This provides a small 
solution but there is no evidence that this practice is actively being carried 
out, despite this being in line with current practices during renal and liver 
transplantation procedures (Andrews et al., 2011). The use of serum 
antibody testing is heavily criticised, as it is a retrospective diagnostic tool: a
positive IgG, or IgM, test does not necessarily indicate the donor is currently 
infectious and therefore, many donors that do not pose any risk are 
potentially being excluded from use. A more appropriate screening 
technique, which is able to definitively determine the presence of CMV in an 
individual donor would be required to overcome this problem. qPCR is used 
in the monitoring of the viral load in patients post organ-transplant (Emery et 
al., 2000), but this is not currently a recommended test for the screening of 
sperm donors. In addition, if there was better scientific evidence surrounding 
the relationship between CMV and sperm, it maybe possible to employ 
sperm washing techniques, as has been possible for some time in cases of 
HIV serodiscordant couples (Semprini et al., 1992), in order to make samples 
safer for use. Whilst there are many avenues to explore for improvement of 
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the current screening practices, allowing for more availability in sperm 
donors, firstly there needs to be a better understanding of the interactions 
between CMV and sperm on which to make clinical judgments.
1.2.4 Impact of pathogens on male fertility and reproductive potential
The presence of pathogens in semen has been widely reported over the 
years (reviewed in Garolla et al., 2013a). For example, Bezold et al., (2007) 
reported the presence of CMV, Human Papillomavirus (HPV), Human 
Herpesvirus-6 (HHV-6), Herpes Simplex Virus (HSV), Epstein-Barr Virus
(EBV), and C. trachomatis in 18.7% of samples from 241 infertile patients 
with or without leukocytospermia. Furthermore, infections with multiple 
pathogens have been reported in the semen of 40.5% of men with an 
existing infection (Gimenes et al., 2014a). The presence of pathogens in 
semen raises many questions about transmission risks and effects on sperm 
production or function, which might affect reproductive potential (reviewed in 
Dejucq and Jegou, 2001; Gimenes et al., 2014b).
Whilst there is currently little evidence for the role of CMV in male infertility, 
there is a host of evidence surrounding other pathogens. Three different 
pathogens will be discussed in turn, focusing on the unique lesson that can 
be learnt from understanding their interactions with human sperm. After this, 
the current evidence for the interactions between the Herpesviridae family
and sperm will be presented, before discussing what is already known about 
CMV. 
1.2.4.1 Human Immunodeficiency Virus (HIV) - how can treatment be made 
safer?
It is known that semen is a vector for HIV transmission (Mermin et al., 1991) 
and it was originally thought that the main source of HIV in semen was due to 
the presence of T cells and macrophages, as opposed to direct infection of 
the spermatozoon (Mermin et al., 1991; Quayle et al., 1997; Pudney et al., 
1999). However, it is now known that HIV can bind to (Figure 1.10a) (Dussaix 
putative sperm receptor is thought to be the mannose receptor (Liu et al., 
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Figure 1.10: The relationship between sperm and HIV is shown with Panel (a) 
depicting an electron microscopy image of HIV interacting with the sperm head. 
Panel (b) shows HIV inside the sperm head by transmission electron microscopy 
(TEM) and Panel (c) shows HIV in the sperm tail via immunogold detection. Despite 
reported interaction between HIV and sperm, Panel (d) shows a modified version of 
density gradient centrifugation, which prevents re-contamination of the sperm pellet 
upon removal, and is efficient at removing >99.99% of HIV from infected semen 
samples. Figure Key: A = Acrosome, AX = Axoneme, M = Mitochondria, N = 
Nucleus, PM = Plasma Membrane. Figure a was reprinted from (Dussaix et al., 1993)
with permission from Elsevier. Figures b & c were reprinted from (Baccetti et al., 1994) with 
permission from The Rockefeller University Press, under the Creative Commons license NC-
SA-2.0. Figure d was reprinted from (Politch et al., 2004) with permission from Elsevier.
d
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et al., 1993) and penetrate (Figure 1.10b,c) sperm (Baccetti et al., 1994). The 
2004; Cardona-Maya et al., 2011), but this is still debated and reports of the 
involvement of other receptors, including Heparin Sulphate Proteoglycans 
(HSPGs) has been reported (Ceballos et al., 2011).
A direct interaction between HIV and sperm supports the findings that HIV 
infection effects sperm function and reproductive potential. Poor IVF 
outcomes have been correlated with high HIV RNA viral loads (Nicopoullos 
et al., 2004), which could be explained by the integration of viral DNA into 
sperm chromosomes (Muciaccia et al., 2007), leading to the possibility of 
vertical transmission (Wang et al., 2011b). In addition, HIV infection in men 
has been shown to be associated with decreased sperm concentration, 
progressive motility, and an increase in morphological abnormalities 
(Dondero et al., 1996), as well as increased DNA damage (Muciaccia et al., 
2007). A correlation between a low number of CD4+ cells (>350/μl) and 
increased morphological abnormalities, and a decrease in progressive 
motility and concentration was also found (Dondero et al., 1996; Nicopoullos 
et al., 2004; Wang et al., 2014). Whilst the exact mechanism by which sperm 
is affected by HIV infection is still under investigation, evidence suggesting 
HIV binds directly to sperm provides strong evidence to suggest that the 
negative effects are due to a direct action of HIV on sperm. 
The evidence supporting the role of sperm as a vector for transmission of 
HIV is clear, demonstrating the potential of both horizontal (Fanibunda et al., 
2011) and vertical transmission (Baccetti et al., 1994). Due to the significant 
health risks associated with HIV infection, transmission of the virus has to be 
prevented between serodiscordant couples. Prior to any of the knowledge 
about how HIV and sperm interact, it was believed that HIV resided only as 
non-sperm cell associated virions. Based on this evidence, research focused 
on eliminating transmission by removing sperm from all other seminal 
components, in an attempt to eliminate HIV. Semprini et al., (1992) was the 
first to report the safe insemination of HIV negative women with sperm from a 
HIV seropositive man without seroconversion. Sperm were separated from 
infected seminal components by density gradient centrifugation, followed by 
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multiple washing steps and a final swim-up, resulting in an absence of HIV-
infected cells in the motile sperm fraction (Semprini et al., 1992). 
Insemination of 29 women resulted in 17 pregnancies and no seroconversion 
occurred in any inseminated women, and no HIV infection was detected in 
any of the offspring. 
However, some studies reported this technique as inefficient, with Marina et 
al., (1998) reporting the presence of HIV in 5.6% of samples after washing.
Importantly, Politch et al., (2004) observed that during the density gradient 
step of the sperm washing procedure, contamination occurred when 
harvesting the pellet after centrifugation. Using a “double tube gradient” 
method (Figure 1.10d), which reduces the risk of re-contamination, the 
authors demonstrated that HIV-1 RNA levels were significantly reduced
(Politch et al., 2004). Further studies using commercially available ‘ProInsert 
tubes’ reported the removal of HIV from 98.1% of samples from HIV-1 
infected men (Fourie et al., 2015). The presence of HIV-1 proviral DNA after 
washing in 2/103 samples in this study highlights that whilst this method is 
clearly superior at removing the majority of HIV in vitro and in vivo, it is not 
foolproof.
The use of sperm washing to eliminate HIV from semen was used for a 
number of years and was shown to be safe and effective. A number of 
studies provided evidence to support this (Marina et al., 1998; Semprini et 
al., 2013), including a meta-analysis and systematic review which determined 
no horizontal or vertical transmission in >11,000 cycles of IUI/IVF/ICSI 
performed with washed semen (Zafer et al., 2015). However, this practice is 
no longer carried out in fertility clinics. It is now standard practice to monitor 
HIV RNA blood levels until undetectable, or <1500 copies/ml, at which point 
the risk of transmission is thought to be negligible (Castilla et al., 2005; Quinn 
et al., 2000). Current guidelines recommend that after 6 months of an
undetectable viral load, it is safe for patients to have unprotected intercourse 
during ovulation in order to achieve pregnancy (NICE, 2013). Whilst this is 
now the currently accepted guideline, some studies have highlighted 
differences in the levels of viral load in semen compared to blood (Rinaldo et 
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al., 1992; Coombs et al., 1998; Gupta et al., 2000; Halfon et al., 2010; Lisco 
et al., 2012; Ferraretto et al., 2015). This evidence highlights differences 
between laboratory measures for detecting infections and epidemiology. 
Whilst this may not be of clinical concern currently, this is an interesting 
biological phenomenon that should be considered when investigating the 
shedding of other viruses in the semen of infected individuals. 
Whilst the exact relationship between HIV and sperm is still unclear, what 
can be learned from this research is that steps can be taken to reduce the 
risks of transmission of the virus through an understanding of the relationship 
between the virus and sperm. In this case, whilst an understanding of the 
interaction between HIV and sperm was not needed to implement sperm 
washing for a number of years, an understanding of the shedding of HIV in 
the semen of infected individuals has ultimately led to better care for 
serodiscordant couples. 
1.2.4.2 Human Papillomavirus (HPV) - can we understand the mechanism of 
interaction? 
HPV is a highly prevalent DNA virus, which can lead to a range of different
cancers, including anal and cervical. Due to this, the role sperm plays in the 
transmission of HPV has been intensely studied. Multiple types of HPV, 
including the ‘high-risk’ types responsible for causing cancer, have been 
found in semen samples from men attending fertility clinics (Kaspersen et al., 
2011) and semen samples cryopreserved for donor insemination (Foresta et 
al., 2010a). The prevalence of HPV in semen is estimated to be ~2.3% in 
fertile men. However, in men experiencing fertility problems, the prevalence 
is higher, ~10 to 35.7% (Foresta et al., 2015) and in those with symptoms of 
HPV infection, the reported prevalence is as high as 53.8% (Foresta et al., 
2010b). 
The relationship between HPV infection and male infertility has been 
intensely studied with some studies suggesting there is no effect on sperm 
function (Schillaci et al., 2013; Golob et al., 2014; Luttmer et al., 2016), 
whereas others have reported an association with male accessory gland 
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infection (La Vignera et al., 2015), in addition to effects on sperm motility 
(Foresta et al., 2010c; Nasseri et al., 2015), sperm concentration (Gimenes 
et al., 2014a; Nasseri et al., 2015), morphology (Gimenes et al., 2014a; Cai 
et al., 2014) and increased levels of DNA damage (Kaspersen et al., 2011). 
An association with HPV infection and the presence of anti-sperm antibodies 
has also been reported (Garolla et al., 2013b). 
Evidence also supports the transmission of HPV via sperm (Foresta et al., 
2011a) and correlations with negative reproductive outcomes have been 
reported for both natural (Garolla et al., 2016) and assisted conception 
(Perino et al., 2011; Garolla et al., 2016). Given this, it is clear that during 
assisted conception, every effort should be taken to remove HPV from 
semen samples.  However, unlike HIV, it is apparent that conventional sperm 
washing is not able to eliminate HPV (Foresta et al., 2011b). 
Through investigating the interaction between HPV and sperm, methods to 
improve the efficiency of sperm washing have been found. This research 
highlighted that HPV is capable of binding to sperm, with 
immunofluorescence studies supporting a binding at the equatorial segment 
of the sperm head (Figure 1.11a) (Perez-Andino et al., 2009; Kaspersen et 
al., 2011; Schillaci et al., 2013). Further investigation showed that HPV is 
able to bind to sperm through interaction with the HSPG, syndecan-1 (Figure 
1.11b) (Foresta et al., 2011b). In sperm bound with HPV, there was a clear 
correlation with decreased DAPI staining, suggesting the DNA integrity had 
been compromised (Figure 1.11c). Initiation of the acrosome reaction does 
not abolish this interaction (Figure 1.11d), unlike the addition of Heparinase-
III (Figure 1.11b). When Heparinase-III is added to the sperm washing 
preparation, it is able to completely eliminate HPV from semen samples 
(Garolla et al., 2012). Through an understanding of the direct interaction 
between HPV and sperm, it has been possible to design a way of eliminating 
this virus from semen samples, making assisted conception safer for those 
affected. 
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Figure 1.11: The relationship between HPV and sperm is depicted with Panel (a) 
showing HPV binding to the equatorial segment of the sperm head, which was not 
an artefact of the fluorescent label used (A1488), as specific fluorescence is absent 
when MBP (maltose binding protein) was used alone. Panel (b) demonstrates this 
interaction was due to the presence of a heparin sulphate proteoglycan on the 
sperm head surface, but this interaction was abolished in the presence of 
Heparinase-III (red=HPV-16 and green=syndecan-1). Panel (c) shows that when 
HPV was seen to be binding to sperm, the DAPI staining was reduced. Panel (d) 
shows that the interaction between HPV and sperm was not abolished when the 
acrosome reaction was induced (red=HPV-16, green=acrosome). Figure a was 
reprinted from (Perez-Andino et al., 2009), Figures b & d from (Foresta et al., 2011) and 
Figure c from (Kaspersen et al., 2012). All were reprinted with permission from PLOS one 
under the Creative Commons license CC-BY-4.0.
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1.2.4.3 Chlamydia trachomatis - can we understand how sperm are affected?
For other pathogens, the focus has been to understand the mechanism of 
interaction with sperm, in order to eliminate it from semen samples. However
investigations into the relationship between C. trachomatis and sperm, have 
led to a detailed understanding of how sperm can be affected by exposure to 
this bacteria.
It is well known that prolonged infection with C. trachomatis can lead to 
problems with fertility in both males and females due to inflammation of the 
reproductive tract (Malik et al., 2009; Mazzoli et al., 2010). The prevalence of 
the bacterium in semen varies significantly and the incidence seems to be 
correlated with a history of infertility, or symptoms of infection in the male. A 
range of ~2.5 to 38.6% prevalence in semen has been reported (Vigil et al., 
2002; Bezold et al., 2007; Gimenes et al., 2014a). 
Like other pathogens that are present in semen, investigations into whether 
there is a direct interaction with sperm have been performed. Electron 
microscopy studies initially suggested that C. trachomatis attached to the 
spermatozoon head (Erbengi, 1993) (Figure 1.12a) and evidence to support 
the penetration into the sperm tail was found (Figure 1.12b). Attempts to 
remove C. trachomatis by density gradient centrifugation supported the idea 
that the bacterium was bound to the sperm (Al-Mously et al., 2009), as in 
both naturally and artificially infected semen samples, infectious C. 
trachomatis was recovered after washing, possibly due to it being directly 
attached to the spermatozoon. 
Infection with C. trachomatis is also known to affect sperm function. A 
correlation with reduced sperm count (Veznik et al., 2004; Gallegos et al., 
2008; Mazzoli et al., 2010; Sellami et al., 2014), reduced motility
(Hosseinzadeh et al., 2001; Veznik et al., 2004; Kokab et al., 2010; Mazzolli 
et al., 2010; Sellami et al., 2014), increased DNA damage (Gallegos et al., 
2008; Sellami et al., 2014), and an increase in seminal leukocytes 
(Hosseinzadeh et al., 2004; Kokab et al., 2010) have been reported in men 
with an active infection. 
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Figure 1.12: The relationship between C. trachomatis and sperm is shown with 
Panel (a) depicting the penetration of Chlamydial elementary bodies (EB) into the 
sperm head and Panel (b) into the sperm tail, as observed by electron microscopy. 
Panels (e&f) show that co-incubation of sperm with C. trachomatis elementary 
bodies results in phosphorylation of tyrosine residues along the sperm tail, in a 
manner analogous to the tyrosine phosphorylation patterns observed when sperm 
are capacitated, Panels (c & d). Figure a & b were reprinted from (Erbengi, 1993), with 
permission from Oxford University Press. Figures c-f were reprinted from (Hosseinzadah et 
al., 2000) with permission from the American Society for Microbiology.
b
a
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An increase in apoptotic markers and loss of mitochondrial membrane 
potential has also been observed (Satta et al., 2006; Sellami et al., 2014).  
Unlike other pathogens the direct mechanisms by which C. trachomatis is 
able to affect sperm function have been uncovered. Biochemical evidence 
showed that co-incubation with C. trachomatis elementary bodies (EB)
increased the levels of tyrosine phosphorylation along the sperm tail (Figure 
1.12c) (Hosseinzadeh et al., 2000). Similarly, a correlation with infection and 
the percentage of acrosome reacted sperm was observed (Jungwirth et al., 
2003). These biochemical alterations, in addition to an increase in sperm 
death (Hosseinzadeh et al., 2001) provide indirect evidence to support a 
receptor-mediated interaction between C. trachomatis and sperm, which is 
able to trigger intracellular signalling pathways, such as those that regulate 
apoptosis. The increase in sperm death when exposed to C. trachomatis has 
been shown to be due to a component of the bacterial cell membrane; 
lipopolysaccharide (LPS) (Hosseinzadeh et al., 2003), triggering apoptotic 
pathways and inducing cell death (Gorga et al., 2001; Eley et al., 2005a). 
The exact method of interaction between C. trachomatis and sperm is still to 
be determined. However, the story of C. trachomatis highlights how 
biochemical evidence of how a pathogen can affect sperm function can lead 
to a deeper understanding of the mechanism of interaction between a 
pathogen and sperm. 
1.2.4.4 The Herpesviridae family - what can we learn from similar viruses?
This section of the introduction has so far covered how an understanding of 
the relationship between pathogens and sperm can lead to changes in 
clinical practice, new methods for elimination and a deeper understanding of 
the molecular mechanisms of impairing sperm function. Before considering 
the current evidence for any interaction between CMV and sperm, it is 
important to consider the wider Herpesviridae family. The interaction 
between sperm and other members of this family, such as HSV, have been
more intensely studied due to the immediate clinical complications 
associated with infection. With a high degree of homology between the 
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viruses (Mar Alba et al., 2001), it is likely that information about how other 
members of this family interact with sperm can be used to inform the 
discussion about CMV and sperm. 
Interestingly, all eight human herpesviruses (HHV), except Varicella Zoster 
Virus (VZV) have been reported in semen at high frequencies ranging from
16.6 to 83.1% (Bezold et al., 2001; Kapranos et al., 2003; Bezold et al., 
2007; Neofytou et al., 2009; Kaspersen et al., 2012; Michou et al., 2012; 
Chen et al., 2013), reviewed in (Kaspersen and Hollsberg et al., 2013). 
A number of studies have investigated the presence of various HHV’s in 
semen and a comparison of the most prevalent types can be seen in Table 
1.1. It is clear that the prevalence of HHV in semen varies significantly and of 
the studies presented in Table 1.1, it is clear that the most prevalent HHV’s 
are CMV, EBV and HSV, with one study finding a high prevalence of 66.8% 
for HHV-6 (Neofytou et al., 2009). However, very few studies have 
investigated the presence of VZV, HHV-7 and HHV-8. More studies might 
highlight that these HHV strains are just as prevalent as the others, however 
the current evidence suggests this is not that case. Table 1.1 also highlights 
that the presence of CMV and EBV is much higher in those infected with HIV 
(Howard et al., 1997; Rinaldo et al., 1992; Lisco et al., 2012). This is not 
surprising as it is widely reported that men infected with HIV often have co-
infections with opportunistic pathogens, such as EBV and CMV (Lupton et 
al., 2013). Whilst the prevalence varies significantly for men seeking help 
with fertility, the presence is generally quite low in healthy sperm donors. 
With only HHV-6 being detected at 13.5% (Kaspersen et al., 2012), the 
remaining strains are detected at levels less than 6%. 
Given the high prevalence of HHV’s in the semen of men, the effect of these 
viruses on male fertility and sperm function have naturally been investigated. 
The majority of studies investigated this in vivo and in most cases concluded 
that the presence of HHV’s did not have any significant effect on
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Table 1.1: Details of HHV prevalence in semen from studies where the presence of multiple strains were found. (Blue=men attending fertility 
clinics, red=HIV positive men, green=health sperm donors).
Study HSV1/2 VZV EBV CMV HHV-6 HHV-7 HHV-8
Aynaud et al., 2002 
(n=111)
9% 6.3%
Bezold et al., 2001 
(n=252)
3.2% 0% 7.1% 3.6% 4.0% 0.4% 0%
Bezold et al., 2007 
(n=241)
3.7% 0.4% 8.7% 3.7%
Chen et al., 2013 
(n=153)
25.5% 3.9% 21.6% 2.0%
Kapranos et al., 2003 
(n=113)
49.5% 16.8% 7.1%
McGowan et al., 
1983 
0% (n=210) 2.4% (n=170)
Michou et al., 2012 
(n=109)
29% 0% 45% 43% 8.2% 3.6%
Neofytou et al., 2008 
(n=172)
2.3% 2.3% 40.6% 56.9% 66.8% 0%
Naumenko et al., 
2014 (n=232)
3.4% 5.2% 6.5%
Howard et al., 1997 
(n=24)
83.3% 25%
Rinaldo et al., 1992 0% (n=116) 33% (n=58)
Lisco et al., 2012 
(n=50)
8% 56% 70% 2% 12% 6%
Lisco et al., 2012 
(n=28)
0% 3.5% 3.5% 6% 6%
Kaspersen et al., 
2012 (n=198)
0.4%/0.1% 0% 6.3% 2.7% 13.5% 4.2% 0%
Howard et al., 1997 
(n=115)
3.5% 0%
McGowan et al., 
1983 (n=40)
2.5%
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volume, sperm count, motility, morphology, or levels of leukocytes and 
antisperm antibodies (Bezold et al., 2001; Bocharova et al., 2008; Neofytou 
et al., 2009; Eggert-Kruse et al., 2009; Naumenko et al., 2011; Michou et al., 
2012; Pallier et al., 2002; Chen et al., 2013). Interestingly, no correlation was 
observed with even multiple infections of up to four different strains of HHV 
(Michou et al., 2012). However, infection with a HHV and another type of 
pathogen, such as C. trachomatis or HPV, might result in the production of 
abnormal sperm (Gimenes et al., 2014a), but evidence suggests infection 
with multiple types of HHV does not have such a synergistic effect on sperm 
abnormalities. A few studies have observed an effect on sperm concentration 
and motility, mostly in response to HSV infection (Kotrionas and Kapranos, 
1998; Kapranos et al., 2003; Pallier et al., 2002). One study reported a 
correlation between the presence of CMV and HHV-6 with inflammatory 
urogenital tract diseases (Naumenko et al., 2014) and another study reported 
an effect on sperm concentration and motility but did not distinguish between 
HHV strains (Bezold et al., 2007). Pallier et al., (2002) investigated the effect 
on sperm motility in vitro and whilst they found no effect when co-incubating
CMV with sperm, they did observe alterations in sperm kinematic movement 
in response to HSV co-incubation.  When considering the role HHV infection 
plays in infertility, it is important to consider the evidence suggesting that 
men intermittently shed HHV’s in their semen (Kaspersen et al., 2012). This 
evidence shows that results from studies correlating the presence of HHV 
and fertility issues might be underestimating the role HHV’s play in infertility. 
Whilst at the time of the study the individual might not have been shedding 
virus, it does not mean they do not have an infection that could be affecting 
their fertility; it just might not have been detected at the particular time point 
of the study. 
Whilst for most HHV’s there appears to be no correlation with impaired 
sperm, there does appear to be a correlation with HSV. However, unlike HIV 
and C. trachomatis, little investigation into the mechanism of interaction and 
effect on sperm function has been conducted. Some studies have 
investigated the role of HSV thymidine kinase (HSV-tk) on spermatogenesis 
-75-
in mice. They have observed that transgenic mice carrying the HSV-tk gene 
produced sperm with gross morphological defects, acrosomal abnormalities 
and a loss of germ cells due to apoptosis (Huttner et al., 1993; Cai et al., 
2009). Further investigation showed gross abnormalities in the testes 
structure and a failure of the crucial Sertoli-germ cell interaction, which 
undoubtedly contributed to the failure of spermatogenesis to produce 
functional sperm (Cai et al., 2012). Whilst this evidence is interesting and 
shows how a viral gene can affect fertility, it is unlikely to be occurring in 
men. The mice used in these studies have been transgenically altered to 
express the HSV-tk gene and therefore the findings from these studies are 
difficult to translate to a human infection. Some studies using human sperm 
have suggested that HSV can interact with the sperm head (Figure 1.13a) 
and tail (Figure 1.13b) (Pallier et al., 2002), potentially penetrating the sperm
head. The number of instances in this study is few but other studies showing 
the detection of HSV DNA inside the sperm head support this finding (Figure 
1.13c) (Kotrionas and Kapranos, 1998; Bochorova et al., 2008). Interestingly, 
it has been reported that HHV-6 can also associate with sperm, but only 
when the acrosome is intact (Figure 1.13d) (Kaspersen et al., 2012). 
Evidence to support interactions between HHV and sperm are further 
supported by evidence showing that sperm washing fails to remove most of
these viruses from infected semen samples (Witz et al., 1999; Michou et al., 
2012). Interestingly, Michou et al., (2012) did observe that HHV-6 and 7 
could be removed from semen samples, contradicting the evidence from 
Kaspersen et al., (2012), which suggests HHV-6 interacts with the sperm 
head. 
Whilst there is a wealth of evidence supporting the presence of HHV’s in 
semen, few studies have attempted to investigate the mechanisms of 
interaction, which facilitate sexual transmission. The few studies that have 
been carried out provide contradictory evidence and the picture is far from 
clear. 
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Figure 1.13: The relationship between sperm and Herpesviruses is shown with 
Panel (a) depicting an electron microscopy image with HSV-2 particles close to the 
sperm head and tail (Panel b), with the author reporting a direct interaction. Panel 
(c) shows in situ hybridisation demonstrating the presence of HSV DNA in the 
sperm heads of infected men. In Panel (d-c), co-incubation of HHV-6 with sperm 
showed that the virus (green) was able to bind to the sperm head in the presence of 
the acrosome (red). Panel (d-d) shows that when the acrosome reaction was 
induced the interaction was lost. (Panel d-e shows the acrosomal staining in the 
absence of HHV-6). Figure Key: IS = Infected sperm, US = Uninfected sperm.
Figures a & b were reprinted from (Pallier et al., 2002) with permission from Oxford 
University Press. Figure c was reprinted from (Bocharova et al., 2008) with permission from 
the Russion Journal of Developmental Biology. Figure d was reprinted from (Kaspersen et 
al., 2012) with permission from PLOS one under the Creative Commons license CC-BY-4.0.
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Despite being one of the most studied of the HHV’s, as can be seen in 
Kaspersen and Hollsberg, (2013), investigations into the interactions 
between CMV and sperm are also limited.
1.2.4.5 Human Cytomegalovirus - what do we already know? 
The presence of CMV in the semen of both symptomatic and asymptomatic 
men was observed as early as 1975 (Lang and Krummer, 1975). 
Furthermore, CMV has also been detected in semen samples cryopreserved 
for fertility treatment (Bresson et al., 2003; Mansat et al., 1997). The reported 
prevalence ranges from 0% to 56.9% (reviewed in Kaspersen and Hollsberg, 
2013), and CMV infection can often be found in association with other HHV’s 
(Table 1.2). 
Few studies have directly investigated the interaction between CMV and 
sperm, and those that have do not provide convincing data. Pallier et al., 
(2002) reported the presence of a viral particle near the surface of the sperm
head using electron microscopy (Figure 1.14a), but this was only observed in 
<5% of sperm sections analysed. Also, the authors report that the type of 
viral particle depicted ‘interacting’ with the sperm head is actually a non-
infectious form (dense body), rather than a fully formed infectious virion.
Another study reported a direct interaction with sperm, located at the 
equatorial segment (Figure 1.14c), in both samples infected in vivo and in 
vitro. However, despite using samples with high viral concentrations for 
immunoflourescent analysis, an association was only found with 2-6% of 
sperm observed (Naumenko et al., 2014). However, one interesting study 
documented the ability for CMV to infect immature germ cells in vitro (Figure 
1.14b), which could lead to the production of mature sperm carrying CMV 
internally (Naumenko et al., 2011). This study found a reduction in germ cells 
in the presence of CMV infection, which could contribute to male infertility. 
Evidence suggesting sperm washing is inefficient at removing CMV from 
naturally infected semen samples (Witz et al., 1999; Michou et al., 2012; 
Naumenko et al., 2014) does support the possibility of a direct interaction 
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Table 1.2: Details of the prevalence of multiple HHV infections in men attending fertility clinics. Numbers shown as percentage 
prevalence and total number in brackets.
Study E+C E+H6 C+ H6 C+H E+H H+H6 E+H+C C+H7 H+E+H
7
E+C+H
6
H+E+C+H6 E+C+H6+H7
Naumenko et al., 2014 
(n=232)
0.43%
(1)
0.86% 
(2)
1.3% 
(3)
Aynaud et al., 2002 
(n=111)
1.8% 
(2)
Bezold et al., 2001 
(n=252)
0.8% 
(2)
0.4% 
(1)
Chen et al., 2013 
(n=153)
1.6% 
(4)
5.9% 
(15)
0.4% 
(1)
0.8% 
(2)
Kapranos et al., 2003 
(n=113)
3.6% 
(4)
12.4% 
(14)
0.9% 
(1)
Michou et al., 2012 
(n=109)
4.8% 
(10)
1.8% 
(2)
1.8% 
(2)
3.7% 
(4)
5.5% 
(6)
16.5% 
(18)
0.9% 
(1)
1.8% 
(2)
1.8% 
(2)
1.8% (2) 0.9% (1)
Neofytou et al., 2009 
(n=172)
27.9% 
(48)
31.9% 
(55)
44.1% 
(76)
2.3% 
(4)
2.3% 
(4)
22.6% 
(39)
E=EBV
C=CMV
H=HSV
H6= HHV-6
H7= HHV-7
V=VZV
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Figure 1.14: The relationship between CMV and sperm is shown, with Panel (a) 
displaying electron microscopic images showing a non-infectious CMV particle 
(dense body) close to the sperm head in <5% of sections analysed. Panel (b) 
depicts an organotypic culture using human testicular tissue samples infected with 
CMV. Using this method, it was observed that CMV was able to infect both 
spermatogonia and spermatocytes after 14 days of infection. In Panel (c), 
immunofluorescence of CMV pp65 protein shows CMV binding to the sperm head 
and mid-piece (c-a&c). The authors also noted a pattern of binding along the 
equatorial segment (c-d), which is similar to the pattern observed when using 
immunofluorescence to detect acrosome reacted sperm. Figure Key: Sc = 
Spermatocyte, Sg = Spermatogonia. Figure a was reprinted from (Pallier et al., 2002)
with permission from Oxford University Press. Figure b was reprinted from (Naumenko et al., 
2011) with permission from Biomed Central under the Creative Commons license CC-BY-
2.0. Figure c was reprinted from (Naumenko et al., 2014) with permission from Andrology.
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between CMV and sperm. However, the current evidence base is poor and 
does not provide a clear picture of how this interaction might be occurring.
1.3 Summary
Evidence from a variety of pathogens in addition to the wider Herpesviridae
family clearly shows that sperm can act as a vector for viral transmission. 
The HSPG receptor appears to play an important role in this process, but as 
our understanding of the spermatozoon develops, the involvement of other 
receptors might be discovered. Methods of understanding interactions 
between pathogens and sperm have been developed through observing 
effects on sperm function, the efficiency of sperm washing, and by direct 
investigations of the molecular interactions. It is clear that the role sperm 
plays in the transmission of pathogens is something to be concerned about, 
given the severe health complications associated with some of the ones 
discussed in this chapter. A deeper understanding of the interactions that are 
occurring is essential in order to change clinical practice in the assisted 
conception field and make practices as safe as possible. This is no different 
for CMV. Whilst the risks of transmission of CMV are not as immediately 
apparent as for some of the other pathogens, such as HIV, the health 
consequences associated with infection can be just as severe. Given this, an 
understanding of how sperm can act as a vector for transmission of CMV 
should be given just as much concentration as other infectious diseases. 
1.4 Aim(s) and objectives 
It is clear that there is a gap in the knowledge regarding the relationship 
between CMV and sperm. The knowledge that CMV can have severe 
consequences if contracted in utero has had a negative impact on the 
assisted fertility sector, as it has affected who can donate sperm and possibly 
contributed to the falling numbers of sperm donors. Despite this, there is still 
no active investigation into solving the problem and the actual risks of 
contracting CMV through assisted conception are still not known. The first 
objective of this study is to understand how CMV is screened for in the 
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fertility clinic and whether a more in depth understanding of the relationship 
between CMV and sperm can better inform clinical practice with regards to 
the use of CMV positive sperm donors for assisted conception. This will 
serve as the context for investigating the main objective, which is to gain an 
insight into the relationship between CMV and sperm, firstly by investigating 
the effectiveness of sperm washing procedures at removing different 
quantities of virus from both naturally and artificially infected sperm and 
secondly, by assessing the effect of CMV infection on sperm parameters 
through co-incubating laboratory grown CMV with sperm. 
1.4.1 Specific aims
1. Develop a survey to distribute to fertility clinics aimed at investigating 
the screening procedures for CMV in sperm donors and provision of 
fertility treatment.
2. To establish a system for culturing CMV in vitro and quantifying the 
viral load and infectious load by qPCR and the plaque assay, 
respectively.
3. To assess the efficiency of current sperm washing protocols at 
removing CMV from artificially and naturally infected semen samples. 
4. To perform co-incubation experiments with spermatozoa to assess if 
CMV affects sperm function parameters.
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Chapter 2
Materials & Methods
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2.1 Biological safety, donor recruitment and ethics
Permission to grow and use CMV (AD169) was sought by the University of 
Sheffield biosafety committee and the project was approved on 9th May 2013 
(Appendix I). Ethical approval to recruit voluntary sperm donors was granted 
on 28th February 2014 (Study No: SMBRER293) by the University of 
Sheffield ethics committee (Appendix II). Healthy men from the Yorkshire and 
Humber region aged between 18-65 were recruited through posters 
(Appendix III) and email advertisement and compensated £15 per sample in 
lieu of expenses. The recruitment and consent of donors was carried out by a 
laboratory research technician (Dr Sarah Waite), in order to exclude the 
possibility of coercion by researchers. Informed consent was obtained upon 
delivery of each sample to the laboratory and samples were anonymised with 
a unique donor number, before being handed over to be used in the 
experiments described in this thesis. In Chapter 3, a survey evaluating 
services was distributed to fertility clinics throughout the UK and abroad 
(Appendix IV). As this survey was designed to evaluate current practice in 
clinics, according to the National Health Service (NHS) Health Research 
Authority ‘Defining Research’ leaflet, this is defined as service evaluation and 
did not require ethical approval. This was confirmed by the Sheffield 
Teaching Hospitals research coordinator (Angela Driscoll), by telephone. 
2.2 Strains, plasmids and growth conditions
Escerichia coli (DH5α), a kind gift from Professor Dave Hornby (University of 
Sheffield) was used for all molecular cloning techniques in Chapter 4, and 
was grown at 37°C in Luria-Bertani growth medium (LB). LB + agar (12g/L) 
was used to culture E. coli on agar plates, with or without 200μg/ml Ampicillin 
(Sigma-Aldrich, Dorset, UK). A laboratory strain of human Cytomegalovirus 
(CMV) AD169 (Health Protection Agency, Porton Down, Salisbury, UK)
(NCBI: BK000394) was grown on Human Lung Fibroblast cells (MRC-5) 
(American Type Culture Collection, Middlesex, UK), as described in Chapter 
4, and subsequently used in Chapters 5 and 6. CMV strains Towne (NCBI: 
AY446869), Merlin (NCBI: AY446894) and TB40/E (NCBI: AY446866), used 
-85-
in Chapter 6, were provided by Dr Matt Reeves (University College London). 
Plasmid pRcRSV was used to clone the glycoprotein B gene, in Chapter 4,
and was provided by Dr Neil Chapman (University of Sheffield). 
2.3 Buffers and reagents
Details of the composition of all buffers, media and solutions used throughout 
this thesis are detailed in Table 2.1. 
2.4 Tissue culture
MRC-5 cells were cultured in Eagle’s Minimum Essential Medium (EMEM) 
(American Type Culture Collection, Middlesex, UK) with 10% (v/v) Fetal Calf 
Serum (FCS) (Lonza, Basel, Switzerland), 100U penicillin and 0.1mg/ml 
streptomycin (Sigma-Aldrich, Dorset, UK). Dimethyl sulphoxide (DMSO) 
(Sigma-Aldrich, Dorset, UK) was removed by centrifuging cells at 125g for 10 
minutes in 2ml EMEM. Supernatant was removed and replaced with 2ml 
fresh EMEM in which the pellet was re-suspended. Cells were transferred to 
a T75 culture flask (Greiner Bio-one, Frickenhausen, Germany) with 13ml 
EMEM giving a 1:15 dilution.  
Cells were left to grow for seven days with a media change every 48 hours 
until confluent. Cells were passaged 1:3 by removing spent media and 
washing with 6ml Dulbecco’s phosphate buffered solution (PBS) (Sigma-
Aldrich, Dorset, UK). 3ml of trypsin (Sigma-Aldrich, Dorset, UK) was added to 
each T75 flask and incubated for 2-3 minutes to allow cells to detach from 
the flask surface. A 1ml aliquot of trypsinised cells were transferred to each 
T75 flask containing 13ml EMEM and incubated at 37°C. 
Samples of cells were cryopreserved at each passage by trypsinising with 
3ml of trypsin and centrifuging at 1,000g for 10 minutes. Supernatant was 
removed and the pellet re-suspended in 750μl EMEM + 10% (v/v) FCS. The 
cell suspension was divided into three cryovials and a 10% (v/v) DMSO 
solution (diluted in antibiotic free EMEM) was slowly added to the 250μl of 
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Table 2.1: Buffers, media and solutions.
Composition Amount 
(g)
Volume 
(ml)
Percentage 
compositio
n (%)
Molarity 
(M)
LB Tryptone 5
NaCl 5
Yeast Extract 2.5
Distilled Water 500
LB Agar Tryptone 5
NaCl 5
Yeast Extract 2.5
Agar 6
Distilled water 500
SDS lysis 
buffer pH 7.4
Tris 0.61 0.02
EDTA 2.5 0.5
NaCl 7.5 5
SDS 25 10
Distilled water 215
Semi-solid 
overlay
Methyl Cellulose 25 1
2xEMEM 25
5% FCS 2.5 5
L-Glutamine 0.5 0.2
Penicillin/Strepto
mycin Mix
0.5
1% methyl 
cellulose
Methyl Cellulose 5
Distilled water 500
5% 
formaldehyde
Formaldehyde 67.6 37
PBS 432
Formalin NaHCO3 50
Formaldehyde 10 35
Distilled water 1000
MOWIOL/ 
DABCO
Mowiol 2.4
Glycerol 6 4.76
H2O 6
Tris 12 0.2
DABCO 0.569 2.5 (w/v)
TBS TRIS 0.02
NaCl 0.14
H2O 476
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MRC-5 cells giving a final 5% (v/v) DMSO concentration. The samples were 
cooled slowly using a Mr Frosty cooling box, stored at -80°C before being 
stored in liquid nitrogen at -196°C.
For visualisation of MRC-5 cells, cells were grown in 6 wells plates until 
various stages of growth. 500μl of 5% (v/v) formaldehyde (Table 2.1) was 
used to fix the cells for 30 minutes before being washed twice with 1x PBS. 
500μl of 0.5% (w/v) crystal violet solution (Sigma-Aldrich, Dorset, UK) was 
added and left to stain the cells for 10 minutes before being washed off with 
1x PBS twice. Cells were imaged using a 10X objective on an inverted 
Olympus CKX41 microscope (Figure 2.1).
2.4.1 Plaque assays
MRC-5 cells were grown until just confluent in 24-well Cell+ plates (Sarstedt, 
Nümbrecht, Germany). Once confluent, EMEM media was removed and cells 
were infected with either 100μl or 200μl of sample (amount and type of 
sample vary between experiments-precise details can be found in the 
relevant chapters). Samples were diluted in serum-free EMEM over a 2-fold 
or 10-fold dilution series and a different dilution was added to each well. Two 
negative control wells, containing serum-free EMEM only were included on 
each plate. The plates were incubated at 37°C for 1 hour with gentle manual 
rocking every 20 minutes (Plummer & Benyesh-Melnick, 1964). After 1 hour, 
1ml of semi-solid overlay, composed of a 1:1 mix of 2xEMEM and 1% (w/v) 
methyl cellulose (Table 2.1), was added to each well in order to prevent virus 
from spreading and enable the identification of discernable plaques.
The plates were incubated at 37°C for 1-2 weeks, until plaques were 
discernable. Once plaques were visible, the cells were fixed by removing the 
overlay and adding 1ml 5% (v/v) formaldehyde (Table 2.1) to each well and 
incubating at room temperature for 30 minutes. The fixative was removed 
and plaques stained with 0.5% (w/v) crystal violet solution. The cells were left 
to stain for 10 minutes at room temperature. The stain was decanted, 
washed with 1xPBS and left to dry. 
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Figure 2.1: MRC-5 human lung fibroblast cells were grown in EMEM, fixed with 5% 
(v/v) formaldehyde and stained with 0.5% (w/v) crystal violet. Cells were imaged 
using an inverted Olympus CKX41 microscope on a 10X objective. Cell were fixed 
and stained at (a) 48 hours after passage, (b) when cells were at 80% coverage, or 
sub-confluency and (c) at an early stage of confluency. Scale bar shown=50 μm.
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The cells were visualised on a microscope and the plaques were counted. 
The viral titre in PFU/ml was calculated by scaling up to determine the 
number of plaques present in 1ml and then multiplying by the dilution factor 
(Appendix V).
2.5 Semen analysis and sperm function tests
Semen samples from healthy donors aged between 18-65 were used for all 
experiments outlined in this thesis. Donors were asked to abstain for 2-3 
days prior to producing the sample. Samples were produced at home in a 
collection pot (Sigma-Aldrich, Dorset, UK) and delivered to the Academic 
Unit of Reproductive and Developmental Medicine, Jessop Wing, Sheffield 
within 40 minutes of production. Samples were analysed, as outlined below, 
and used immediately. 
2.5.1 Basic semen analysis
Sperm concentration and motility measurements were made according to 
methods described in WHO (2010), with modifications in sperm motility 
assessment as outlined in Bjorndahl et al., (2016). Briefly, a wet prep was 
prepared by adding 10μl of the ejaculate to a microscope slide and analysing 
under a 20x objective to determine the appropriate dilution of the sample to 
carry out. Sperm concentration was assessed by diluting the ejaculate with 
formalin (Table 2.1), and adding 10μl of the diluted sample to each side of an 
improved Neubauer haemocytometer. This was left to settle in a humidified 
chamber for 5-10 minutes. Upon analysis of the concentration, 200 sperm 
were counted on each side of the chamber before taking an average and 
determining the concentration of sperm in 106 per ml. The wet prep was used 
to analyse sperm motility by counting 200 sperm and categorising them into
progressively motile (grades a and b), non-progressively motile (grade c) and
non-motile (grade d). Duplicate measurements were not performed.
2.5.2 CASA motility analysis
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Assessment of sperm motility and kinematics was carried out using the 
Sperm Class Analyzer software, version 5.4.0.0 (MicroOptic, Barcelona, 
Spain), in accordance with standards outlined in WHO (2010). Samples were 
observed on a Microtec LM-2 trinocular microscope (Mazurek, Warwickshire, 
UK) with a 20x objective and visualised using a Basler A312FC digital 
camera (Basler, Ahrensburg, Germany) at 25 frames per second. Briefly, 
10μl of sample was added to a 20μm 2-chamber Microcell slide (Conception 
Technologies, San Diego, USA). The tracks of at least 200 motile sperm 
were obtained per sample, where possible, with a maximum of 400 sperm 
detected. Data collected included the percentage of progressive, non-
progressive and immotile sperm and the percentage sperm velocities, 
categorised as rapid, medium and slow. In addition, sperm kinematic data 
focusing on sperm movement and velocity was also collected. The curvilinear 
velocity (VCL), straight-line velocity (VSL) and average path velocity (VAP) 
were measured in μm/s. Ratios of sperm progression were measured in the 
form of linearity (LIN), straightness (STR) and wobble (WOB). The amplitude 
of lateral head displacement (ALH) was also measured in μM and the beat 
cross frequency (BCF) in Hz. (See Figure 2.2 for details on individual 
kinematic measurements). Finally, a measure of percent hyperactivation was 
collected. Hyperactivation is defined as sperm with VCL >150μm s-1, LIN 
<50% and ALH >7.0 μm (Mortimer et al., 2015). Sperm kinematic data for 
each individual sperm analysed for each sample was collected via a 
Microsoft Excel (Microsoft, Washington, US) spreadsheet. 
2.5.3 Density gradient centrifugation (sperm washing)
Motile sperm was recovered from seminal plasma and immotile sperm by 
density gradient centrifugation (Pertoft et al., 1978; Gorus and Pipeleers, 
1981) using PureSperm (Nidacon, Sweden). Sperm were separated on an 
80:40% gradient, created by gently layering 1ml 40% PureSperm onto a 1ml 
layer of 80% Puresperm, creating a clean and sharp meniscus (Figure 2.3a). 
80% and 40% PureSperm was created by diluting 8ml PureSperm 100
(Nidacon, Sweden) with 2ml PureSperm Buffer (Nidacon, Sweden) and 4ml 
and 6ml, respectively. Between 0.5-1ml of semen (dependent upon 
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Figure 2.2: Diagram depicting some of the sperm kinematic parameters collected by 
CASA analysis in Chapter 6. The curvilinear velocity (VCL) calculates the distance 
travelled by the sperm along its curvilinear path corrected for time. The straight line 
velocity (VSL) calculates the distance travelled between the first and last points of the 
curvilinear trajectory, giving a measure of the net space gain with the period of time 
measured. The average path velocity (VAP) is the average trajectory of the sperm. The 
amplitude of lateral head displacement (ALH) is a measure of how far the position of 
the sperm head deviates from the average path (VAP) (Mortimer, 1994; Mortimer, 
1997). The MAD stands for the mean angular displacement of the sperm head along its 
curvilinear trajectory. This parameter was not measured in this thesis. Figure has been 
adapted from (WHO, 2010), with permission to reprint from WHO Press. 
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Figure 2.3: Diagrams highlighting the differences between density gradient 
centrifugation and the ProInsert tube™. Figure a depicts the conventional density 
gradient centrifugation method of separating seminal components from motile 
sperm. 40% PureSpem is layered onto 80% PureSperm and after centrifugation, 
immotile and dead sperm should remain in between the layers, leaving a pellet of 
motile sperm at the bottom of the 80% layer. The pellet is removed by aspirating off 
the upper layers and retrieving the pellet. In comparison, Figure b presents an 
adapted method aimed at preventing recontamination of the pellet upon retrieval. In 
this method, all components of the gradient are added via the other chamber and 
the pellet is retrieved via the central channel. This avoids recontamination of the 
pellet with debris from the upper layers as the central channel allows direct retrieval 
of the pellet.
Outer Chamber
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experiment being performed) was then gently layered on the top of this 
gradient and centrifuged at 300g for 20 minutes. The remainder of the 
gradient and seminal plasma was gently removed in one swift motion and the
pellet re-suspended by gentle agitation before being transferred via a glass 
Pastuer pipette to 2ml PureSperm Wash Buffer (Nidacon, Sweden). The 
sample was then centrifuged at 500g for 10 minutes before removal of most 
of the remaining wash buffer, leaving 300μl to re-suspend the pellet in. 
An adapted version of the density gradient centrifugation technique was also 
used, using ProInsert tubes (Nidacon, Sweden). These tubes are designed to 
minimise recontamination of the pellet during retrieval by using a double tube 
system, similar to that of Politch et al., (2004). The density gradient, 
consisting of 1ml 40% PureSperm layered onto 1ml 80% PureSperm was 
prepared in the outer chamber (Figure 2.3b). Between 0.5-1ml of semen 
(dependent upon experiment being performed) was gently layered on top of 
the gradient and centrifuged at 300g for 20 minutes. The pellet was then 
retrieved using a sperm-retrieval pipette (provided with the tube), attached to 
a syringe. The pipette was passed through the central channel (Figure 2.3b) 
and the pellet aspirated. The pellet was then transferred to 2ml PureSperm 
Wash Buffer and centrifuged at 500g for 10 minutes before removal of most 
of the remaining wash buffer, leaving 300μl to re-suspend the pellet in. 
2.5.4 Hypo-osmotic swelling test (HOST) and acrosome 
immunoflourescence
After exposure to CMV in Chapter 6, sperm were assessed for viability and
acrosome status using the Hypo-osmotic Swelling Test (HOST) (Jeyendran 
et al., 1984), in combination with immunofluorescence detecting an 
acrosomal protein (Figure 2.4a) (Ellis et al., 1985; Moore et al., 1987).  
Briefly, 10μl of each incubate, containing ~1.0x105 sperm was added to 
100μl HOST media (1:10 dilution) (FertiPro, Belgium) and incubated at 37°C 
for 30 minutes. Samples were smeared on to a poly-lysine microscope slide 
and left to air-dry overnight at room temperature. The slides were fixed by 
incubating for 1 minute in cold methanol before being allowed to air-dry and 
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stored at -20°C for analysis. Slides were warmed to room temperature before 
re-hydrating in 1ml TBS (Table 2.1) for 15 minutes. TBS was drained from 
the slides and 100μl of primary antibody targeted toward a protein present in 
the acrosome of the sperm was added (Ellis et al., 1985). The 18.6 mouse 
monoclonal antibody, a kind gift from Professor Harry Moore (University of 
Sheffield), was diluted 1:10 with PBS before being added to the slide and 
incubated at 37°C for 1 hour in a humidified chamber. The slides were 
washed twice with TBS and 100μl of secondary antibody [rabbit α-mouse 
IgG-fluorescin isothiocynate conjugated] diluted 1:100 with PBS was added 
to each slide and incubated at 37°C for 1 hour. Each slide was washed twice 
with TBS and the back of the slide dried. Slides were mounted using 1-2 
drops of MOWIOL®4-88/1,4-diazobiycyclo-(2,2,2,)-octane (Sigma-Aldrich, 
Dorset, UK) (Table 2.1) and  left overnight at 4°C in the dark. Slides were 
analysed on an Olympus BX41 with both x100 magnification phase contrast 
and epifluorescence objectives (UV filter 492 nm). 
Acrosome fluorescence was determined by sperm displaying fluorescence 
over the entire acrosome classed as acrosome intact, and those with patchy 
fluorescence, a band of fluorescence around the equatorial segment or no 
fluorescence being classed as acrosome reacted sperm (Figure 2.4a). 
Initially, for each incubate, 200 spermatozoa were counted to measure 
viability using the criteria of sperm with curly/bent tails as viable and those 
with straight tails as non-viable, as outlined in Jeyendran et al., (1984) and as 
shown in Figure 2.4b. A further 200 viable (curly/bent tails) sperm were 
counted to determine the status of the acrosome, using definitions described 
above and the criteria outlined in (Zhu et al., 1994).
2.5.5 Terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL)
DNA damage was assessed via the TUNEL assay, using the Terminal 
deoxynucelotidyl transferase (TdT) enzyme (Gavireli et al., 1992; Sun et al., 
1997). Briefly, ~5x106/ml sperm in a volume of 100μl, was added to a poly-
-95-
Figure 2.4: Assessment of acrosome status by immunofluorescence using an 
antibody targeted toward an acrosomal protein (a). Acrosome status was assessed 
by categorising those with fluorescence over the entire acrosomal region as being 
acrosome intact and those with patchy fluorescence, a band of fluorescence around 
the equatorial segment or no fluorescence determined as acrosome reacted. 
Acrosomal immunofluorescence was used in conjunction with the HOST test (b). 
Sperm with straight tails are considered to be dead (b.1). Sperm with varying 
degrees of bent tails (b.2-5) were considered to be viable (Jeyendran et al., 1984). 
Using the two techniques together allows for identification of sperm that are 
acrosome intact and alive (a.1), acrosome intact and dead (a.2), no acrosome and 
alive (a.3) and no acrosome and dead (a.4). Examples of these categories can be 
seen in (a) (Zhu et al., 1994). Sperm were visualised on an Olympus IX73 LED 
fluorescent microscope on a 60x oil immersion objective. Scale bar shown = 10μm.
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lysine slide and left to air dry overnight at room temperature. The slides were 
fixed in methanol for 1 minute before storing at -20°C until analysis.
Slides were warmed to room temperature and re-hydrated using 1ml TBS for 
15 minutes. Sperm were permeabilised by adding 200μl of 20μg/ml 
Proteinase K (Merck Millipore, California, USA) (2mg/ml Proteinase K was 
diluted 1:100 with 10mM Tris pH8) and incubating at room temperature for 5 
minutes. The slides were washed 3 times with TBS and excess liquid tapped 
off. A positive control slide was included to control for specificity of the TdT 
enzyme. Briefly, 100μl of DNase I (Merck Millipore, California, USA) was 
added to the positive control slide and incubated at room temperature for 20 
minutes. The slide was washed with 1ml TBS before removing excess liquid. 
50μl of TUNEL reaction mix was prepared by adding 5μl TUNEL enzyme 
solution, containing TdT from calf thymus recombinant in E. coli (Roche, UK), 
to 45μl TUNEL label mix, constituting a 10% (v/v) mixture of enzyme (Sgonc 
et al., 1994). This reaction mix was added to the slides, covered with a 
coverslip and incubated at 37°C for 60 minutes in a humidified chamber. 
Coverslips were removed and slides washed in TBS twice for 1 minute at 
room temperature. All excess liquid was removed from the slide and the back 
of the slide dried. 
Slides were mounted with one drop of Propidium Iodide (Vector Laboratories, 
Peterborugh, UK) and the addition of a coverslip, sealed using nail varnish. 
Slides were kept in the dark at 4°C overnight and analysed on an Olympus 
BX41 with both x100 magnification phase contrast and epifluorescence
objectives (UV filter 492 nm). For each incubate, the number of sperm with 
red fluorescence (no DNA damage), green fluorescence (DNA damage) or 
mixed fluorescence (partial DNA damage) were counted (Figure 2.5). 200 
sperm per incubate were counted and the number of sperm in each category 
expressed as a percentage. 
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Figure 2.5: Terminal deoxynucelotidyl transferase dUTP nick end labelling 
(TUNEL) was carried out to assess levels of DNA damage in sperm. Staining and 
imaging was carried out as outlined in section 2.5.5. The top panel shows sperm 
incubated with the TUNEL enzyme and label mix. In comparison, the bottom panel 
shows a negative control, containing only the label mix. When the TdT enzyme is 
present, sperm with DNA damage are observed to fluoresce green, or yellow 
depending on the amount of DNA damage. This is in comparison to the negative 
control (lower panel), which shows in the absence of the TdT enzyme, all sperm 
fluoresce red only. Scale bar shown = 10μm.
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2.5.6 Tyrosine phosphorylation immunofluorescence
Levels of tyrosine phosphorylation were measured by immunofluorescence 
using an α-phosphotyrosine mouse monoclonal antibody (clone 4G10) 
(Merck Millipore, California, USA), as outlined in Hosseinzadeh et al., (2000).  
A 100μl aliquot containing ~1.0x105 sperm was added to a poly-lysine 
microscope slide and left to air-dry overnight at room temperature. The slides 
were fixed in methanol for 45 minutes before storing at -20°C until analysis.
Slides were warmed to room temperature and re-hydrated using 1ml TBS for 
15 minutes. The primary α-phosphotyrosine mouse monoclonal antibody 
(clone 4G10) was diluted 1:500 in antibody diluent (final concentration 
0.5μg/ml) and 100μl was added to each slide. The slides were covered with a 
coverslip and incubated at 37°C for 1 hour in a humidified chamber. The 
slides were washed twice with TBS and 100μl of secondary antibody [rabbit 
α-mouse IgG-fluorescin isothiocynate conjugated] diluted 1:100 with PBS 
was added to each slide and incubated at 37°C for 1 hour. Each slide was 
washed twice with TBS and the back of the slide dried. Slides were mounted 
using 1-2 drops of MOWIOL®4-88/1,4-diazobiycyclo-(2,2,2,)-octane and  left 
overnight at 4°C in the dark.
Slides were analysed on an Olympus BX41 with both x100 magnification 
phase contrast and epifluorescence objectives (UV filter 492 nm). For each 
incubate, 200 sperm were counted and the level of tyrosine phosphorylation 
fluorescence assessed. Sperm displaying tyrosine phosphorylation exhibit 
bright fluorescence along the entire length of the tail (Figure 2.6a). In 
comparison to a negative control (Figure 2.6c), which exhibits weak or a 
complete absence of fluorescence. Sperm exhibiting the fluorescence pattern 
seen in Figure 2.6a were scored as tyrosine phosphorylated and those 
exhibiting the pattern seen in Figure 2.6c scored as non-tyrosine 
phosphorylated. To demonstrate the specificity of the primary antibody, 
Figure 2.6b & d show no fluorescence when the secondary antibody is added 
alone. 
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Figure 2.6: Measurement of tyrosine phosphorylation by immunofluorescence 
using an α-phosphotyrosine mouse monoclonal antibody (clone 4G10). When 
incubated with both primary and secondary antibody, as outlined in Section 2.5.6, 
capacitated sperm exhibit an intense fluorescence over the entirety of the sperm tail 
(a), in comparison to non-capacitated sperm which do not exhibit the same pattern 
of fluorescence (c). No fluorescence is observed when only the secondary antibody 
was used in either capacitated (b) or non-capacitated (d) sperm. Sperm were 
visualised on an Olympus IX73 LED fluorescent microscope on a 60x oil immersion 
objective. Scale bar shown = 10μm.
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2.6 Molecular Biology 
2.6.1 RNA extraction of MRC-5 cells
RNA was extracted from the cells using an E Z RNA isolation kit (Geneflow, 
Staffordshire, UK). Briefly, 0.5ml of denaturing solution was added to the 
culture flask and the cells were scraped from the flask surface using a cell 
scraper. The homogenate was stored at room temperature for 5 minutes 
before adding 0.5ml of extraction solution and vigorously shaking for 15 
seconds. The sample was stored at room temperature for 10 minutes before
centrifuging at 12,000g for 15 minutes at 4°C. The aqueous upper phase was 
transferred to a fresh Eppendorf tube (StarLab, Milton Keynes, UK) and 
0.5ml of isopropanol added, mixed and stored overnight at -20°C. The 
following day the sample was centrifuged at 12,000g for 8 minutes at 4°C. 
The supernatant was removed and the RNA pellet washed with 75% (v/v) 
ethanol by vortexing. The sample was centrifuged at 7,500g for 5 minutes at 
4°C. The ethanol wash was removed and the pellet was left to air dry for 5 
minutes before dissolving the RNA in 100μl of DEPC-treated water (Life 
Technologies, Paisley, UK). The purified RNA was quantified and the 
parameters of purity examined by adding 2μl to a nanophotometer 
(Geneflow, Staffordshire, UK).
2.6.2 cDNA synthesis
RNA was reverse transcribed into cDNA using an iScript cDNA synthesis kit 
(BioRad, Hertfordshire, UK). Briefly, 1μg of RNA was added to a 20μl 
reaction volume composed of 4μl 5X iScript reaction mix, 1μl iScript reverse 
transcriptase and 12μl nuclease free water. A no reverse transcriptase 
control was also included, substituting 1μl of enzyme for 1μl of nuclease free 
water. The reaction was incubated for: 5 minutes at 25°C, 30 minutes at 
42°C and 5 minutes at 85°C. A 2μl aliquot of cDNA was used in subsequent 
PCR experiments. 
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2.6.3 DNA extraction of MRC-5 cells
MRC-5 cells were grown until confluent in a T75 culture flask. Cells were 
detached from the flask surface by adding 2ml trypsin and incubating at 
37°C.  Cells were washed from the cell surface and transferred to two 1ml 
Eppendorf tubes (StarLab, Milton Keynes, UK) before centrifuging at 1,000g
for 10 minutes. The supernatant was discarded and 200μl of lysis buffer was 
added to the pellet on ice and incubated for 10 minutes at 37°C. One lysis 
reaction was centrifuged at 12,000g for 25 minutes and the cell lysate stored 
at -20°C for CMV analysis. DNA was extracted from the second lysis reaction 
by adding 200μl phenol chloroform and mixing well. The sample was 
centrifuged at 12,000g for 5 minutes at 4°C. The upper aqueous phase was 
transferred to a new Eppendorf tube and an equal volume of chloroform was 
added and mixed well. The sample was centrifuged at 12,000g for 5 minutes 
at 4°C, before transferring the aqueous upper phase to a new Eppendorf
tube. The salt concentration was adjusted by adding 1/25 volume of NaCl 
and 1μl of glycogen was added. The solution was mixed well and exactly 2 
volumes of ice cold 100% (v/v) ethanol added. The reaction was incubated 
on ice for 30 minutes before centrifuging at 12,000g for 10 minutes at 0°C. 
The supernatant was removed and 1ml of 70% (v/v) ethanol added and 
centrifuged at 12,000g for a further 2 minutes at 4°C. The supernatant was 
removed and the pellet was left to air dry before re-suspending in 50μl of 
DEPC-treated water.
2.6.4 DNA extraction of sperm
DNA was extracted from sperm using a QIAamp DNA Mini Kit (Qiagen, 
Manchester, UK). A 100μl aliquot of semen or sperm was extracted following 
the manufacturer’s bodily fluids spin protocol. Briefly, 100μl of sample was 
added to 20μl QIAGEN proteinase K, to which 200μl of Buffer AL was added 
and mixed by pulse vortexing for 15 seconds. The sample was then 
incubated at 56°C for 10 minutes. Samples were briefly centrifuged (to 
remove drops from inside of the lid) and 230μl of 100% ethanol was added. 
This mixture was then applied to the QIAamp Mini spin column and 
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centrifuged at 6000g for 1 minute. The QIAamp spin column was removed, 
placed in a fresh collection tube and 500μl of Buffer AW1 was added. The 
columns were centrifuged at 6000g for 1 minute and the QIAamp spin 
column removed and placed in a fresh collection tube. 500μl of Buffer AW2 
was added and samples centrifuged at 20 000g for 3 minutes. Following this 
final centrifugation step, the QIAamp column was removed and placed in a 
fresh Eppendorf tube. 100μl of Buffer AE was added directly to the column 
and incubated at room temperature for 1 minute. Samples were centrifuged 
for 1 minute at 6000g and the eluate retained for analysis. All DNA samples 
were analysed for quality and quantity by adding 3μl to a nanophotometer 
(Geneflow, Staffordshire, UK). The presence of genomic DNA was assessed 
by amplifying GAPDH by PCR (Section 2.6.5) 
2.6.5 Polymerase Chain Reaction (PCR) conditions
All PCR reactions were carried out in a Sensoquest Labcycler (Geneflow, 
Staffordshire, UK). Two PCR master mixes were used throughout this thesis: 
(1) Promega PCR master mix (Promega, Southampton, UK) and (2) 
MyTaq™ HotStart Mix (Bioline, London, UK). The polymerase used was 
changed to MyTaq™ HotStart Mix as it was more efficient, needing fewer 
PCR cycles and less amplification time. Subsequently, this master mix was 
found to be more specific at amplifying the correct products and was 
therefore used in all later PCR reactions. The cycling conditions and reaction 
components for each amplification product and each PCR master mix are 
detailed below. 
Thy1
Amplification to detect the presence of Thy1, a fibroblast specific gene, in 
MRC-5 cells. In a total reaction volume of 25μl, 2μl of cDNA, 25μM of both 
upstream and downstream primers (provided by Dr Sarah Waite, University 
of Sheffield) (Table 2.2) and 12.5μl of 2x PCR master mix (composed of 50 
units/ml Taq polymerase, 400μM of each dNTP and 3mM MgCl2), were 
added. The reaction was cycled 25 times for 2 minutes at 94°C, 25 seconds 
at 94°C, 30 seconds at 65°C, 45 seconds at 72°C and 5 minutes at 72°C.
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Table 2.2: Primer sequences used throughout Chapter 4 in the construction of 
PcRsV-gB plasmid, detection of CMV and characterisation of MRC-5 cells.
Primer Sequence 5’-3’
Thy1-forward CTGGGTGCAGCAACCGGAGG
Thy1-reverse TGCTCAGGCACCCCCACAGT
GAPDH-forward GACATCAAGAAGGTGGTGAAG
GAPDH-reverse GTCCACACCCTGTTGCTGTAG
gB1 GAGGACAACGAAATCCTGTTGGGCA
gB2 TCGACGGTGGAGATACTGCTGAGG
gBA GCGAAGCTTCGACGCGCCTCATCGCTGCT
gBB GTCTAGACCTCCTGGTTCAGACGTTCT
gBF CTGAAGTCGGTATTTTCCAGC
gBR GGGCGAGGACAACGAATC
QgBF TGAAGTCGGTATTTTCCAGC
QgBR GGGCGAGGACAACGAATC
gB3 CAATCATGCGTTTGAAGAGGTAGTCCACG
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GAPDH
In a total reaction volume of 25μl, 2μl of MRC-5 DNA, 25μM of each 
upstream and downstream primer specific to a 200bp region of the GAPDH 
housekeeping gene (provided by Dr Neil Chapman, University of Sheffield) 
(Table 2.2) and 12.5μl of 2x PCR master mix (composed of 50 units/ml Taq
polymerase, 400μM of each dNTP and 3mM MgCl2) were added. The 
reaction was cycled 25 times for 2 minutes at 95°C, 30 seconds at 95°C, 30 
seconds at 53°C, 45 seconds at 72°C and 5 minutes at 72°C. For sperm 
DNA, in a total reaction volume of 25μl, 5μl of sperm DNA, 25μM of each 
upstream and downstream primer and 12.5μl of 2x MyTaq™ HS Mix were 
added. The reaction was cycled 25 times for 1 minute at 95°C, 15 seconds at 
95°C, 15 seconds at 60°C and 10 seconds at 72°C. 
Glycoprotein B
In a total reaction volume of 25μl, 2μl of MRC-5 DNA, 25μM of each 
upstream (gB1) and downstream (gB2) primer specific to a 149bp region of 
the CMV glycoprotein B gene (Mattes et al., 2004) (Table 2.2) and 12.5μl of 
2x PCR master mix (composed of 50 units/ml Taq polymerase, 400μM of 
each dNTP and 3mM MgCl2), were added. The reaction was cycled 30 times 
for 2 minutes at 95°C, 30 seconds at 95°C, 30 seconds at 61°C, 45 seconds 
at 72°C and 5 minutes at 72°C.
An alternate set of primers was used in later experiments, gBF and gBR 
(designed using Primer3) (Table 2.2), specific to a 200bp region of the CMV 
glycoprotein B gene. These primers were used in conjunction with the 
MyTaq™ HS Mix, the reaction volume and components were the same as 
listed above but the reaction was cycled 25 times for 1 minute at 95°C, 15 
seconds at 95°C, 15 seconds at 59.5°C and 10 seconds at 72°C.
Glycoprotein B-whole gene
The whole glycoprotein B gene was amplified for the purpose of cloning into 
a vector as a standard for quantitative PCR (Section 2.6.6). In a total reaction 
volume of 25μl, 0.6μl of CMV DNA (Health Protection Agency, Porton Down, 
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Salisbury, UK), 25μM of each upstream (gBA) and downstream (gBB) 
primers specific to the 2.8kB glycoprotein B gene (Temperton et al., 2003) 
(Table 2.2) and 12.5μl of 2x PCR master mix (composed of 50 units/ml Taq
polymerase, 400μM of each dNTP and 3mM MgCl2), were added. The 
reaction was cycled 30 times for 2 minutes at 95°C, 30 seconds at 95°C, 30 
seconds at 65°C, 3 minutes at 72°C and 5 minutes at 72°C. Primer design 
and PCR conditions were based on those published by Temperton et al., 
(2003). 
2.6.6 Quantitative PCR (qPCR) conditions
In-house qPCR, reported in Chapter 4, was carried out on an Applied 
Biosystems 7900 Real-Time PCR machine, using a clear 384 well plate 
(StarLab, Milton Keynes, UK). Plates were sealed with an optically clear 
heat-sealing film (StarLab, Milton Keynes, UK). PCR set-up was performed in 
a PCR hood (Geneflow, Staffordshire, UK) and all plastic ware sterilised with 
UV light prior to use. 
Absolute quantification using a TaqMan hydrolysis probe was carried out 
using the SensiFAST™ Probe Hi-ROX kit (Bioline, London, UK). In a total 
reaction volume of 20μl, 2.5μl of each flanking primers, QgBF and QgBR 
(Mattes et al., 2004) and hydrolysis probe (gB3) (labelled at the 5’ end with 6-
FAM and at the 3’ end with TAMRA) (Mattes et al., 2004) (Table 2.2) were 
added at a final concentration of 125nM, 250nM and 300nM respectively. A 
no template control, constituting H2O alone was included on each plate. 10μl 
of master mix was added in addition to 2.5μl of sample or standard.  The 
reaction was cycled 40 times for 5 minutes at 95°C, 10 seconds at 95°C and 
20 seconds at 60°C. 
The Virus Detection Group at University College London performed a 
clinically validated PCR assay on all DNA samples in Chapter 6. This PCR 
assay was carried out in a clinical virology laboratory, which takes part in the 
EQA programme. The qPCR assay used is outlined in Mattes et al., 2004. 
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Chapter 3
How do fertility clinics diagnose and 
manage CMV infection in sperm 
donors?
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3.1 Introduction
Since the introduction of recommended screening for CMV in sperm donors, 
by the British Andrology Society (Barratt et al., 1993), it has been a 
controversial issue. Most of the controversy surrounded the recommendation 
to exclude all CMV positive donors (British Andrology Society, 1999). This 
sparked much debate, with Curson & Karakosta (2000) pointing out the 
inevitable reduction in the number of available donors if all positive donors 
were excluded from donating sperm. 
Further questions were raised regarding the practicality of this approach, with 
some asking “where do we draw the line” with sperm donor screening 
(Matson, 2001). The multiple possible sources of CMV infection, such as; 
sexual partners, infected children and reactivation of latent virus, led some to 
question the relevance of CMV screening, in particular relation to 
seropositive recipients (Liesnard et al., 2001). Furthermore, the evidence that 
infectious CMV is present in less than 5% of seropositive donors (Mansat et 
al., 1997) supports the argument that these donors might present a minimal 
risk level. Similar questions surrounding the need to screen for rare genetic 
disorders, such as hypertrophic cardiomyopathy (Maron et al., 2009), have
also been debated and is an example of where the risk is considered too 
small to justify screening.
Despite these points, in a letter to the editor of Human Reproduction in 1999, 
then British Andrology chairman, Eileen McLaughlin, argued “it is not the size 
of the risk that is important but the fact that simple steps can be taken to 
reduce the risk” (McLaughlin, 2000). She also reiterated that the main aim of 
the 1999 guidelines was to “reduce as far as possible the risk of a child 
suffering from a serious disability, which could have been avoided” 
(McLaughlin, 2000). Whilst an ideal stand point, the 2008 guidelines took a 
more pragmatic view and recommend that whilst “it is always preferable to 
recruit CMV-negative donors”, this was not always feasible and “in situations 
where insufficient CMV-negative donors are available, CMV IgG positive 
(IgM negative) donors may be recruited but their use should be limited to 
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CMV IgG positive recipients”. The guidelines also state “the decision to treat 
a patient with a seropositive donor should be a matter of clinical judgement” 
(Association of Biomedical Andrologists et al., 2008). This is an approach 
that is considered to be a practical and viable option (Liesnard et al., 1998). 
The relevant UK regulatory bodies have made their view on CMV screening 
clear but there is a degree of variation across the world. For example, current 
UK guidelines fall short of the recommendations of clinics in the USA to carry 
out urine and throat cultures, to diagnose an active infection (American 
Society for Reproductive Medicine, 2013), and to assess IgG titre levels to 
diagnose a reactivation event (Dolan et al., 1989). Along with the UK 
guidelines, whilst the ASRM recommends seromatching, they acknowledge 
this is not without risk due to the risk of re-infection with an exogenous strain 
of CMV. In comparison, the EU Tissue Directive (Directive 2006/17/EC) does 
not require clinics in Europe to carry out CMV testing at all. This might add 
further complications to the issues surrounding CMV screening in the UK, as 
clinics rely on overseas donors from European sperm banks to meet demand 
for donors in the UK (HFEA, 2014). Despite routine CMV screening not being 
conducted in these clinics, the HFEA does stipulate that imported sperm 
should be screened as if it were sourced in the UK, from a UK donor.
It is clear therefore that there is wide variation in the recommended practice 
and opinions surrounding CMV screening within clinics in the UK and around 
the world. The lack of data regarding the risk CMV poses in donor 
insemination further confuses the issue and as pointed out in Liesnard et al., 
(2001), “it is urgent to investigate this risk and its consequences more 
deeply”. Throughout this controversy and confusion, the actual approach 
clinics are taking to implement professional body guidelines has failed to be 
explored in a robust way. Given the apparent differing opinions, many 
questions need to be asked about what ‘clinical judgements’ are being made, 
for example, to what extent does seromatching donors and recipients 
actually occur? Through obtaining answers to these questions, it might be 
possible to identify any problems being caused by CMV screening and steps 
-110-
to solve any issues could be taken to improve these procedures for clinics 
and patients. 
3.2 Rationale
In light of the obvious pressure of reduction in availability of donors, possibly 
as a result of the requirement to screen for CMV, it was hypothesised that 
UK clinics may increasingly choose to ignore current screening guidelines, in 
order to increase the supply of donors. In turn, it was proposed that this 
would lead to variation and inconsistency in screening practices across the 
UK. Therefore, a simple service evaluation tool in the form of a survey was 
designed to understand the approaches currently used by UK clinics for the 
diagnosis of CMV and management of CMV positive donors. Clinics outside 
the UK were also approached to see how their procedures compared and 
whether they differed in any way. 
The aim of the survey was to answer the following questions;
1. How is screening for CMV managed in fertility clinics, including; what 
type of laboratory test is performed, when this test is performed and 
how the results are interpreted.
2. How a clinic takes CMV screening into consideration when buying 
donor sperm from other centres.
3. How CMV infection in sperm donors is managed with regards to 
seromatching donors and recipients, and whether this causes issues 
with donor supply.
4. Identify if practices between UK and non-UK clinics differ and if this 
identifies any particular problems.
5. What are the views in clinics regarding CMV screening and the effects 
on their clinics.
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3.3 Methods
A survey tool was developed to capture the screening practices in each 
clinic, in addition to capturing information about sperm donor recruitment and 
donor/recipient matching in the context of CMV infection. The questionnaire
(Appendix IV) was divided into eight parts: (i) details of the clinic size, clinical 
activities and scale of the donor recruitment programme (if applicable); (ii) 
the clinic approach to CMV screening and how they managed the process 
including any use of (iii) serum antibody testing; (iv) PCR; or (v) viral culture. 
Part (vi) asked about the clinic policy of buying donor sperm from other 
centres and how the clinic assessed the CMV screening performed by the 
distributing centre (if applicable); and part (vii) asked about how the clinic 
matched CMV status of donors and recipients, with a view to understanding if 
they carry out seromatching and if CMV infection in donors was perceived as 
a problem. Each of the sections (i) to (vii) was comprised of a series of 
questions with a number of tick boxes to capture the responses, with a box at 
the end of each section where free-text responses were encouraged. The 
final part (viii) was a free text box where the respondent was asked to 
provide any further information about their views on CMV screening if the 
previous sections did not cover them.
In December 2013, the questionnaire was sent to 103 clinics listed on the 
HFEA website as being licenced to provide fertility treatment within the UK. 
In addition, in April 2014 the questionnaire was also circulated via Androlog 
(an internet user's group moderated by Craig Niederberger from the 
University of Illinois at Chicago and Andy Meacham at the University of 
Colorado at Denver) with over 1547 subscribers [Neiderberger, C., Personal 
Communication]. Recipients of the survey were encouraged to pass it on to 
colleagues in other clinics and we also circulated the questionnaire more 
opportunistically through a ‘Snowballing’ method often used to contact hard 
to reach groups (Faugier and Sargeant, 1997). Data collection ended at the 
end of November 2014 and any responses received after this date were not 
included.
-112-
Upon receipt, all responses were double entered into an Excel Spreadsheet 
(Microsoft, Washington, US) and checked for accuracy, before being 
summarised and examined using SPSS (Version 21, IBM corporation). Some 
data points were missing but were not excluded from analysis. Free text 
responses were examined using a thematic analysis approach outlined in 
Braun and Clarke (2006).
3.4 Results
A total of 52 responses were received from the 103 UK clinics approached by 
email (50.5% response rate) and a further 31 from non-UK clinics (response 
rate estimated at <10%). The majority of UK (84.6%) and non-UK clinics 
(77.4%) provided treatment with donor sperm, performing a median number 
of 64 (range 6-300) and 190 (range 5-2257) treatment cycles respectively in 
2012. The majority of UK clinics (67.3%) recruited a median of 5 donors 
(range 0-79), compared to a median of 23 (range 0-16453) in 74.2% of non-
UK clinics. The majority of UK (75.0%) clinics bought donor sperm from other 
centres, in comparison to only 64.5% of non-UK clinics. A summary of all the 
demographics of responding clinics can be found in Table 3.1. 
3.4.1 How is CMV screening being performed and managed in clinics? 
The majority of UK clinics and sperm banks that recruited donors in 2012 
reported screening donors for CMV (97.1%), in comparison to only 65.2% of 
non-UK clinics and sperm banks. When screening donors, current guidelines 
recommend that semen samples should be quarantined for 180 days and 
70.5% of UK clinics reported to follow these guidelines, in comparison to 
80.0% of non-UK clinics (Table 3.2a). Clinics that did not report following the 
guidelines for quarantine stated that the use of NAT testing or instances of 
‘known donation’ were situations where the quarantine period was shortened, 
or not carried out at all. When the quarantine period was performed, the 
majority of clinics screened donors both before and after quarantine (Table 
3.2b). However, a minority of clinics in both UK and non-UK clinics stated 
they only screened before quarantine, 12.5% and 13.3%, respectively. 
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Table 3.1: Demographics of responding clinics.
1Median (Range)
Item UK (n=52 ) Non-UK  (n=31)
Provide treatment with donor 
sperm
   84.6% (n=44) 77.4% (n=24)
Recruitment of sperm donors    67.3% (n=35) 74.2% (n=23)
Buy sperm from other centres    75.0% (n=39) 64.5% (n=20)
Supply sperm to other centres 17.3% (n=9) 32.3% (n=10)
Number of cycles 1 64.0 (6-300) 190.0 (2-2257)
Number of donors screened1        5.0 (0-79)      23.0 (0-16453)
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A smaller percentage reported only screening donors after the quarantine 
period (3.1% and 6.7% respectively). The majority of UK clinics (94.1%) 
reported to screen donors by the recommended serum antibody test, in 
comparison to 100% of non-UK clinics (Table 3.2c). When performing this 
test, the majority of UK (78.1%) and non-UK (86.7%) clinics screened for 
both CMV IgG and IgM antibodies (Table 3.2d). However, a minority of 
clinics only screened for CMV IgG antibodies, with some clinics stating this 
was because IgM antibody testing was found to be unreliable. 
Table 3.2 shows that the interpretation of serology test results varies 
between UK and non-UK clinics. An overview of how test results should be 
interpreted, in line with the current guidelines for the management of CMV 
positive donors can be seen in Figure 3.1. This flow chart also highlights how 
clinics are deviating from these guidelines based on findings from this 
survey. When interpreting CMV IgG antibody test results, 26.9% of UK clinics 
and 41.7% of non-UK clinics stated they would exclude an IgG positive donor 
after quarantine, if previously negative (Table 3.2g). Similarly, if the IgG 
antibody titre had increased after quarantine, only 3.8% of UK and 16.7% of 
non-UK clinics reported they would exclude a donor on this basis (Table 
3.2h). The presence of IgM antibodies is indicative of an active infection and 
the guidelines are clear about how donors found to be CMV IgM positive 
should be managed. Despite this, only 76.0% of UK clinics stated they would 
exclude a donor if found to be IgM positive before quarantine (Table 3.2i) and 
71.4% if positive after quarantine (Table 3.2j). In comparison 90.9% and 
91.7% of non-UK clinics reported they would exclude in these scenarios, 
respectively. Despite not being recommended by the current guidelines, 
26.5% of UK and 13.3% of non-UK clinics stated they used PCR to detect 
CMV (Table 3.2k). The majority of clinics used blood as the source for the 
test, however one clinic from each category reported to use semen (Table 
3.2j). Approximately half of both UK and non-UK clinics stated they would 
exclude a donor if CMV DNA were present (Table 3.2n). Clinics were also 
asked if they performed viral culture as a test for CMV infection, in line with 
the current ASRM guidelines (American Society for Reproductive Medicine, 
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Table 3.2: How do clinics perform CMV screening in sperm donors?
Item UK (n=34) Non-UK (n=15)
Quarantine
a. Quarantine samples for 
recommended period?
70.5% (n=24/34) 80.0% (n=12/15)
b. Time of 
Screening
Both: 81.3% (n=26/32) 73.3% (n=11/15)
Before only: 12.5% (n=4/32) 13.3% (n=1/15)
After only: 3.1% (n=1/32) 6.7% (n=2/15)
c. Serum Antibody Screening: 94.1% (n=32) 100.0% (n=15/15)
d. Type of 
antibody?
Both: 78.1% (n=25/32) 86.7% (n=13/15)
IgG only: 15.6% (n=5/32) 13.3% (n=2/15)
IgM only: 0.0% 0.0%
e. Exclude all positive donors 
(IgG or IgM)?
3.1% (n=1/32) 0.0%
f. Exclude IgG at start of 
quarantine?
3.3% (n=1/30) 0.0%
g. Exclude IgG at end of 
quarantine if originally 
negative?
26.9% (n=7/26) 41.7% (n=5/12)
h. Exclude IgG at end of 
quarantine if the antibody titre 
has increased?
3.8% (n=1/26) 16.7% (n=2/12)
i. Exclude IgM at start of 
quarantine period?
76.0% (n=19/25) 90.9% (n=10/11)
j. Exclude IgM at end of 
quarantine, if previously 
negative?
71.4% (n=15/21) 91.7% (n=11/12)
k. PCR: 26.5% (n=9) 13.3% (n=2/15)
l. Specimen used Blood: 88.9% (n=8/9) 50.0% (n=1/2)
Semen: 11.1% (n=1/9) 50.0% (n=1/2)
m. Type of PCR Quantitative: 33.3% (n=3/9) 0.0% (n=1/2)
Qualitative: 11.1% (n=1/9) 50.0% (n=1/2)
n. Exclude if CMV DNA is 
present?
55.6% (n=5/9) 50.0% (n=1/2)
o. Viral Culture: 0.0% 6.7% (n=1/15)
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Figure 3.1: A flowchart summarising the screening process for CMV in sperm 
donors and those undergoing donor insemination. Briefly, current guidelines state all 
sperm donors should be screened for CMV by serum antibody testing. IgM positive 
donors should be deferred from donating but seronegative and IgG positive donors 
are allowed to be used, dependent upon continued IgM negative results after a 
quarantine period. Donors and recipients should be matched based on their CMV 
serostatus and CMV IgG positive donors should only be given to seropositive 
recipients. Shapes with dashed lines indicate procedures that are recommended but 
not always carried out. Green boxes and lines indicate procedures being carried out 
in clinics that are not current recommended. NB. Whilst no clinics actively reported 
offering IgM positive donors to recipients, this can be inferred by the lack of IgM 
testing in some clinics, the lack of exclusion of IgM positive donors after quarantine 
and the lack of sero-matching.
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2013). No UK clinics reported to use this method, in comparison to one non-
UK clinic (6.7%) (Table 3.2o). A graph summarising all of the types of 
exclusion criteria and the percentage of clinics following these criteria is 
shown in Figure 3.2.
3.4.2 How is CMV screening managed when sperm is imported from 
other centres? 
Due to most clinics not being able to recruit enough donors to meet the 
demand in the UK (Hamilton et al., 2008), the majority of clinics that 
answered the survey also bought sperm from other centres. Fortunately, this 
survey has found that most UK clinics operate the same policy regarding 
CMV screening when buying sperm from other centres, as when recruiting 
and screening within their own clinics (Table 3.3). 92.3% of UK clinics 
reported to check that the donor had been screened for CMV in comparison 
to only 60.0% of non-UK clinics. However, only 23.1% of UK clinics stated 
that they checked how the screening had been performed, with a similar 
percentage of non-UK clinics stating the same. The majority (>80%) of both 
UK and non-UK clinics checked that the donors had been quarantined for the 
recommended time and >70% requested an official certificate. Analysis of the 
free-text responses in this section revealed that some clinics experienced 
problems when buying sperm from other centres, as not all non-UK based 
clinics have to screen for CMV. This means they have to request the 
additional information, which is sometimes difficult to obtain.
3.4.3 How is CMV infection in sperm donors managed in the fertility 
clinic?
In order to seromatch donors and recipients, as recommended in the current 
guidelines, the female recipient also has to be screened for CMV. According 
to the survey, the majority of UK clinics (88.6%) did screen the female 
recipient, in comparison to only 41.6% of non-UK clinics (Table 3.4a). 
Interestingly, 20.5% of UK and 29.1% of non-UK clinics also screened the 
male partner, if there was one (Table 3.4b). 
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Figure 3.2: The percentage of clinics in the UK and non-UK stating they would 
exclude a sperm donor with test results indicating presence of CMV infection. Not all 
of the parameters included in this graph are criteria outlined in the current 
guidelines, but are all potential results from the current tests being performed in 
clinics that could indicate a current infection of CMV in a sperm donor. All of these 
test results could be associated with the presence of CMV in semen.
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Table 3.3: How do clinics manage the documentation of CMV screening when 
buying from other centres?
Table 3.4: Management of CMV screening in clinics that provide treatment with 
donor sperm (including clinics that recruit their own donors and those that buy from 
other centres). *Please note, total numbers are based on the number of clinics 
screening either the donor or patient for clinics that recruit (UK n=33, non-UK n=9) 
and the number of clinics screening the patient only for clinics that do not recruit (UK 
n=7, non-UK n =4).
Item UK (n=44) Non-UK (n=24)
Recruit
(n=34)
Buy
sperm  
(n=10)
Average Recruit
(n=17)
Buy 
sperm 
(n=7)
Average
a. Clinics 
screening female 
patient for CMV?
94.1%
(n=32)
70.0%
(n=7)
88.6% 35.3%
(n=6)
57.1%
(n=4)
41.6%
b. Clinics 
screening male 
partner (if there 
is one)?
20.6%
(n=7)
20.0%
(n=2)
20.5% 29.4%
(n=5)
28.6%
(n=2)
29.1%
c. Clinics that 
seromatch CMV 
status of donor to 
recipient?*
93.9%
(n=31)
85.7%
(n=6)
92.5% 44.4%
(n=4)
75.0%
(n=3)
53.8%
d. Clinics that 
claim CMV 
screening causes 
donor supply 
problem?*
72.7%
(n=24)
71.4%
(n=5)
72.5% 44.4%
(n=4)
25.0%
(n=1)
38.5%
e. Clinics that 
inform recipient 
of theoretical risk 
of CMV 
transmission?*
75.8% 
(n=25)
85.7% 
(n=6)
77.5% 44.4% 
(n=4)
100.0%
(n=4)
61.5%
Item UK (n=39) Non-UK  (n=20)
Check they have been 
screened?
92.3% (n=36) 60.0% (n=12)
Check how they have been 
screened?
23.1% (n=9) 30.0% (n=6)
Check they have been 
quarantined for recommended 
time?
84.6% (n=33) 80.0% (n=16)
Request official copy of 
certificate?
76.9% (n=30) 70.0% (n=14)
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UK clinics reported to seromatch donors and recipients based on CMV status 
more often than non-UK clinics, 92.5% and 53.8%, respectively (Table 3.4c). 
When asked to provide details on how seromatching was conducted, most 
provided a response that falls in line with current screening guidelines.  
However, clinics did report deviating from these guidelines by offering CMV 
positive donors to CMV negative recipients in instances such as a shortage 
of CMV negative donors or ‘difficult to obtain phenotype or ethnic origin’. 
When asked if they thought screening for CMV was contributing to a donor 
supply problem, only 38.5% of non-UK clinics reported that this was the 
case, in comparison to 72.5% of UK clinics (Table 3.4d). When asked to 
provide reasons for this, the majority of clinics reported that having to 
seromatch causes limited availability and choice for CMV negative patients. 
Some clinics felt that they no longer had a problem with sperm donor supply 
as they either had a sufficient pool of CMV negative donors, or the patients 
had sufficient choice from overseas donors. In some instances, relaxing of 
the guidelines with regards to CMV seromatching had relieved the problem.
When a seropositive recipient was offered sperm from a seropositive donor, 
the majority of clinics in the UK (77.5%) and 61.5% of non-UK clinics 
reported informing patients of the theoretical risk of infection (Table 3.4e). 
When clinics were asked to explain what the response was from recipients, 
some clinics stated that patients were generally not concerned, whilst others
stated that CMV status was a big concern for patients as they were worried 
about the risk of transmission. However, the majority of clinics stated that in 
most cases, once the risks had been explained as ‘small and theoretical’, 
most patients would decide to then use a positive donor, if it provided the 
best match. Some clinics failed to see the relevance of the question as they 
reported to only use CMV positive sperm on CMV positive recipients, failing 
to acknowledge the risk of re-infection.
3.4.4 What are the views of clinics regarding CMV screening? 
Analysis of all the free-text responses provided throughout the survey 
identified three key themes surrounding the process of screening and 
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Table 3.5: Details of individual themes identified in the thematic analysis and examples of representative comments made by clinics.
Themes (sub-themes) Comments
(a) Relevance of CMV 
seromatching
(a1) Risk of transmission We screen all donors for CMV IgG and IgM but we do not screen recipients or their 
partners as we do not match based on CMV status. This was a fairly recent policy 
change (within the last year) based on the very small risk of transmission from a CMV 
IgG positive donor to a CMV IgG negative recipient. This has also had the significant 
benefit of increasing patients’ choice of donors, which was previously very limited for 
CMV IgG negative recipients. [UK clinic]
(a2) External risk factors As CMV is only tested for donor eggs and sperm, I feel it is a pointless test as couples 
for standard IVF neither partner is screened. This causes the patients extra anxiety as 
to why we are testing. CMV is around in the environment and can therefore be 
contracted any time via an outside source and therefore it can be proven whether it is 
from the gametes or not. [UK clinic]
(a3) Partner screening I feel CMV screening is necessary but I do think that we should also test patients 
partners at the treatment stage especially if they are using sperm which the donor has 
had a past infection. [UK clinic]
(a4) Approach to seromatching We continue to do so because of the guidelines. We are uncertain of the clinical 
significance particularly when the couples may be discordant themselves. We 
generally try to match a CMV negative donor with CMV negative recipient but will still 
offer treatment with CMV positive donor if this is all that is suitable/available otherwise 
following discussion with the recipient about the concerns. [UK clinic]
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Themes (sub-themes) Comments
(b) Consequences of CMV 
seromatching
(b1) Availability of donors Sometimes the number of CMV negative donors is reduced so this limits the choice of donors. 
[UK clinic]
(b2) Patient care I think that without sufficient evidence to demonstrate any risk, this should not be a 
requirement. It only serves to reduce availability of donors, cause more anxiety and put more 
financial burden on patients. Individuals can be exposed to all sorts of other potential infections 
and toxins, and unless there is evidence for causing harm, then we need to draw the line. [UK 
clinic]
(b3) Patient concern Of the CMV negative recipients we have discussed using CMV positive donors with, most are 
concerned about risks of transmission, but usually make the choice to continue when they 
understand that those risks are small. [UK clinic]
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Themes (sub-themes) Comments
(c) CMV screening 
methods
(c1) Difference between 
UK/non-UK
The patients obtain sperm from CRYOS/European Sperm Bank and it appears that the UK is 
the only country who worries about it. [UK clinic]
(c2) Value of testing 
methods
IgM screening is not always particularly accurate. We have donors with low level IgM who over 
the space of 6 months are still showing levels of IgM in their blood work. In these cases, we 
have been informed that DNA PCR for CMV is a much more accurate test to determine 
whether or not an infection is current. [UK clinic]
(c3) Inconsistencies We screen for total antibodies, as well as for CMV IgG and IgM. Screening is not the problem, 
interpretation is often an issue when we see a negative IgG and a positive IgM; or a positive 
IgG one time and then negative next screen. [Non-UK clinic]
(c4) Importance of testing I think it is a valuable tool to try to minimise possibility of CMV infection during conception and 
early pregnancy. I do not believe that we should restrict CMV + sperm to treating only CMV+ 
patients, particularly if there is a problem with matching ethnicity. If the patient is counselled to 
the risks and are happy to proceed then I think we should. If a patient has a CMV+ partner and 
is CMV- herself then the risk of infection is the same. [UK clinic]
(c5) Screening standards I believe we screen to the required standard, screening both patients and donors for CMV IgG 
and IgM antibodies. Any donor samples procured during a period of seroconversion would be 
discarded. This has happened once to date. [UK clinic]
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managing CMV infection in sperm donors. The breakdown of the themes and 
representative quotes can be seen in Table 3.5. Briefly, the three major 
themes are (a) the relevance of CMV seromatching, (b) the consequences of 
CMV seromatching and (c) CMV screening methods. The relevance of 
seromatching is questioned on the basis of the theoretical risk of 
transmission, the risk of contracting CMV through external factors and the 
lack of screening of the male partner in non-donor assisted conception. The 
approach an individual clinic takes to CMV seromatching appears to be 
based upon these questions in addition to the consequences of 
seromatching. These include the impact on the availability and choice of 
donors, the effect it has on patient care, such as increasing waiting times, 
and the consequence for patient concern. Finally, when discussing the 
screening methods used, clinics were concerned about the discrepancies 
between UK and non-UK clinics and the problems this causes, the value of 
the current testing methods, and inconsistencies with testing results. 
However, clinics recognised the importance of testing for CMV infection in 
sperm donors and as such, the majority of clinics reported keeping high 
standards for screening that follow the current guidelines. 
3.5 Discussion
This survey has shown that UK clinics are generally following UK screening 
guidelines. However, there are clear discrepancies with the management of 
CMV positive donors, with clinics openly reporting deviating from 
seromatching guidelines, by offering sperm from seropositive donors to 
seronegative recipients, in an attempt to relieve problems of supply. The 
outcomes of this survey provide evidence to show that CMV screening is 
causing problems in fertility clinics and has identified a number of issues, 
which need to be resolved. 
Before discussing the results, it is important to evaluate the survey itself and 
the approach taken. To conduct this study, a pilot version of the survey was 
initially sent to 3 centres and feedback was given on how to improve the 
questions and format, after which amendments were made. A successful 
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response rate of 50.5% was obtained for UK clinics, however more 
responses from the non-UK clinics would have been preferable, to balance 
out numbers. Overseas clinics were approached opportunistically; therefore it 
was unlikely that any more replies would have been received. However, of 
the respondents from non-UK clinics, there is a wide spread across Europe, 
USA and Australia. Results from these clinics are therefore unlikely to be 
biased by any one set of alternative screening guidelines, such as the USA, 
where guidelines for CMV screening are stricter.
The survey itself was well designed with ‘N/A’ and ‘Do not Know” options 
available for most questions. However, there were some issues with the data 
collected. In some instances, rather than choosing the N/A option, some 
clinics would answer ‘No’, when the question was actually not relevant to 
them, potentially affecting the results. This was a particular problem with 
regards to the seromatching question where some clinics chose the ‘No’ 
option, when they should have selected ‘N/A’, as they also stated they did 
not screen for CMV in female recipients. This is one area of the survey 
design that could have been clearer. Similarly, when answering the questions 
regarding how they would interpret screening test results (serology or PCR), 
the answers given were inconsistent. Some data points were missing 
throughout this section as clinics chose not to answer the question, or that 
they did not know. This was not thought to be due to the design of the 
survey. Rather it could have been because the wrong person at the clinic 
was filling out the survey, or they simply did not know as the test was 
performed elsewhere, or that they had never encountered that particular 
situation before. Despite this, the percentage of clinics reporting yes or no to 
a question is still important, regardless of what the other available options 
were. The findings highlight that there are inconsistencies with how tests are 
being performed, or at the very least, the lack of understanding clinics have 
regarding the tests being carried out. 
This survey was successful in showing that the majority of UK clinics follow 
the current guidelines and screen for CMV. Whilst clinics reported to 
recognise the importance of screening, some clinics did question the need to 
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seromatch, due to other environmental exposure risks (Table 3.5a) (Liesnard 
et al., 2001). Whilst there are other potential sources of transmission to a 
pregnant woman, it is known that due to the short time frame of pregnancy, 
the ‘natural’ risk of acquisition of CMV in seronegative women in the USA is 
estimated to be as small as 1% (Colugnati et al., 2007). Therefore, if the risk 
of contracting the virus is small elsewhere, every effort should be taken to 
avoid exposure during donor insemination. A second argument is the 
perceived small risk of vertical transmission, particularly for seropositive 
recipients, where the risk of transmission of the virus is lower than for 
seronegative mothers (Fowler et al., 1992). Currently there is little evidence 
to refute this argument for CMV; however, a case has been reported of 
horizontal transmission of HSV-2 from a sperm donor to a seronegative 
recipient (Moore et al., 1989). No vertical transmission to the fetus was 
reported but infection with HSV-2 still has health complications for the female 
recipient (Moore et al., 1989). Unlike HSV-2, CMV is not generally associated 
with health issues in healthy individuals, however recent evidence suggests a 
link between increased levels of CMV IgG antibodies and increased mortality 
rates in seropositive individuals (Gkrania-Klotsas et al., 2013; Simanek et al., 
2011). Furthermore, infection with CMV is thought to deplete the number of 
naïve CD8+ T lymphocytes, due to repeated reactivation events, resulting in 
an inability for cellular immunity to respond to other infections acquired in old 
age (Almanzar et al., 2005). Given these health consequences associated 
with being CMV seropositive, every step should be taken to prevent 
horizontal transmission of CMV from a seropositive donor to recipient, 
regardless of the risks of vertical transmission. The only way to ensure this 
when following the current guidelines is to screen and seromatch based on 
CMV status.
Fortunately most clinics are conducting CMV screening in sperm donors and 
are doing so using the recommended method of serum antibody testing. 
However, there are limitations with this technique, as it is a retrospective test. 
It is able to detect if a person has previously been infected, but is not able to 
reliably detect current and active infections, due to the immune system taking 
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time to produce antibodies to an infection. Based on the evidence available 
at the time of writing the current guidelines, a combination of both CMV IgG 
and IgM antibodies was felt to be satisfactory in deciding whether to include 
or exclude a donor, with IgM testing highlighting those donors with a recent 
infection, a basis on which they should be excluded. However, this survey 
has shown that 15.6% of UK clinics are only screening donors for IgG 
antibodies (Table 3.2d). Therefore, these clinics are failing to rule out the 
possibility of a current infection, or a seroconversion event, in sperm donors 
prior to their use. This is concerning given the evidence that IgM positivity is 
strongly linked with an active infection, where high titres of infectious virus 
can be found in semen (Bresson et al., 2003). Analysis of the free text 
responses from this section highlighted that some clinics believed IgM testing 
to be unreliable. However, a study investigating the presence of CMV in HIV 
positive men found that the presence of IgM antibodies always correlated 
with the detection of CMV in semen. Conversely, in two instances, where 
CMV was found in semen, IgG tests were found to be negative (Lupton et al., 
2013). This suggests that the presence of IgM antibodies is a better predictor 
for the presence of CMV in semen than IgG alone. 
Whilst IgM positive donors should be excluded based on the potential risk 
they pose, it is thought that IgG positive (IgM negative) donors pose a 
minimal risk, as this combination of antibodies is thought to show a past 
infection only. However, IgG positivity in the absence of a positive IgM result 
does not always rule out an active infection. Multiple studies have found 
detectable CMV by PCR in the semen of IgG positive, IgM negative men 
(Bresson et al., 2003; Mansat et al., 1997; Witz et al., 1999). Also, Lupton et 
al., (2013), found that some IgG tests are unreliable. Men with CMV in their 
semen were initially found to be IgG negative, but upon re-testing with a 
different assay, they were IgG positive. Due to this, it cannot be said that the 
use of a CMV IgG positive, IgM negative donor is completely free of risk, as 
the current testing method is not reliable enough to predict the presence of 
CMV in the semen of a sperm donor. 
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Despite these limitations, serology is currently the most appropriate 
technique to use, based on the evidence available. However, clinics are 
further complicating the interpretation of the risks these results imply, by 
deviating from the current guidelines, as shown in the flowchart in Figure 3.1. 
Only a small percentage of clinics reported they would exclude an IgG 
positive donor after quarantine if they were previously negative, or if the 
antibody titre had increased (Table 3.2g,h). This highlights that the 
importance of IgG antibodies in detecting re-infection or reactivation events is 
clearly being underestimated. In post-transplant patients undergoing a 
secondary infection (re-infection or reactivation), IgG antibody titres 
increased in the absence of IgM antibodies (Dolan et al., 1989). Furthermore, 
infectious CMV was isolated from their urine samples, indicating these 
patients were infectious and therefore able to transmit CMV.
It is likely that clinics are not measuring antibody titre levels, as this is not 
currently recommended, but it is important for clinics to acknowledge 
differences in IgG antibody levels, as a failure to interpret these test results 
appropriately might result in a failure to detect an active infection. A more 
concerning finding is that not all clinics reported that they would exclude an 
IgM positive donor (Table 3.2i,j). As discussed above, IgM positivity is 
strongly linked with shedding of infectious virus (Bresson et al., 2003), and 
therefore poses a risk of transmission. The lack of clarity from clinics on this 
matter is alarming. Free text responses highlighted that clinics felt they were 
performing screening to the highest standards and that if unsure they would 
seek advice from consultant virologists. In addition, some clinics stated they 
could not provide an answer, as they had not encountered that particular 
situation. Regardless of this, the guidelines and the evidence are clear on 
how these tests should be interpreted. 
It is interesting that some clinics report to use PCR to detect CMV in sperm 
donors, either in conjunction with serum antibody testing, or alone. When 
conducting PCR, most clinics reported to use blood as the source for the test 
(Table 3.2l). However, the choice of specimen to use for a test such as this is 
critical due to the phenomenon of compartmentalisation. It has been well 
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documented that some viruses can be present in higher loads in semen than 
blood, a finding which has been widely reported for HIV (Coombs et al., 
1998; Gupta et al., 2000). Currently, there is no evidence to support that this 
is occurring with CMV, however, there is evidence to show men intermittently 
shed Herpesviruses in their semen (Kaspersen et al., 2012). This suggests
that PCR on individual semen samples would be a better method for 
detecting an active infection than tests that use specimens of blood.
The importance of accurate screening for CMV lies in preventing horizontal, 
or vertical transmission of the virus. The current approach to ensuring no 
transmission occurs is to seromatch donors and recipients, if seropositive 
donors need to be used at all (Association of Biomedical Andrologists et al., 
2008). Most clinics do report to follow these guidelines, however clinics also 
report deviating from these guidelines to offer sperm from seropositive 
donors to seronegative recipients. As justification for their decisions, clinics 
cited concerns over availability of donors, patient care and patient concern 
(Table 3.5b). The biggest contributing factor appeared to be the lack of 
availability of donors, with 72.5% of UK clinics reporting this as a problem 
(Table 3.4d). Conversely, only 38.5% of non-UK clinics reported the same, 
which is probably due to the lower percentage of clinics actually conducting 
CMV seromatching. 
The discrepancy in sperm donor supply problem between UK and non-UK 
clinics is only one complication that arises from the different screening 
recommendations. The fact that non-UK clinics do not have to screen for 
CMV is an issue for UK clinics, as it presents difficulties when importing 
sperm from non-UK centres. Most clinics reported that they attempt to uphold 
the UK guidelines when importing donors, but often have difficulties obtaining 
the correct documentation from certain clinics due to differences in screening 
procedures. The Cryos International Sperm Bank list on their website that 
CMV screening is only carried out when the country the sperm is being 
shipped too requires it, such as the UK (Cryos International Sperm Bank, 
2016). This presents a further problem clinics are experiencing in relation to 
CMV screening.
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The choice of available donors, in relation to ethnicity, was also raised as a 
concern. Between 2009-2013, there were only 90 registered donors with an 
Asian ethnicity (HFEA, 2013b). As the prevalence of CMV is so high, this 
would clearly limit the number of available donors for seronegative recipients 
in this ethnic group. Whilst clinics recognise the potential risk of offering 
sperm from CMV positive sperm donors to CMV negative women and inform 
patients of the theoretical risk, this practice is not recommended in the 
current guidelines, as it is not known if it is safe. In fact, the guidelines clearly 
state that the use of “CMV IgG positive (IgM negative) donors may be 
recruited but their use should be limited to CMV IgG positive recipients” 
(Association of Biomedical Andrologists et al., 2008).
Even though seromatching donors and recipients based on CMV positivity is 
suggested as an option, it is not without risk, as an IgG positive (IgM 
negative) result does not always rule out the presence of CMV in semen. 
However, there appeared to be a lack of awareness regarding this. When 
clinics were asked if they informed patients of the risk when using 
seropositive sperm, some replied that “seropositive sperm was used for 
seropositive recipients only”. This is of concern as prior immunity to CMV 
only infers partial protection. Re-infection with a different strain (Boppana et 
al., 2001), or multiple strains (Yamamoto et al., 2010) can still lead to 
intrauterine transmission and symptomatic congenital infection. Moreover, in 
the USA, it is estimated that three quarters of congenital CMV infections are 
attributable to re-infection or reactivation events, as opposed to only one 
quarter of primary infections (Wang et al., 2011c). Therefore, the risk of re-
infections and reactivation events in seropositive recipients of donor sperm 
should be of equal concern to clinicians as is the risk of primary infection in 
seronegative women.
It is clear to understand the complex decision a clinic faces in choosing to 
deviate from the guidelines. Clinics do recognise the importance of screening 
and stated on many occasions that they felt they were screening to the 
highest standards and consulting professional virologists if required. 
However, the need for screening is being questioned and although testing is 
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being carried out, the interpretation of test results varies significantly. An 
overall lack of understanding regarding the relationship between CMV 
infection and the risk it poses when using donor sperm is contributing to 
these problems. Better guidelines need to be written that are clearer and are 
able to give clinics concise, well-informed direction on the use of CMV 
positive donors in donor insemination programmes. To do this, better testing 
methods need to be used, to rule out the presence of CMV in an individual 
semen sample, improving safety and increasing the availability of sperm 
donors, which is the reason individual practice is becoming inconsistent. 
Before any improvements can be made to the current guidelines in order to 
alleviate these problems, more evidence needs to be gathered on which to 
base new decisions. The remaining chapters of this thesis will focus on 
increasing the understanding of the relationship between CMV and sperm, so 
as to provide a better evidence base on which to make informed decisions 
regarding the use of CMV positive sperm donors in fertility clinics.
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Chapter 4
Development of a system to culture 
and quantify CMV in vitro
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4.1 Introduction
It is clear from Chapter 3 that the management of sperm donors with CMV 
infection in fertility clinics around the world, but particularly the UK, is causing 
problems. Most of these issues arise from the blanket recommendation that 
CMV seropositive donors should not be used for seronegative recipients, 
given that they may pose a risk of infection (Association of Biomedical 
Andrologists et al., 2008). The lack of evidence to support or refute this 
statement is causing issues in clinics with regards to making clinical 
judgements on the safety of practice using seropositive donors. Better 
evidence surrounding the relationship between CMV and sperm is needed 
before changes to the guidelines can be made, or before the current 
guidelines can be fully accepted as the most appropriate method of 
screening for CMV. 
There is a need to directly investigate how CMV and sperm interact, rather 
than just investigate its presence in semen (Bresson et al., 2003; Kapranos 
et al., 2003; Mansat et al., 1997) and how that correlates with fertility 
disorders (Naumenko et al., 2014). Throughout this thesis, laboratory grown 
CMV has been used to directly examine sperm-CMV interactions, in order to 
provide better evidence, which clinics can use in making judgements 
regarding CMV screening and the management of CMV positive sperm 
donors in the UK. To do this, techniques to grow and quantify CMV in the 
laboratory had to be established and this chapter will detail how the methods 
employed to do this were developed. 
4.2 Experimental rationale
For the majority of viruses, permissive cells lines are required in order to 
grow them in the laboratory. Unlike bacteria, which are able to grow on 
nutrient-supplemented media, viruses are obligate intracellular organisms 
and can only be cultured in permissive vectors, or cell lines. These cell lines 
often differ from the cell type a virus would usually infect in vivo and for CMV, 
fibroblast cell lines are routinely used (Dolan et al., 2004). The cell line 
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chosen to use in this thesis are MRC-5, human lung fibroblast cells (Jacobs 
et al., 1970). This cell line has been used in clinics for diagnosis of CMV 
using patient samples and has been shown to be more sensitive to infection 
than other cell lines, such as WI-38 (Gregory & Menegus, 1983). 
CMV was first isolated in vitro in 1956 from the liver biopsy of a child, now 
known as the Davis strain (Weller et al., 1957). Subsequently, multiple 
strains of CMV, from a variety of sources have been cultured in vitro, 
including CMV AD169, which was cultured from the adenoids of a 7-year old 
female (Rowe et al., 1956) and the Towne strain, isolated as a potential 
vaccine target (Plotkin et al., 1975). When comparing these high passage 
laboratory strains with low passage wild-type strains, such as Merlin, (Dolan 
et al., 2004), it is apparent that these older strains of CMV have acquired 
multiple mutations and alterations to the genome that are a direct result of 
multiple passages in culture. It is therefore considered that that no laboratory 
strain of CMV can be considered genetically intact, although low passage 
strains have a higher genetic similarity to wild-type CMV than high passage 
strains. Despite this, CMV AD169 was the strain of virus used for the majority 
of experiments throughout this thesis, given that this strain is more adapted 
to growth in fibroblast cells. A single round of replication takes less than 96 
hours and distinctive plaques are formed within 7 days, a much shorter time 
frame than low passage strains of CMV (Prichard et al., 2001). However, in 
Chapter 6, a strain of Merlin, provided by Dr Matthew Reeves at UCL, was 
also used to compare effects on sperm function between a laboratory strain 
and a wild-type strain of CMV.
Once CMV was grown, it was essential to quantify the amount of virus, for 
the design of experiments, and to assess the success of some experiments. 
An effective quantitative PCR (qPCR) assay for CMV has been developed 
and is routinely used in clinical virology laboratories to diagnose infection in 
post-transplant patients (Mattes et al., 2004). Collaboration with the research 
group, at University College London (UCL), involved with pioneering this 
technique for CMV detection provided access to this as a method for 
quantification of CMV. 
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A common virology technique, known as a plaque assay, has been utilised 
throughout this thesis to determine the titre of infectious virus present in 
laboratory grown stocks of CMV. This technique was first described in 1969 
for herpes simplex virus (Wentworth & French, 1969) and utilises the 
infection of a monolayer of cells with the addition of an overlay medium. The 
addition of an overlay medium is the unique feature of this assay as it 
prevents viral dissemination across the surface of the monolayer, creating 
localised areas of infection, which can be quantified. Both agarose and 
methyl cellulose have been reported to be used in a plaque assay overlay 
medium for CMV (Plummer & Benyesh-Melnick, 1964; Wentworth & French, 
1970). This technique relies on the formation of discrete and distinguishable 
foci of viral replication and/or cell loss, which can be counted, and therefore 
the initial viral concentration can be calculated (Appendix V).  
4.2.1 Specific aim(s):
1. Grow CMV (AD169) in vitro and establish a bank of viral stock to use 
in experiments throughout this thesis.
2. Develop a system for quantifying the amount of infectious virus 
(plaque forming units) in virus stocks and semen samples.
3. Develop a qPCR assay for determining total viral load in both virus 
stocks and semen samples.
4.3 Materials and Methods
This section will detail the experimental conditions for the characterisation of 
MRC-5 cells, prior to the growth of CMV (AD169) and methods for 
quantification of the virus, via two different methods, qPCR and the plaque 
assay.
4.3.1 Growth of CMV (AD169) on MRC-5 cells
4.3.1.1 Characterisation of MRC-5 cells
Before beginning to grow CMV, MRC-5 cells were grown as outlined in
Section 2.4 and characterised as fibroblast cells. These cells were also 
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tested to ensure they were both CMV and Mycoplasma negative, as 
described below.
MRC-5 cells were grown until confluent in a T25 tissue culture flask and RNA 
was extracted as outlined in Section 2.6.1. The concentration of RNA was 
determined and reverse transcribed into DNA as outlined in Section 2.6.2. A 
2μl aliquot of cDNA was amplified with primers specific to a 307bp region of 
the Thy1 gene, a gene present in all fibroblast cells (Moore-Morris et al., 
2014), with a 2x Promega PCR master mix. In addition, detection of GAPDH 
and a no reverse transcriptase control were carried out as positive and 
negative controls (using 2μl of cDNA). Specific components and cycling 
temperatures of each reaction are outlined in Section 2.6.5.
The CMV status of MRC-5 cells was determined by detecting a 149bp region
of the glycoprotein B gene (gB), as outlined in Section 2.6.5. MRC-5 cells 
were grown until 100% confluent in a T75 culture flask. The media was 
removed and kept for CMV analysis and DNA from the MRC-5 cells 
extracted as outlined in Section 2.6.3. 
A 0.3μl aliquot of MRC-5 DNA (200ng/μl), a 0.6μl aliquot of MRC-5 cell lysate
(190ng/μl) and a 0.6μl aliquot of spent media (concentration not determined) 
were amplified with gB1 and gB2 primers and a 2x Promega PCR master 
mix. 0.6μl of CMV viral DNA (6.6ng/μl) was used a positive control, along 
with GAPDH amplification. PCR components and conditions are outlined in 
Section 2.6.5.
Mycoplasma testing was performed using the E-Z PCR Mycoplasma test kit 
(Geneflow, Staffordshire, UK). Briefly, 1ml spent cell culture media from 
confluent MRC-5 cells was centrifuged briefly at 250xg. The supernatant was 
transferred to a fresh sterile tube and centrifuged at 15,000xg for 10 minutes. 
The supernatant was decanted and the pellet re-suspended in 50μl of Buffer 
Solution. The sample was incubated at 95°C for 3 minutes and stored at -
20°C before analysis. The PCR reaction was carried out in a total volume of 
50μl, constituting 35μl H2O, 10μl of the Reaction Mix and 5μl of the test 
sample. The samples were cycled in a Sensoquest Labcycler for 30 seconds 
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at 94°C, then cycled 35 times for 30 seconds at 94°C, 120 seconds at 60°C 
and 60 seconds at 72°C. Finally, the reaction was incubated for 30 seconds 
at 94°C, 120 seconds at 60°C and 5 minutes at 72°C. 
All PCR reactions in this section were resolved on a 1.5% (w/v) agarose gel 
(GeneFlow, Staffordshire, UK) at 80V for 45 minutes, using a High-Current 
Power Supply PowerPac (BioRad, Hertfordshire, UK). 
4.3.1.2 Propagation of CMV using MRC-5 cells 
MRC-5 cells were grown in EMEM until sub-confluent, approximately 80% 
coverage. The media was removed from two flasks and replaced with 5 ml of 
serum-free EMEM. One flask was infected with 200μl of virus stock and 
200μl more serum-free EMEM added to the mock-infected flask. Both flasks 
were incubated at 37°C for 1 hour with gentle manual rocking from side to 
side every 20 minutes. After 1 hour, the flasks were replenished with 10 ml of 
‘maintenance medium’, containing normal growth supplements and 5% (v/v) 
FCS. Flasks were incubated at 37°C until the infection process was 
complete.
The course of the viral infection was followed and when 60% of cells were 
exhibiting the typical cytopathic effect (CPE) of CMV, virus was harvested. 
Briefly, supernatant from both infected and mock-infected flasks was 
removed and centrifuged at 200g for 10 minutes to remove cellular debris. 
The supernatants were decanted and spread into 1ml aliquots and stored at  
-80°C. After the first viral harvesting, virus was harvested every 48 hours in 
the same manner until all the cells were infected and dying. At this stage, the 
flasks were frozen at -80°C and thawed, twice, to allow the cells to lyse. After 
the second freeze-thaw cycle, the cells were scraped from the surface of the 
flask with a cell scraper. The supernatant was then collected and treated in 
the same manner as previous harvestings and divided into 1ml aliquots. 
Growth of CMV was confirmed by PCR analysis to determine the presence of 
a 200bp region of the CMV gB gene. DNA was extracted from MRC-5 cell 
spent media from both cells infected with CMV and mock-infected cells via 
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the protocol outlined in Section 2.6.3. 2μl of DNA was amplified with gBF and 
gBR primers and MyTaq™ HS Mix, using the components and conditions 
outlined in Section 2.6.5. 2μl of CMV viral DNA was used as a positive 
control, and 2μl of H2O used as a negative control. The PCR reaction was 
resolved on a 1.5% (w/v) agarose gel at 80V for 45 minutes. 
4.3.2 Quantification of infectious CMV via plaque assays
General details of how the plaque assay is performed can be found in 
Section 2.4.1. In this chapter, the plaque assay was performed to determine 
the infectious titre of virus stocks (in Chapter 5, the plaque assay is used in a 
different manner). The specific details of how the plaque assays performed in 
this chapter were carried out are outlined below. 
Viral stocks were diluted 10-fold until a dilution of 10-6 was reached by adding 
100μl of virus stock to 900μl of serum-free EMEM. A 200μl aliquot of each 
dilution was added in triplicate to confluent MRC-5 cells in 24-well plates. 
The plates were incubated and stained as outlined in Section 2.4.1. A worked 
example of how the viral titre in PFU/ml was calculated is outlined in 
Appendix V.
4.3.3 Development of a qPCR assay to quantify viral load
4.3.3.1 Construction of glycoprotein B plasmid
CMV glycoprotein B, 2720bp, was amplified using primers containing HindIII 
(AAGCCT) and XbaI (TCTAGA) restriction sites (Table 2.2) (Figure 4.1a) 
(Temperton et al., 2003). The PCR reaction and cycling conditions were 
performed as outlined in Section 2.6.5.
After resolving the PCR reaction on a 1% (w/v) agarose gel at 80V for 60 
minutes, the 2.7kB band was extracted using a QIEX II gel extraction kit 
(Qiagen, Manchester, UK).  To create sticky ends for ligating into a vector 
with corresponding restriction sites to the ones engineered into the 2.7kB 
construct, 14μl of purified DNA was digested with 0.3μl of HindIII (20U/μl) 
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Figure 4.1: Construction of the gB-pRcRSV plasmid was carried out by amplifying 
the 2.7kB glycoprotein B gene (panel a) with flanking primers gBA and gBB and 
introducing corresponding HindIII and XbaI sites. Panel (b) shows the final gB-
pRcRSV product, constructed by ligation of the amplified gB gene into a linearised 
5.3kB pRcRSV plasmid backbone.
a
b
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and XbaI (20U/μl) (New England Biolabs, Ipswich, UK) in a 20μl total reaction 
volume containing 2μl NEBuffer 2 (10X) (New England Biolabs, Ipswich, UK) 
and 2μl BSA (1mg/ml) (New England Biolabs, Ipswich, UK). The reaction 
was incubated at 37°C for 60 minutes and resolved on a 1% (w/v) agarose 
gel at 80V for 60 minutes before extracting the band from the gel using a 
QIEX II gel extraction kit.
A 5.3kB plasmid, pRcRSV, containing a β-lactam ampicillin resistance gene, 
and a multiple cloning site was digested with HindIII and XbaI. Briefly, a 1μl
aliquot of pRcRSV (2.5μg/μl) was digested with 0.3μl of each restriction 
enzyme (20U/μl) in a total reaction volume of 20μl, containing 2μl NEBuffer 2 
(10x) and 2μl BSA. The reaction was incubated at 37°C for 60 minutes 
before adding 1μl of antartic phosphatase (5U/μl) (New England Biolabs, 
Ipswich, UK) and incubating for a further 15 minutes. The reaction was
resolved on a 1% (w/v) gel at 80V for 60 minutes before the 5.3kB band 
corresponding to the linear plasmid backbone was extracted using a QIEX II 
gel extraction kit. 
To perform the ligation step, 9μl of digested insert (24ng/μl) was added to 1μl 
of linear plasmid (25ng/μl) backbone in a total reaction volume of 20μl, 
containing 2μl T4 ligase buffer (New England Biolabs, Ipswich, UK), 1μl T4 
ligase (400U/μl) (New England Biolabs, Ipswich, UK) and 7μl nuclease free 
water. The reaction was incubated overnight at 16°C. After ligation, 5μl of 
each ligation reaction was transformed into 45μl competent DH5α cells, 
along with 5μl digested vector, as a negative control. The transformation was 
placed on ice for 30 minutes then heat shocked at 42°C for 90 seconds and 
placed back on ice for 90 seconds. In order for the cells to recover, 100μl LB 
was added and incubated at 37°C for 60 minutes. Transformed cells were 
plated onto agar plates containing ampicillin (200μg/ml) and incubated 
overnight at 37°C.
Colonies were picked using a sterile tip and inoculated in 5ml LB and 
incubated overnight at 37°C. The following day, plasmid was extracted from 
the inoculated colonies, using a Qiagen QIAprep spin miniprep kit.  
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Clones were screened for the presence of the gB insert by digesting 2μl of 
extracted plasmid with 0.2μl of each HindIII and XbaI in a total reaction 
volume of 20μl for 60 minutes at 37°C. Restriction digests were resolved on a 
1% (w/v) agarose gel at 80V for 60 minutes. Plasmids exhibiting two bands 
corresponding to a 2.7kB insert and the 5.3kB plasmid backbone (Figure 
4.1b) were sent for sequencing. Those clones exhibiting the AD169 
(BK000394) glycoprotein B sequence were considered successfully ligated 
plasmids and one was chosen for future qPCR work. The yield of plasmid 
recovered from the miniprep protocol was 295ng/μl, as determined by a 
nanophotometer. To increase the amount of plasmid available to work with, a 
Qiagen MaxiPrep kit was used to isolate plasmid from 100ml of competent 
DH5α cells, in comparison to 5ml used for the miniprep protocol. This 
increased the yield significantly, to 3935ng/μl.
The plasmid copy number was determined using the following equation from 
the Integrated DNA Technologies website (Integrated DNA Technologies, 
2013).
Number of copies= amount of DNA (ng/μl)*6.022x1023/bp*660*1x109
6.022x1023=Avogadro’s Constant-used to determine the number of 
molecules of the DNA template per gram.
660=average weight of a base pair in Daltons.
1x109=used to convert the number of copies of template into ng.
4.3.3.2 qPCR assay development
The components and cycling conditions of the qPCR assay are as outlined in 
Section 2.6.6. The primer concentrations were optimised to 125nM (qgBF) 
and 250nM (qgBR) by titrating across a 1000nM-125nM concentration range. 
The combination of primer concentrations with the earliest CT, highest ΔRn 
and latest CT in the corresponding no template control (NTC) were chosen as 
the most optimal.  
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To construct the standard curve, a 10-fold dilution series of the plasmid gB-
pRcRSV was performed. Given that the plasmid stock had 4.6x1011 copies/μl 
(3935ng/μl) this was initially diluted to 900ng/μl in sterile H2O, to obtain a 
copy number of 1x1011. A starting copy number of 109 for the 10-fold dilution 
was found to be most optimal as in higher concentrations non-specific bands 
were detected by conventional end-point PCR, due to the high abundance of 
DNA present in the reaction. For each standard curve, a plasmid copy 
number range from 101 to 109 copies was established by transferring 10μl of 
each concentration into 90μl sterile H2O until the desired dilution was 
reached. In a 20μl total reaction volume, 2.5μl of each plasmid concentration 
was combined, in triplicate, with 2.5μl qgBF, 2.5μl qgBR, 2.5μl gB3 and 10μl 
master mix. For the NTC, 2.5μl of H2O was added, instead of the plasmid. 
The reaction was then cycled as outlined in Section 2.6.6. Replicates that 
had an undetermined result were eliminated from analysis and not included 
in the construction of the standard curve. 
Once the standard curve was constructed, the ability of the assay to 
accurately detect samples was measured. A standard curve was set up in 
the manner outlined above and 20 DNA samples were analysed for the 
presence of CMV. 2.5μl of each sample was added instead of 2.5μl of 
plasmid and the reaction cycled in the same manner as outlined above. 
Aliquots of the same 20 samples were analysed by the validated assay at 
UCL for direct comparison. 
4.4 Results
4.4.1 Growth of CMV (AD169) on MRC-5 cells
4.4.1.1 Characterisation of MRC-5 cells
MRC-5 cells were successfully grown and characterised as fibroblast cells by 
the expression of Thy1, a fibroblast specific gene (Moore-Morris et al., 2014). 
RNA was extracted from MRC-5 cells and reverse transcribed into cDNA. 
Expression of Thy1 was analysed by PCR and a band of 307bp (Figure 4.2a) 
was amplified (Lane 2), showing that the MRC-5 grown cells express Thy1 
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Figure 4.2: Characterisation of MRC-5 cells as a fibroblast cell was performed by 
detection of the fibroblast specific gene, Thy1 (Panel a). A 200bp band 
corresponding to the amplification of the housekeeping gene, GAPDH, was used as 
a positive control for RNA extraction and cDNA synthesis (Lane 1). Lane 2 displays 
a 300bp band specific to the Thy1 gene and Lane 3 is a no reverse transcriptase 
(RT) control. The absence of a band in the no RT control confirms the absence of 
genomic DNA contamination. Panel (b) shows the characterisation of MRC-5 cells 
as CMV negative by PCR amplification of a 149bp region of the glycoprotein B gene 
(gB). A 200bp band corresponding to the amplification of the housekeeping gene, 
GAPDH, was used as a positive control (Lane 1). CMV (AD169) DNA was used a 
positive control (Lane 2). MRC-5 DNA (Lane 3), cell lysate (Lane 4) and spent 
media (Lane 5) were all negative for the presence of CMV gB. Both reactions were 
resolved on a 1.5% (w/v) agarose gel and calibrated with 10μl of Norgen DNA 
LowRanger ladder.
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and are therefore fibroblast cells and susceptible to infection by CMV AD169. 
The presence of a 200bp band in Lane 1, corresponding to GAPDH, a 
constitutively expressed housekeeping gene, confirms the successful 
extraction of RNA and cDNA synthesis. No band corresponding to GAPDH 
was observed in the no reverse transcriptase control (Lane 3), ruling out 
genomic DNA contamination, confirming the presence of Thy1 is due to 
expression, as opposed to the presence of the gene alone.
Prior to growing CMV, it was important to establish that MRC-5 cells were not 
previously infected by CMV and potentially producing a different strain. To be 
confident that any virus stock produced was homogenously AD169, cells 
were analysed for the presence of a 149bp region of the glycoprotein B gene. 
DNA extracted from MRC-5 cells, along with cell lysate and spent media 
were amplified by PCR (Figure 4.2b). CMV (AD169) DNA purchased from 
NCPV was used as a positive control, to ensure the primers gB1 and gB2 
amplified the correct region (Lane 2). Amplification of GAPDH from the 
extracted DNA was used as a control for the successful extraction of DNA 
from the cells (Lane 1). No detection of CMV glycoprotein B was detected in 
any of the MRC-5 samples in comparison to the positive control (Lanes 3-5), 
confirming that MRC-5 cells grown in culture are CMV negative. The cells 
were also tested for the presence of Mycoplasma and were confirmed as 
negative (Appendix VI). 
4.4.1.2 Propagation of CMV using MRC-5 cells 
Sub-confluent MRC-5 cells were infected with an unknown titre of virus and 
the process of infection observed until the first signs of CMV CPE were 
apparent (Figure 4.3b), in comparison to a mock-infected flask (Figure 4.3a). 
Early signs of CMV infection present as dark spots in the cells, representing 
formation of inclusion bodies, which are areas of replicating virus in the 
nuclei of the cell (Andrade et al., 2004). As the infection progresses, the 
accumulation of virus inside the cells causes them to become swollen and 
eventually large areas of the monolayer become devoid of cells, indicating 
the beginning of cell death (Figure 4.3c). 
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Figure 4.3: The effect of CMV on MRC-5 cells can be seen in panels b-d, in 
comparison to panel (a), which shows the normal appearance of uninfected MRC-5 
cells. Panel (b) shows early signs of CMV infection, with the black circles identifying 
patches of MRC-5 cells showing typical signs of infection, with areas of swollen and 
darkened cells. Panel (c) shows that as the infection progresses, cells become more 
swollen due to intracellular viral replication and areas of cell loss start to appear. 
Finally, panel (d) shows that ultimately the majority of cells become infected and the 
cell monolayer becomes depleted. All images were taken on an inverted Olympus 
CKX41 microscope on a 10X objective. Scale bar = 100μm
100μM
100μM
100μM
100μM
a b
c d
100μM
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Once 60% of the monolayer was exhibiting typical CMV CPE, the first 
harvest of virus was taken. Subsequently, virus was harvested every 48 
hours until the majority of cells were showing signs of infection (Figure 4.3d). 
At this point, a final harvest of virus was taken and the cells lysed to release 
intracellular virus. Typically, 12ml of virus stock was stored per harvest.  To 
confirm the presence and therefore successful growth of CMV, DNA was 
extracted from the spent media of MRC-5 cells infected with CMV and mock-
infected cells and analysed by PCR analysis for the presence of CMV 
glycoprotein B gene (Figure 4.4). CMV (AD169) DNA purchased from NCPV 
was used as a positive control and H2O used as a negative control. The 
presence of a 200bp band corresponding to the region of the glycoprotein B 
gene amplified by primers gBF and gBR was present in both the positive 
control (Lane 1) and CMV-infected spent media (Lane 2). No band was 
present in the mock-infected spent media (Lane 3) and the negative control 
(Lane 4). These results confirm the growth of CMV in MRC-5 human lung 
fibroblast cells.
4.4.2 Quantification of infectious CMV via plaque assays
For each stock of virus used in the experiments throughout this thesis, the 
number of infectious viral particles, the ‘plaque forming units’ (PFU) per ml, 
was determined using a plaque assay. This was used in conjunction with the 
total viral load, determined by qPCR, which is detailed in Section 4.4.3. After 
incubating MRC-5 cells with a serial dilution of virus stock for 1-2 weeks, 
various stages of plaque formation were observed. If the optimal dilution was 
reached, distinct areas of swollen and deeply stained cells, characteristic of 
CMV CPE were visualised (Figure 4.5a) . With the larger plaques, cell loss 
can be observed in the central area of the plaque, characteristic of what has 
previously been reported for CMV plaque assays. These changes can be 
seen clearly when compared to a mock-infected layer of cells (Figure 4.5b). If 
the dilution was too low, these plaques merge together (Figure 4.5c) making 
it hard to quantify the amount of virus present. Similarly, if the dilution was 
too great, no plaques are observed (Figure 4.5d). 
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Figure 4.4: Confirmation of growth of CMV by extraction of DNA from the spent 
media of infected and non-infected MRC-5 cells. CMV (AD169) DNA was used a 
positive control (Lane 1) and H2O as a negative control (Lane 4). The presence of a 
200bp band in Lanes 1&2 confirms the presence of CMV glycoprotein B gene in the 
infected MRC-5 cells and the absence of the same band in Lanes 3&4 confirms the 
absence of CMV in non-infected cells and the absence of any contamination in the 
PCR reaction. Resolved on a 1.5% agarose gel and calibrated with 10μl Norgen 
DNA LowRanger ladder.
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Figure 4.5: Images displaying typical ‘plaques’, or areas of cells loss (Panel a) are 
caused by the infection of a single virus particle and subsequent cell loss. These 
effects of viral replication are apparent in comparison to a mock-infected cell 
monolayer (panel b). Panel (c) shows that if too much virus is present the plaques 
are too concentrated and merge together and similarly, panel (d) shows that if there 
is a low concentration of virus, no plaques are observed. All images were taken on 
an inverted Olympus CKX41 microscope on a 10X objective. Scale bar = 100μm
100μM 100μM
100μM 100μM
a b
c d
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The type of dilution series performed is paramount to the success of the 
plaque assay and for stocks of virus harvested from MRC-5 cells in the 
manner outlined in the previous section, a 10-fold dilution series was found to 
be most optimal. By performing the plaque assay under these conditions, the 
viral titre of the three different virus stocks used in this thesis could be 
determined. The individual viral titres were calculated as 2.2x104, 4.3x104
and 1.7x105 PFU/ml, respectively.
4.4.3 Development of a qPCR assay to quantify viral load
4.4.3.1 Construction of glycoprotein B plasmid
The construction of a plasmid containing the 2.7kB gene encoding for one of 
the cell surface receptors, glycoprotein B (gB) was carried out in order to 
generate a qPCR assay for accurate quantification of viral load. The plasmid 
was used to generate a standard curve of known plasmid concentrations and 
copy numbers of gB gene. 
The glycoprotein B gene was amplified using primers, gBA and gBB, 
incorporating restriction sites HindIII and XbaI (Temperton et al., 2003). A 
plasmid containing a multiple cloning site containing the same restriction 
sites was linearised. The cloned gB fragment was digested and ligated with 
the linearised plasmid backbone, in order to generate a 7.75kB vector 
containing the gB gene. Upon transformation into DH5α cells, Ampicillin 
resistance clones were recovered, indicating successful ligation. Plasmid 
DNA was then isolated and restricted with HindIII and XbaI to confirm the 
presence of the insert. All clones screened exhibited two bands, one 
corresponding to the 2.7kB insert and the 5.0kB plasmid backbone (Figure 
4.6). Successfully cloned plasmids were analysed for the correct AD169 gB 
sequence via DNA sequencing and the concentration of the chosen plasmid 
determined to be 3935ng/μl. Subsequently, the plasmid copy number was 
determined to be 4.6x1011copies/μl.
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Figure 4.6: Confirmation of successful construction of gB-pRcRSV, with Lane 1 
showing a band corresponding to the 2.7kB insert. Lanes 2 & 4 are unrestricted 
plasmids from two bacterial clones. Lanes 3 & 5 are double digested plasmids 
exhibiting two bands corresponding to the insert and the plasmid backbone. The gel 
was calibrated with Norgen HighRanger DNA ladder.
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4.4.3.2 qPCR assay development
A qPCR assay using the absolute method of quantification was developed to 
determine CMV viral load. This method determines the number of copies of 
viral DNA in an unknown sample against pre-determined standards, The gB-
pRcRSV plasmid constructed in Section 4.4.3.1 was used to generate a 
standard curve of known concentrations of the gB gene. The standard curve 
is designed to plot the gene copy number (as determined by the amount of 
plasmid added) against the CT value, which is the number of cycles in the 
PCR reaction it takes for the amount of fluorescence detected to cross a pre-
defined threshold level. The CT value is therefore proportional to the amount 
of starting template in the sample. Using the standard curve, samples of 
unknown viral load can be quantified by determining the CT value and plotting 
on the standard curve. From this, the number of copies of gB in the starting 
template/sample can be determined and the viral load/titre can be calculated.
Certain parameters relating to the standard curve determine the efficiency 
and reproducibility of the assay. The MIQE guidelines set out the minimum 
requirements when constructing an assay (Bustin et al., 2009) and details of 
specific values are reported in (Taylor et al., 2010). For this assay, a 
standard curve was constructed (Figure 4.7) with a slope of -3.14, which lies 
within the acceptable range of -3.58 to -3.10. This corresponds to a PCR 
efficiency of 90-110%, which is within the acceptable range. The R2 value of 
0.913 falls below the expected value of 0.999, highlighting a lack of 
reproducibility. The Y-intercept was calculated to be 39.7, which provides a 
theoretical limit suggesting this assay would not be able to reliably detect 
values above this CT value, which corresponds to a DNA copy number of 
>1x101copies/ml.
When the accuracy of this assay was compared to a clinically validated 
assay, routinely performed at UCL, there were some discrepancies between 
viral loads for the same samples. A series of DNA samples determined to be 
both positive and negative for the presence of CMV as per the validated 
assay were analysed through the in-house assay (Table 4.1). 
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Figure 4.7: Construction of quantitative PCR standard curve using gB-pRcRSV 
plasmid. A plasmid copy number range of 101-109 was used (black circles) and 
plotted against the CT (PCR cycle at which the signal crosses a threshold level) 
value. The CT of unknown samples (red squares) can be plotted on the graph to 
determine the viral load (copies/ml). The slope of the standard curve was calculated 
as -3.15, the Y-intercept value is 39.73 and the R2 value is 0.913. Repeats that were 
undetermined were removed from analysis.
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Table 4.1: Table outlining the amount of CMV in viral copies/ml of 20 DNA samples 
detected in an in-house assay developed for this thesis in comparison to a clinically 
validated assay.
Sample Validated Assay In-House Assay
1 7.8x109 3.13x108
2 3.0x108 NEG
3 54584 NEG
4 24391 NEG
5 11472 37.6
6 8034 NEG
7 6640 11.9
8 2861 NEG
9 1750 NEG
10 754 NEG
11 490 NEG
12 185 NEG
13 NEG NEG
14 NEG 5.4
15 NEG NEG
16 NEG NEG
17 NEG NEG
18 NEG 8.0
19 NEG NEG
20 NEG NEG
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Only 3/12 positive samples were also found to be positive by the in-house 
assay and the viral loads determined by the in-house assay were incorrect by 
1-2 orders of magnitude. Also, this assay incorrectly determined 2/8 negative 
samples as positive. 
Given the discrepancies between the two assays, it was decided to use the 
clinically validated assay for all qPCR analysis of CMV viral load throughout 
this thesis for more accurate and reliable results. Using this assay, the 
individual viral loads of the stocks of virus used throughout this thesis were 
calculated as 2x108, 5.4x107 and 4.7x109 copies/ml, respectively.
4.5 Discussion 
The aim of this chapter was to develop the fundamental virology techniques 
needed to grow and quantify CMV in order to carry out in vitro experiments to 
examine the relationship between the virus and sperm. These include
examining the effects of co-incubation with CMV on sperm function (Chapter 
6) and whether sperm washing techniques are able to remove CMV from 
semen samples (Chapter 5). To do this MRC-5 cells were infected with a 
laboratory strain of CMV, allowing for viral propagation and the creation of 
homogenous stocks of virus. Also, viral stocks were quantified via the use of 
a plaque assay, which determined the infectious titre of viral stocks and 
attempts were made to develop an in-house qPCR assay to detect viral load. 
In this chapter, CMV AD169 was successfully grown and propagated in 
culture, producing multiple viral stocks for use in subsequent experiments. 
The AD169 strain of CMV was chosen due to the extensive genomic 
information available, as this was the first CMV strain to be fully sequenced 
(Chee et al., 1990). This strain is also easier to grow, with short cycles of 
replication (96 hours) (Prichard et al., 2001) and produces higher yields of 
virus after growth in fibroblast cells, in comparison to other strains (Dargan et 
al., 2010). These are all desirable features when wanting to establish large 
stocks of virus for subsequent use in other experiments. 
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When considering the choice of CMV strain chosen, it is important to note the 
genetic differences between AD169 and other strains such as Merlin 
(reviewed in Prichard et al., 2001) (Figure 4.8). Due to multiple passages in 
vitro, laboratory strains such as AD169 and Towne, have acquired multiple 
genetic alterations that are more favourable for growth in culture. The most 
notable for AD169 is the loss of 19 genes (UL133-150) in the unique long 
(UL) region of the genome (Cha et al., 1996) (Figure 4.8a). In comparison, 
Merlin, a low passage strain does not have these substantial alterations, but 
has acquired a single point mutation through growth in vitro (Figure 4.8b), 
although it is still highly genetically similar to clinical isolates of CMV (Dolan 
et al., 2004) From this evidence, it is clear that no laboratory strain of CMV 
can be considered as genetically intact.
Another important point to consider when evaluating the choice of strain used 
is that the loss of the genes in the UL region changes the cell tropism of the 
virus. Normally, CMV has a broad host cell range in vivo (Sinzger et al., 
1995), however, laboratory strains are no longer able to infect endothelial or 
epithelial cells (Hahn et al., 2004; Sinzger et al., 2008; Wang & Shenk, 2005) 
and can only be grown in fibroblast cell lines. This is thought to be due to the 
role these genes play in mediating cell entry by endocytosis, which is 
required for entry to epitheliail/endothelial cells (Ryckman et al., 2006), as 
opposed to fusion-mediated entry, which is the mechanism of entry 
employed when infecting fibroblast cells (Compton et al., 1992). The deletion 
of these genes in AD169 results in the loss of receptors involved in the 
endocytosis-mediated entry mechanism, but retains the ability to bind and 
enter via fusion of membranes, allowing this strain to continue to infect 
fibroblast cells. 
As it is only the mechanism of entry to cells that is affected by these 
alterations, this is not of concern for how this strain of CMV will be used 
throughout this thesis. The experiments conducted are concerned with 
binding events between CMV and sperm, rather than entry and subsequent 
replication, as it is unlikely that CMV would be able to replicate inside sperm, 
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Figure 4.8: Schematic diagrams of the genomes of CMV AD169 and Merlin
showing sites of known mutations (Dolan et al., 2004). Panel (a) shows the known 
AD169 mutations including the replacement of genes UL133-150 by an inverted 
duplication of the RL region of the genome. These genes are all involved in the 
penetration and entry of CMV into epithelial cells (Ryckman et al., 2006). There are 
mutations in the TRL region, including frameshift mutations in RL5A, RL13 and 
UL131a, resulting in truncated proteins (Akter et al., 2003; Davison et al., 2003; Yu 
et al., 2002). In comparison, Panel (b) shows that Merlin only possesses one known 
mutation in the UL128 gene due to a one-nucleotide insertion resulting in the 
incorporation of a stop codon. Evidence suggests UL128 has a chemokine like 
domain and therefore may play a role in the infectivity of CMV.
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due to the condensed nature of the sperm genome. Furthermore, CMV is 
known to make initial contact with cells via HSPGs (Compton et al., 1993), 
which are also present on sperm, suggesting this might be a mechanism by 
which CMV might bind to sperm, as has been shown for HPV (Foresta et al., 
2011a). Given that the receptors involved in this initial interaction via HSPGs 
remain intact in AD169 (Chee et al., 1990), the genetic alterations in this 
strain are not of concern to the primary objective of this thesis. However, 
these fundamental differences are important to remember and consider when 
analysing results. 
Typically, when viral preparations are made in the manner outlined in this 
thesis, subsequent concentration and purification steps are normally 
performed. This can be carried out by ultracentrifugation and serves to 
separate infectious viral particles from aberrant products produced during the 
lytic cycle (Lou and Zhou, 2007), such as dense bodies and non-infectious 
enveloped particles (NIEP) (Talbot & Almeida, 1997; Irmiere & Gibson, 
1983). These particles are defective and non-infectious as both lack any viral 
DNA (Craighead et al., 1972; Irmiere & Gibson, 1983; Stannard et al., 1989). 
They are produced in excess of the mature infectious virion and are thought 
to act as a decoy for the immune system, as they are still capable of binding 
to and entering cells (Topilko & Michelson, 1994), distracting the immune 
system and allowing for survival of the infectious particles. Given this, the 
presence of these impurities in viral preparations may induce adverse effects 
on experimental outcomes; therefore virus preparations are usually purified 
to eliminate the presence of these erroneous factors. Due to technical 
limitations, the preparations of CMV used throughout this thesis were not 
purified. Consequently, these viral stocks still contain impurities associated 
with propagation in MRC-5 cells, such as cellular debris, in addition to dense 
bodies and NIEP’s. However, low speed centrifugation of the virus-infected 
media after harvesting from MRC-5 cells was performed and is thought to be 
sufficient at removing cellular debris (Talbot & Almeida, 1977). Confirmation 
of this could have been carried out by analysing viral preparations by western 
blotting for the presence of host cell markers, such as calnexin and actin, as 
-159-
was performed in Zhou et al., (2015). However, no purification step to 
remove dense bodies and NIEP’s was performed and due to the lack of viral 
DNA present in these particles, they are unquantifiable by qPCR or plaque 
assays, making them an unknown entity within un-purified viral preparations. 
As a result of this, it is probable that the concentration of virus used within 
the individual experiments throughout this thesis is a gross underestimation 
of the actual number of viral particles being added to each experiment. 
Despite this, given that dense bodies and NIEP’s are by-products of the 
normal viral replication process, it is reasonable to assume that they would 
be present in an infection within a male in vivo, therefore their presence 
could be considered to reflect the in vivo situation. As outlined earlier in this 
section, this thesis is primarily concerned with binding events, rather than 
viral entry and replication, so the presence of these non-infectious particles 
appears appropriate in this context. 
In order to quantify virus infectivity for viral stocks grown in this chapter and 
experiments conducted throughout this thesis, the viral plaque assay was 
used. This technique relies on the addition of viral serial dilutions to a 
monolayer of permissive cells and the formation of ‘plaques’. These plaques 
arise from the presence of a single infectious particle and by counting the 
number of plaques present at a given dilution, the number of ‘plaque forming 
units’ (PFU) can be calculated, which is a measure of virus infectivity. 
Another tissue culture based method of quantification is the end point dilution 
(TCID50) assay (Gray, 1999), which determines the highest dilution of virus to 
result in CPE in 50% of cells. It is thought that the plaque assay method is 
thought to be more precise in quantifying infectivity (Boeckh & Boivin, 1998). 
These traditional tissue culture based methods are known to be time 
consuming and have low sensitivity but are well-established methods that are 
able to provide an estimate of CMV quantity (Boeckh & Boivin, 1998). 
Variations in technique are known to result in poor reproducibility, including 
the type of semi-solid overlay used (Plummer & Benyesh-Melnick, 1964; 
Wentworth & French, 1970), the method of viral adsorption employed (Chou 
& Scott, 1988), the dye used to visualise plaques, and the number of cells 
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used to seed the plates (Wentworth & French, 1970). In this case, the 
chosen combination of overlay medium and stain, methylcellulose and crystal 
violet, did not appear to affect the identification of discernable plaques. In 
addition, no plaques were ever observed in the absence of inoculum, 
suggesting the assay was specific and no cross-contamination was 
occurring. However, plates were not seeded with a particular number of cells 
and plates were not centrifuged to increase viral adsorption (Chou et al., 
1988), which may have affected the accuracy of quantification, which cannot 
be ruled out as validation tests were not performed. Regardless of the 
limitations of this technique, the plaque assay is able to give an estimate of 
the quantity of infectious virus present, which can be considered useful when 
used in conjunction with qPCR data.
Two main experimental limitations encountered with the plaque assay were
related to the large sets of dilutions required, in order to obtain the right 
dilution at which an accurate number of plaques can be counted, and the 
long incubation period, which often resulted in bacterial and/or fungal 
infection. These are two well-known disadvantages of tissue culture based 
methods of viral quantification (Boeckh & Boivin, 1998).
Replacement of these traditional techniques with more rapid and effective 
tests has been previously investigated and would bypass the main limitations 
of the plaque assay. An immunofluorescence test to detect the presence of 
CMV by targeting a monoclonal antibody to an immediate early antigen 
(Stinski et al., 1981) was determined to have a specificity and sensitivity of 
100% and 80%, respectively, only 24 hours after infection (Griffiths et al., 
1984). It was also shown to produce comparable titres of infectious virus to 
the plaque assay after only 20 hours of incubation, as opposed to 2 weeks 
(Chou et al., 1988). Incorporation of a similar method into the design of this 
study would have bypassed the two main limitations outlined above and 
might have provided more accurate quantitation of the virus. However, these 
assays have their own limitations with regards to antibody specificity and 
sensitivity. 
-161-
Tissue culture based methods of CMV quantification are thought to be less 
accurate than methods that detect viral DNA (Boeckh & Boivin, 1998), such 
as qPCR. Detection of CMV by qPCR was proven to be sensitive enough to 
detect low titres of virus and allowed accurate measurement of the amount of 
virus in a sample (Lao et al., 1997), in addition to reducing the time to 
diagnosis when using tissue culture based methods. This method has been 
shown to be effective at monitoring CMV levels post organ transplant in order 
to provide anti-viral drugs prior to onset of clinical symptoms (Emery et al., 
2000). 
Since one of the objectives of this thesis was to identify men with CMV 
present in their semen, it was clear that a qPCR assay would be best method 
to do this due to its sensitivity and accuracy. A collaboration was established 
with a CMV research group at University College London (UCL) who perform 
this qPCR assay routinely. Advice was sought and attempts to replicate the 
Mattes et al., (2004) qPCR assay ‘in-house’ were made. Repeated problems 
were encountered during the optimisation of the assay with regards to DNA 
contamination. Despite using a PCR set up hood and decontaminating all 
plasticware prior to use with UV light, the no template control (NTC) samples 
consistently produced a peak at a late CT. Adjustments to primer 
concentrations and annealing temperatures were made in order to optimise 
the assay and eliminate primer dimer formation but ultimately, contamination 
was always observed in the no template controls (NTC). 
The parameters of the final standard curve constructed were close to the 
desired values, suggesting the assay was reliable. The efficiency of the ‘in-
house’ assay lies within the acceptable range of 90-110%, suggesting it 
should produce accurate and reliable results. However, the viral load values 
calculated by the in-house qPCR assay were significantly lower than those 
predicted by the clinically validated assay at UCL (Table 4.1). One 
explanation of this could be the presence of primer dimers, which were 
difficult to rule out in this assay and are known to effect the efficiency of 
probe-based PCR assays (Bustin et al., 2009). The presence of primer 
dimers could also explain the apparent contamination in the NTC samples.
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It is likely that the inconsistency between the ‘in-house’ and clinically 
validated assays is due to a poor R2 value. This is a measure of how well the 
data fit the curve and is an indicator of an error with intra-assay variance. 
Ideally, the R2 value should be around 0.999, but the value for this assay was 
0.914. The variance could be due to pipetting error, inconsistencies with the 
qPCR machine or problems with the plasmid standard. Using electronic 
pipettes controlled for pipetting error, however inconsistencies with the qPCR 
machine could not be ruled out and it is possible that the preparation of 
plasmid was not homogenous, possibly contributing to the intra-assay 
variance. Inaccurate quantification of the initial plasmid concentration could 
explain why the values calculated by the clinically validated assay were all 
approximately one order of magnitude higher than the in-house calculated 
values. Also, it is unlikely that each plasmid within the plasmid population 
contained the viral gene, which might also contribute to inaccurate 
quantification. 
The Y-intercept for the assay was 39.7, which corresponds to the theoretical 
limit of detection for the reaction. However, given the problems with 
contamination and that the NTC samples consistently amplified a signal 
around CT = 36, the detection limit was actually much lower. The Minimum 
Information for Publication of Quantitative PCR Experiments (MIQE) 
guidelines (Bustin et al., 2009) state that amplification in a NTC can be 
ignored if the CT ≥ 40 and if the highest unknown value is CT<35. Therefore, 
the actual limit of detection for this assay should be around CT = 31, 
corresponding to a viral load of approximately 103 copies, which does not 
give the assay a high level of analytical sensitivity. The continual presence of 
amplification in the NTC samples suggests the assay also does not have a 
high level of analytical specificity, conferring yet another area of criticism.
Given the inaccuracies outlined above with regards to specificity, sensitivity 
and repeatability, it was decided to have all of the samples collected during 
the work outlined in this thesis analysed by the validated UCL assay. Despite 
the work put into developing an in-house assay, it was clear that using the 
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validated assay would be the best method for obtaining accurate, clinically 
meaningful and reliable results.
It is clear that the infectious titre (PFU/ml), calculated by the plaque assay, 
and the total viral load (copies/ml), calculated by the qPCR assay, differ by at 
least 3-4 orders of magnitude (Sections 4.4.2 & 4.4.3). This is because CMV 
(AD169) has a high particle-to-PFU ratio, due to the large number of particles 
present in the viral preparation that are unable to establish an active 
infection, such as dense bodies and NIEPs (Zhou et al., 2015). For 
calculation of the amount of virus to include in each experiment throughout 
this thesis, the copies/ml value was used, rather than the number of PFU/ml, 
as the potential binding of any viral particle, regardless of whether it can 
establish an infection or not, is of interest in studying the interactions 
between CMV and sperm. 
In summary, a laboratory strain of CMV (AD169) has been successfully 
grown and methods for quantification established. It is important to recognise 
that whilst there are criticisms with the chosen methods and strain of virus 
used, these do not affect the use of this strain in investigating the overall 
objective of this thesis, which is to examine the relationship between CMV 
and sperm. Many of the limitations outlined in this discussion pertain to 
studies investigating the replication and pathogenesis of CMV, which is not 
important at this stage of investigation in this study. The techniques for 
growing and quantifying CMV outlined in this chapter can now be used for 
incubating semen and sperm with CMV in vitro and evaluating the outcomes 
of these experiments. The next chapter will use this laboratory grown CMV to 
examine if sperm washing is effective at removing CMV from artificially 
infected semen samples. The methods for quantification developed in this 
chapter will allow the efficiency of these techniques to be evaluated for 
samples infected both artificially and naturally.
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Chapter 5
The efficiency of density gradient 
centrifugation in removing CMV from 
donor semen samples
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5.1 Introduction
Sperm washing is a technique used in fertility clinics to separate 
spermatozoa from seminal components (WHO, 2010). Prior to performing 
assisted conception techniques, sperm has to be separated from seminal 
plasma, as the presence of prostaglandins in semen can result in uterine 
cramping during IUI (Barwin, 1974; Tarlatzis et al., 1991). Also, prolonged 
exposure to seminal components can affect the fertilising capacity of sperm 
(Rogers et al., 1983). Simple dilution and subsequent centrifugation steps 
are two simple ways to wash sperm, however there is no selection for good 
quality sperm using this technique. Techniques involving a sperm selection 
step, such as sperm migration through a culture medium (Mortimer, 1994) 
were shown to be more successful with regards to IVF outcomes (reviewed 
in Mortimer, 1991). These techniques are known as the swim up or swim 
down methods. 
Further techniques were developed utilising the method of density gradient 
centrifugation. With the aid of a well-known cell separation media, known as 
Percoll, which contains polyvinylpyrrolidone (PVP) colloidal silica particles 
(Pertoft et al., 1978), sperm were shown to separate from seminal 
components based on their own density, known as an isopycnic point (Gorus 
& Pipeleers, 1981). Sperm washing by density gradient centrifugation has 
been reported to increase clinical pregnancy rates (Guerin et al., 1989). 
However, it was found that whilst this technique improved the concentration 
of sperm recovered, the swim-up technique allowed for selection of better 
quality sperm (Ng et al., 1992). Percoll was withdrawn from use as a sperm 
separation medium in 1996, primarily due to endotoxin contamination 
(Mortimer, 1994), but it has also been shown to have detrimental effects on 
sperm (Claassens et al., 1998). This resulted in the development of 
numerous other media that could replace Percoll as a sperm separation 
agent. A replacement product, containing saline-coated silica particles, 
known as PureSperm, was found to be equally as effective and efficient at 
sperm separation in comparison to Percoll, as were other saline-coated silica 
particle based solutions (Claassens et al., 1998). 
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As well as being used in the preparation of sperm for IUI or IVF, sperm 
washing was also found to be useful in the elimination of HIV from semen 
samples of infected men (Semprini et al., 1992). No horizontal transmission 
of HIV was recorded in 367 couples inseminated with semen from HIV-
positive men when density gradient centrifugation, in combination with the 
swim-up technique, was performed (Semprini et al., 2013). In addition, a 
systematic review found no vertical transmission and no effect on clinical 
pregnancy rates (Zafar et al., 2015), providing evidence that this technique is 
safe and effective in helping HIV serodiscordant couples conceive. 
Similar studies have been carried out investigating other pathogens, 
including C. trachomatis (Al-Mously et al., 2009). This study concluded that, 
unlike HIV, sperm washing was not effective at removing bacteria from 
semen samples. Other research groups investigating the role sperm washing 
plays in removing different pathogens have modified the techniques further, 
including the addition of Heparinase-III for the removal of HPV (Garolla et al., 
2012). In an attempt to rule out potential re-contamination of the sperm pellet 
upon retrieval from the bottom of the tube, the double tube gradient method 
was developed by Politch et al., (2004) and further developed into a 
commercially available product, known as the ProInsert™ tube (Figure 2.3b), 
which was found to be effective at removing HIV (Fourie et al., 2015).
Little investigation into the role sperm washing plays in the removal of CMV 
from semen samples has been performed. One study investigated the 
removal of CMV in men attending fertility clinics using density gradient 
centrifugation with PureSperm. The authors reported that CMV DNA was 
detected in the sperm pellet in 89% of CMV positive samples after washing 
(Michou et al., 2012). Similarly, Naumenko et al., (2014) reported detection of 
CMV in the sperm pellet of 92% of ejaculates washed by density gradient 
centrifugation. The presence of CMV after sperm washing at such high rates, 
suggests that CMV might be tightly associated with the spermatozoa. 
However, apart from these studies, no other investigations into the efficiency 
of sperm washing by density gradient centrifugation, or other methods, at 
removing CMV from semen samples has been carried out. 
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5.2 Experimental rationale
The aim of this chapter was to determine if sperm washing is able to remove 
CMV from semen samples. As sperm washing is already routinely carried out 
in fertility clinics, evidence supporting its role in CMV removal would be 
further beneficial. It would provide a simple and immediate solution to some 
of the problems associated with the management of CMV positive sperm 
donors outlined in Chapter 3. 
In addition, the efficacy of sperm washing might provide insight in into the 
potential interactions between CMV and sperm, as has been shown for HPV 
(Foresta et al., 2011b; Garolla et al., 2012). The failure to remove a pathogen 
from a semen sample by density gradient centrifugation indicates a potential 
direct interaction. Due to the effects on sperm tyrosine phosphorylation levels 
when co-incubated with C. trachomatis (Hosseinzadeh et al., 2000), a direct 
receptor mediated interaction was proposed. A tight association between the 
bacterium and sperm would explain why density gradient centrifugation fails 
to remove C. trachomatis from semen samples (Al-Mously et al., 2009).
The efficiency of both conventional sperm washing techniques, currently 
used in UK fertility clinics, and modified experimental techniques will be 
explored. This chapter will primarily follow the in vitro approach used 
throughout this thesis, using laboratory grown CMV to answer this question. 
One advantage of this is the novel addition of the plaque assay to the 
experimental design, as outlined in Chapter 4. After washing, samples will be 
subject to detection of viral DNA by qPCR and detection of infectious virus 
via the plaque assay. This will provide evidence to show whether any virus 
remaining after washing is able to establish an infection or not. Given the 
argument that any virus remaining after washing might be due to an 
interaction with sperm, this might also provide evidence to show that sperm 
act as a vector for CMV transmission. The addition of an assay to detect live 
virus after sperm washing is a unique aspect of this study, which has not 
been investigated before. 
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It is important to investigate the presence and shedding pattern of CMV in 
naturally infected men and the efficiency of sperm washing in removing CMV 
from these naturally infected semen samples. This will provide evidence to 
support the role sperm washing might play in removal of CMV from semen 
samples in fertility clinics.
A combination of in vitro data, incorporating the plaque assay, and in vivo
data showing the presence of CMV in semen, will provide a strong basis to 
show if sperm washing is effective at removing CMV and how this might be 
incorporated into the fertility clinic. By answering this one question, this study 
will also provide insight into the interaction between CMV and sperm and the 
potential impact sperm washing might have on improving the process of 
screening and management of CMV positive sperm donors.
5.2.1 Specific aim(s) 
1. Investigate the efficiency of conventional density gradient 
centrifugation methods at removing CMV from naturally and artificially 
infected samples.
2. Assess if modified versions of sperm washing, such as Proinsert™ 
tubes, are more effective.
3. Investigate the presence of CMV in semen of infected men over an 
extended donation period.
5.3 Materials and Methods
To achieve the objectives outlined above, the efficiency of sperm washing in 
removing CMV was investigated in a number of different ways. Initially, the 
efficiency of conventional density gradient centrifugation was assessed in 
vitro, using laboratory grown CMV. The dose of virus used and the length of 
co-incubation period with sperm were investigated. An alternative technique, 
thought to reduce viral contamination, known as the Proinsert™ tube (Figure 
2.3b) was also utilised. In addition to these in vitro experiments, the efficiency 
of density gradient centrifugation to remove CMV from naturally infected 
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semen samples was also investigated. In these men, the presence and
shedding pattern of CMV was also examined. 
For all of the experiments outlined in this section, semen samples were 
assessed for sperm concentration and motility, as outlined in Section 2.5.1, 
prior to density gradient centrifugation, as outlined in Section 2.5.3. All 
samples were used regardless of the quality, provided there was a sufficient 
volume for the specific experiment being performed, which ranged from 1.5-
2.5ml and is indicated in the relevant sections below. In order to prevent any 
inconsistent changes in the rheological properties of the semen, the same 
volume of virus was added to each sample. As the concentration of virus 
varied dependent upon the concentration of sperm in a sample, the 
concentration of virus was adjusted prior to addition to the semen, in order to 
keep the volume of virus added consistent across all experiments.
After the initial set up of each experiment, all of the samples were incubated 
in the same manner and the same methods were used to assess the 
efficiency of the different sperm washing techniques used. These conditions 
are outlined in Section 5.3.5, and the individual experimental conditions are 
outlined in each relevant section below. 
5.3.1 Efficiency of conventional density gradient centrifugation 
techniques at removing CMV from artificially infected semen samples
Semen samples from 5 healthy donors, with an initial semen volume of 
>2.0ml were divided into 4 x 500μl aliquots in 4 x 5ml polystyrene round-
bottom tubes (VWR, Pennsylvania, USA). Two 500μl aliquots were infected 
with 500μl CMV (AD169)-infected supernatant at a ratio of 1 virus particle to 
1 sperm. The other two aliquots were mock-infected with 500μl serum-free 
EMEM. One incubate of each condition was incubated at 37°C 5% CO2 for 
either one hour or six hours prior to sperm washing with standard density 
gradient centrifugation, as outlined in Section 2.5.3.
5.3.2 Efficiency of Proinsert™ tubes at removing CMV from artificially 
infected semen samples
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Semen samples from 9 healthy donors, with an initial semen volume of 
>1.5ml were divided into 2 x 750μl aliquots in 4 x 5ml polystyrene round-
bottom tubes. One 750μl aliquot of semen was infected with 750μl CMV 
(AD169)-infected supernatant at a ratio of 1 virus particle to 1 sperm. The 
second aliquot was mock-infected with 750μl serum-free EMEM. Samples 
were incubated for one hour at 37°C 5% CO2 prior to sperm washing. In this 
experiment, 500μl of each condition was loaded onto either a conventional 
density gradient column or loaded onto a gradient created in a ProInsert™ 
tube and washed as outlined in Section 2.5.3.
5.3.3 Use of naturally infected semen samples to investigate the 
efficiency of sperm washing and the viral shedding of CMV in semen
A total of 102 normozoospermic semen samples from 41 men were washed 
by adding 500μl of semen to a conventional density gradient centrifugation 
column and washing as outlined in Section 2.5.3. Pre-wash samples were 
analysed for the presence of CMV by qPCR and if positive, the 
corresponding post-wash samples were also examined by PCR. Any positive 
pre-wash samples were used to investigate the viral shedding pattern of 
CMV in semen and the paired positive pre-wash/post-wash samples used to 
analyse the efficiency of sperm washing. All DNA extracted from samples 
were analysed for the presence of genomic DNA by GAPDH, as outlined in 
Section 2.6.5 to confirm successful extraction of DNA. Samples negative for 
GAPDH were excluded from analysis. 
5.3.4 Effect of viral dose on the efficiency of conventional density 
gradient centrifugation techniques at removing CMV from artificially 
infected semen samples
Semen samples from 7 healthy donors, with an initial semen volume of 
>2.5ml were divided into 5 x 500μl aliquots in 4 x 5ml polystyrene round-
bottom tubes. A 10-fold dilution series of CMV (AD169)-infected supernatant 
was performed with an initial ratio of 1 virus particle to 1 sperm. 10μl of this 
initial concentration was added to 90μl serum-free EMEM to obtain dilutions 
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of 10-1, 10-2 and 10-3. These four concentrations of virus were added to four 
of the 500μl aliquots and the final aliquot was mock-infected with 500μl
serum-free EMEM. The samples were incubated for one hour at 37°C 5% 
CO2 before washing by standard density gradient centrifugation, carried out 
as outlined in Section 2.5.3.
5.3.5 Incubation conditions and sample analysis
For the experiments outlined in Section 5.3.1, 5.3.2 and 5.3.4, after the initial 
incubation period, 200μl was removed for detection of CMV viral load by 
qPCR and 200μl was removed for detection of infectious virus, or plaque 
forming units (PFU), by performing a plaque assay, for each incubate. In 
addition, 10μl was removed to analyse sperm motility and 40μl used to 
measure sperm concentration. For Section 5.3.3, no plaque assay was 
performed and no incubation period was carried out. Semen analysis was 
performed on the raw semen sample, as outlined in Section 2.5.1, and 200μl 
removed for qPCR analysis. 
For all experiments, after washing, the sperm pellet was resuspended in 
~500μl PureSperm wash buffer and the same aliquots outlined above taken 
again for post-wash analysis. 
DNA was extracted from all samples as outlined in Section 2.6.4. For each 
batch of samples extracted, a negative H2O control was included. If the 
negative control tested positive for CMV DNA, the samples were extracted 
and tested again, or excluded from the final analysis. The concentration of 
DNA and optical density (OD) ratios of the DNA extracted in each experiment 
can be found in Appendix VII. The OD260/280 ratio should be in the range of 
~1.8 for DNA and the majority of sets of data were calculated to be in that 
range. The OD260/230 ratio should be in the range of ~2.0-2.2. None of the 
sets of data collected were within this range, with all of them <1.5. This 
suggests that the samples contained a type of contaminant that absorbs at 
230nm. The presence of some reagents in the final elution, such as EDTA 
might account for this lower absorption. However, no inhibitory effects on 
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qPCR were observed and all negative samples were confirmed as true 
values by GAPDH analysis. 
5.3.6 Statistics
For each data set, a test of normality was performed using GraphPad Prism 
(Version 6.0c). For data sets with at least 8 repeats, the D’Agostino Pearson 
omnibus normality test was used, those with at least 7 repeats, the Shapiro 
Wilk test was used and for those with at least 5 repeats, the Kolmogorov-
Smirnov test with Dallal-Wilkinson-Lilliefor P Value test was performed. For 
those data sets with less than 5 repeats, a non-Gaussian distribution was 
assumed and a non-parametric test performed. 
When comparing pre-wash to post-wash samples for a significant difference, 
a paired test was used (details of specific tests used for each data set can be 
found in corresponding figure/table legends). For sperm concentration, viral 
load and infectious virus, a one-tailed test was performed as these 
parameters could only decrease after washing. However, for sperm motility, 
a two tailed test was performed as this could increase or decrease. For 
comparison of samples of the same type, such as post-wash density gradient 
centrifugation vs Proinsert™, a two-tailed independent test was used. 
5.4 Results
5.4.1 Do conventional density gradient centrifugation techniques 
remove CMV from artificially infected semen samples and is this 
affected by the length of time sperm are exposed to CMV?
Semen samples from five healthy sperm donors with a mean volume of 
2.76±0.24ml, a mean sperm concentration of 50.3±10.10x106/ml and a mean
progressive motility of 56.3±6.11% were incubated with CMV (AD169). After 
either one or six hours incubation, samples were washed using an 80:40% 
Puresperm density gradient and the amount of virus remaining determined 
by qPCR (n=5) and a plaque assay (n=3). 
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There was a statistically significant difference (P<0.05) in the viral load 
present before and after washing when samples were incubated for both one 
and six hours (Figure 5.1a). The median percentage of CMV remaining after 
washing was 0.7 (range 0.1-19.6)% and 1.1 (range 0.7-17.6)% of the initial 
load, respectively. Although the same trend was also observed when 
analysing the number of plaque forming units (PFU), this difference was not 
statistically significant, perhaps due to the smaller number of repeats and the 
spread of data (Figure 5.1b). No differences were observed in the viral load 
or PFU between the two different incubation periods, either before or after 
washing. This shows that the efficiency of sperm washing is not affected by 
the amount of time semen samples are exposed to CMV. A negative control 
of serum-free EMEM was included in all experiments. All controls were found 
to be negative for CMV DNA, except for one repeat, which produced some 
positive results, thought to be due to a naturally occurring infection as this 
donor also was found to be positive in Section 5.4.3. No PFU were observed 
in any of the negative control samples. 
Analysis of the quality of sperm after washing shows that motility was 
generally increased after a one-hour incubation period with CMV. However, 
the post-wash motility was decreased significantly (P<0.05) after a six-hour 
incubation period in both the infected samples and in a negative control 
(Table 5.1). The post-wash sperm concentration decreased significantly in all 
conditions, as would be expected. However, the post-wash concentration 
after a one-hour incubation with CMV appeared to be much lower (P<0.01).
5.4.2 Are Proinsert™ tubes more effective than density gradient 
centrifugation at removing CMV from artificially infected semen 
samples? 
The conventional density gradient centrifugation method is criticised due to 
the risk of re-contamination of the pellet upon its retrieval from the bottom of
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Figure 5.1: Details of CMV (AD169) viral load (a) and PFU (b), present before and 
after sperm washing by density gradient centrifugation. Semen samples from five (a) 
and three (b) healthy donors were incubated with CMV (AD169) at a ratio of 1 virus 
particle to 1 sperm. Samples were incubated with CMV or with EMEM for either one 
hour or six hours prior to washing. Data shown are mean ± SEM and circles and 
squares represent individual replicates for each experimental condition. Statistical 
significance was determined using a one-tailed paired t-test for comparing pre-wash 
samples to post-wash samples. A two-tailed independent t-test was used when 
comparing 1hr and 6hr pre-wash samples and 1hr and 6hr post-wash samples 
separately. The symbol (*) indicates a difference at the significance level of P <0.05.
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Table 5.1: Details of sperm motility and concentration before and after density 
gradient centrifugation incubated with and without CMV (AD169). Data shown are 
the mean±SEM of incubations with semen from five healthy sperm donors for either 
one hour or six hours.
* Statistical significance was analysed using two-tailed paired and independent 
t-tests on log transformed data. The symbol (*) indicates a difference between 
the pre-wash and post wash samples at a significance level of P <0.05. 
+ Statistical significance was analysed using a one-tailed paired t-test and a 
two-tailed independent t-test. The symbol (*) denotes a difference between 
the pre-wash and post wash samples with two symbols (**) indicating a 
significance level of P <0.001 and three symbols (***) indicating a 
significance level of P <0.001.
Condition Motility (%)* Concentration (x106/ml)+
1hr Pre Infected 28.5±7.6 19.5±0.6
1hr Pre Control 31.7±9.0 19.1±2.7
1hr Post Infected 40.7±12.5   0.9±0.3 ***
1hr Post Control 33.9± 8.4     2.0±0.6 **
6hr Pre Infected   9.6±3.5 19.6±4.2
6hr Pre Control   7.2±3.2 16.5±3.5
6hr Post Infected   2.7±2.2 *   1.3±0.3 **
6hr Post Control   4.5±3.0 *   1.5±0.4 **
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the gradient. To investigate this, a comparison between density gradient 
centrifugation and a modified method, the Proinsert™ tube, designed to 
reduce the risk of re-contamination, was performed. 
Semen samples from nine healthy sperm donors with a mean volume of 
3.1±0.31ml, a mean sperm concentration of 76.4±25.9x106/ml and a mean 
progressive motility of 54.0±4.6% were incubated with CMV (AD169) for one 
hour. Samples were then washed using either density gradient centrifugation 
or the Proinsert™ tube. The amount of virus remaining after washing was 
determined by qPCR (n=9) and a plaque assay (n=5). 
In line with the experiment performed in section 5.4.1, there was a significant 
reduction (P<0.05) in the amount of virus present after washing when using 
the density gradient centrifugation method. In comparison, the Proinsert™ 
tube appears to reduce the amount of virus further (P<0.01). There was also 
a significant difference in the amount of virus present after washing between 
the two different methods (P<0.05) (Figure 5.2a), with the median percentage 
of CMV remaining after washing being only 1.6 (range 0-101)% when using 
the Proinsert tube, in comparison to density gradient centrifugation, where 
the median percentage of CMV remaining after washing was 15.2 (range 0.6-
61)%. Interestingly, when examining the amount of infectious virus present, 
the Proinsert™ tube was better at removing infectious CMV than density 
gradient centrifugation (P<0.01), as no PFU’s were observed in the post-
wash samples using the Proinsert™ tubes (Figure 5.2b). All negative controls 
were found to be negative for CMV DNA, except for three positive results, 
with low values (322-2434 copies/ml), thought to be due to low-level 
contamination, or due to a naturally occurring infection. No PFU were 
observed in any of the negative control samples.
After washing with the Proinsert™ tube, sperm motility was generally higher 
than when density gradient centrifugation was performed (Table 5.2). 
However, the sperm concentration was generally lower when using the 
modified sperm washing procedure, although the concentration of sperm 
present after washing was significantly different in all conditions (Table 5.2). 
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Figure 5.2: Details of CMV (AD169) viral load (a) and PFU (b), present before 
(pre) and after sperm washing by either density gradient centrifugation (DG), or the 
ProInsert™ method (PI). Semen samples from nine (a) and five (b) healthy donors 
were incubated with CMV (AD169) at a ratio of 1 virus particle to 1 sperm. Samples 
were incubated with CMV or with EMEM for one hour. Data shown are mean ± SEM 
and circles, squares and triangles represent individual replicates for each condition. 
Statistical significance was analysed using a one-tailed Wilcoxon matched-pairs 
signed rank test for comparing pre-wash samples to post-wash samples. A two-
tailed Mann Whitney test was used when comparing DG with PI. The symbol (*) 
indicates a difference at the significance level of P<0.05 and the symbol (**) 
indicates a difference at the significance level of P<0.01.
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Table 5.2: Details of sperm motility and concentration before (pre) and after 
washing with either density gradient centrifugation (DG) or ProInsert™ (PI) tubes. 
Semen samples were incubated with or without CMV (AD169) for one hour. Data 
shown are the mean±SEM of incubations with semen from nine healthy sperm 
donors. 
* Statistical significance was analysed using two-tailed paired and 
independent t-tests on log-transformed data. The symbol (*) indicates a 
difference between the pre-wash and post wash sample at a significance 
level of P <0.05. 
+ Statistical significance was analysed using a one-tailed paired t-test and a 
two-tailed independent t-test. The symbol (*) denotes a difference between 
the pre-wash and post wash samples at a significance level of P <0.05 and 
two symbols (**), a significance level of P <0.01.
Condition Motility (%)* Concentration (x106/ml)+
Pre Infected 42.4±5.0   21.16±5.6
Pre Control 42.6+5.3   17.92±4.7
DG Post Infected 51.0±7.8     5.4±1.7 **
DG Post Control 51.4±8.1     5.3±1.4 **
PI Post Infected 68.0±10.4 *     4.9±1.4 *
PI Post Control 63.3±10.8     3.4±1.0 **
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5.4.3 Is sperm washing effective at removing CMV from naturally 
infected samples? 
To investigate if the same findings for semen infected in vitro were found in 
naturally infected men, 102 ejaculates from 41 normozoospermic donors with 
a mean volume of 3.1±0.14ml, a mean sperm concentration of 59.0±4.9x106 
/ml and a mean progressive motility of 48±2.1% were washed by density 
gradient centrifugation. After washing, the mean sperm count was 
10±1.3x106 /ml and a mean progressive motility of 50.3±2.8% was observed. 
DNA extracted from samples before washing were analysed for the presence 
of CMV DNA and 21/102 (20.6%) were positive. For all positive samples, the 
corresponding post-wash samples were analysed to check for the presence 
of CMV after washing and 5/21 (23.8%) were positive. 
A H2O control was included for each extraction to determine if any 
contamination occurred during the extraction process. On one occasion, this 
negative control tested positive, therefore the 15 samples included in this 
batch of extraction were excluded from the analysis. Similarly, all samples 
were analysed for the presence of the housekeeping gene, GAPDH, by PCR. 
This analysis was carried out to ensure that any negative results were not 
due to an absence of genomic DNA because of an extraction error. Eight 
samples were negative for the presence of GAPDH and were excluded. 
After excluding these 23 samples, 79 ejaculates from 35 donors were 
included in the final analysis. The number of pre-wash CMV positive samples 
in the final analysis was 13/79 (16.5%), with only 2/13 (15.4%) samples 
positive after washing. The mean viral load pre-wash was 19,416±11,568
copies/ml and post-wash 146.9±109.7 copies/ml, giving a statistically 
significant difference of P<0.001 (Figure 5.3). In comparison to the in vitro
experiments outlined previously, the median percentage of CMV remaining 
after washing was slightly lower, at 6.2 (range 2.2-10.2)% of the initial 
amount. 
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Figure 5.3: Details of the CMV viral load of 13 ejaculates from naturally infected 
men before and after washing. Semen samples were washed on an 80:40% 
Puresperm gradient and the presence of CMV before and after washing was 
analysed by qPCR. Data shown are mean ± SEM. Statistical differences were 
examined using a one-tailed Wilcoxon matched-pairs signed rank test. The symbol 
(***) indicates a difference at the significance level of P <0.001.
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Furthermore, there were no significant differences in semen volume, sperm 
concentration or progressive motility between CMV positive and CMV 
negative ejaculates (Table 5.3).
5.4.4 Is the dose of CMV important in the efficiency of removal of CMV 
from artificially infected semen samples? 
From observing the viral load in naturally infected men, it was clear that the 
amount of virus used in the experiments outlined in Sections 5.4.1 and 5.4.2 
were not representative of what was occurring in vivo. The mean viral load 
included in the first two experiments was 7.5x107±3.148x107 and 
2.3x106±1.261x106 copies/ml, respectively, in comparison to the 
19,416±11,568 copies/ml found in vivo. Therefore, to investigate if the dose 
of virus sperm is exposed to effects the efficiency of sperm washing, a 
dilution series of different amounts of virus was carried out. 
Semen samples from seven healthy sperm donors with a mean volume of 
3.6±0.26ml, a mean sperm concentration of 64.5±18.2x106/ml and a mean 
progressive motility of 57.3±8.0% were incubated with CMV (AD169) for one 
hour. Samples were then washed by density gradient centrifugation and the 
amount of virus remaining determined by qPCR (n=7) and a plaque assay 
(n=4). 
In line with the experiments performed in Sections 5.4.1 and 5.4.2, the 
amount of virus present after washing was significantly reduced when a ratio 
of 1 virus particle was incubated with 1 sperm (P<0.05) (Figure 5.4a). The 
same was observed when the amount of virus was diluted 10-fold (0.1). 
However, when dilutions of 100 (0.01) and 1000-fold (0.001) were used in 
co-incubations, there was no statistically significant reduction in viral load 
after washing. The median percentage of CMV remaining after washing, at 
the two highest concentrations, was 5.1 (range 0.76-18.3)% and 17.4 (range 
5.4-34.5)%, respectively. However, with a 100-fold dilution, 17.8 (range 0-
241)% of CMV remained after washing. When a 1000-fold dilution was used, 
the amount of virus was slightly higher after washing, with a mean of 
217.6±167 copies/ml detected post-wash in comparison to a mean of 
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Table 5.3: Comparison of sperm concentration, progressive motility and semen 
volume between CMV positive and negative ejaculates.
Data are shown as mean±SEM
* Statistical significance was analysed using the Mann-Whitney test on log-
transformed data. No statistically significant difference was found.
+ Statistical significance was analysed using a two-tailed independent t-test. 
No statistically significant difference was found.
CMV Negative (66) CMV Positive (13)
Sperm Concentration 
(x106/ml)*
58.2±5.3 72.6±18.7
Progressive motility 
(A+B) %+
48.9±2.4 52.8±5.1
Semen Volume (ml)+   3.3±0.2   2.6±0.2
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Figure 5.4: Details of CMV (AD169) viral load (a) and PFU (b), present before and 
after sperm washing by density gradient centrifugation. Semen samples from seven 
(a) and four (b) healthy donors were incubated with CMV (AD169) at various doses. 
A ratio of 1 virus particles to 1 sperm was the starting dose, after which a 10-fold 
dilution was carried out until a dilution of 0.001 (1000-fold). Samples were incubated 
with CMV or with EMEM for one hour prior to washing. Data shown are mean ± 
SEM with symbols indicating individual replicates for each dilution. Statistical 
significance was analysed using a one-tailed Wilcoxon matched-pairs signed rank 
test. The symbol (*) indicates a difference at the significance level of P <0.05.
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215.5±215.5 copies/ml detected before washing. This discrepancy could be 
due to contamination, as some of the negative control samples tested 
positive after washing (with values in the range of 1027-2729 copies/ml). 
Alternatively, the presence of CMV due to a natural infection was not ruled 
out and could have adversely affected the results at these low 
concentrations. 
No statistical differences were observed upon analysis of the amount of PFU 
(Figure 5.4b), although the amount of virus was reduced for the starting 
concentration, but this was not statistically significant. Unfortunately, for the 
higher dilutions, the small amount of virus present pre-wash was not 
detected by this assay and therefore no comparison can be made.
Progressive sperm motility was significantly increased (P<0.05) for each 
condition, except for the negative control (Table 5.4). Conversely, sperm 
concentration was significantly decreased (P<0.05) for each condition, 
except for the negative control, which had a significant reduction of P<0.01 
(Table 5.4). 
5.4.5 Does removal of CMV by sperm washing have a place in the 
fertility clinic? 
The evidence outlined so far in this chapter suggests that sperm washing by 
density gradient centrifugation is effective at significantly reducing the viral 
load in naturally infected men. However, it was important to establish the 
significance of these findings for a fertility clinic. Currently, upon screening for 
CMV in sperm donors, no analysis of the individual semen sample is 
performed; therefore the impact of sperm washing on the removal of CMV is 
unknown. This section will investigate if there is a requirement for testing 
individual ejaculates, as has been suggested previously (Kaspersen et al., 
2012), and whether this would influence the impact of removal of CMV by 
sperm washing in the fertility clinic. 
PCR data from the 79 semen samples analysed for the presence of CMV in 
Section 5.4.4 was used to investigate the shedding of CMV in semen.  
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Table 5.4: Details of sperm motility and concentration before (pre) and after (post) 
density gradient centrifugation incubated with a 10-fold dilution series of CMV 
(AD169) and a negative control. Data shown are the mean±SEM of incubations with 
semen from seven healthy sperm donors.
* Statistical significance was analysed using two-tailed paired and 
independent t-tests. The symbol (*) indicates a difference between the pre-
wash and post wash sample at a significance level of P <0.05. 
+ Statistical significance was analysed using a one-tailed paired t-test. The 
symbol (*) denotes a difference between the pre-wash and post wash 
samples at a significance level of P <0.05 and two symbols (**), a 
significance level of P <0.01.
Condition Motility (%)* Concentration (x106/ml)+
1:1 Pre 30.7±6.7 15.4±4.7
1:1 Post 46.0±.0 *   2.7±0.9 *
101 Pre 30.9±6.6 13.4±4.0
101 Post 54.7±10.5 *   4.4±1.4 *
102 Pre 33.9±7.5 14.8±4.6
102 Post 58.1±9.3 *   3.3±1.1 *
103 Pre 32.6±7.1 17.2±5.0
103 Post 54.4±10.0 *   2.8±0.9 *
Pre Control 33.1±8.0 18.1±5.4
Post Control 48.8±10.8   3.4±1.2 **
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In Section 5.4.4, each ejaculate was tested by PCR for the presence of CMV 
and Figure 5.5 shows the spread of positive and negative samples for each 
donor, over their entire donation period. Out of 79 ejaculates, 66 were 
negative (83.5%) and 13 were positive (16.5%). Whilst the majority of donors 
(23/35) only produced samples negative for CMV, 11 donors produced one 
positive sample, with one donor producing two positive samples. Of the 12 
donors that produced at least one positive sample, 9 intermittently shed CMV 
in their semen (Donors 7, 18, 20, 23, 25, 26, 27, 30, 31). Interestingly, the 
time period between producing a positive sample and a negative sample was 
quite short in some instances. For example, Donor 25 produced a positive 
sample on day 52, but then provided a negative sample three days later, on 
day 55. Likewise, Donor 23 produced a positive sample on day 70 and a 
negative sample one week later, on day 77. Donor 26 provided 5 samples 
over a period of 71 days (~2.5 months) and was the only donor to produce 
more than one positive sample. The first sample produced was negative, 
followed by a positive sample on day 9, a further two negative samples on 
days 20 and 48, and finally a positive sample on day 71 (Figure 5.5). 
Analysis of the individual viral loads of the 12 men who produced at least one 
positive sample shows the range of concentrations of CMV detected in 
semen (Figure 5.6). The viral load ranged from 337 to 155,247.5 copies/ml 
with an average viral load of 19,416±11,568 copies/ml. Interestingly, Donor H 
had the highest viral load in any sample (Figure 5.6), but after producing this 
sample, only 3 days later a negative sample was produced (Donor 25 in 
Figure 5.5). 
Figure 5.7 shows that there was no correlation between the amount of virus 
present in a semen sample and the sperm concentration (Figure 5.7a) or 
motility (Figure 5.7b). This suggests that there is no relationship between 
semen quality and viral load.
-1
8
8
-
Figure 5.5: Details of the 
viral shedding of 35 different 
donors. The viral shedding in 
each ejaculate is shown 
against the days since an 
individual donor made their 
first donation. The CMV 
status of each ejaculate was 
confirmed by qPCR. Donors 
7, 8, 9 and 33 do not have 
data points at time point 0 
due to the exclusion criteria 
outlined in Sections 5.3.3 & 
5.3.5.
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Figure 5.6: Details of the 
viral loads of the individual 
ejaculates of 12 donors 
with at least one positive 
sample. CMV viral load 
was determined by qPCR.
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Figure 5.7: Correlations between the pre-wash CMV viral load and pre-wash 
sperm concentration (a) and progressive motility (b), of 79 ejaculates from 33 
healthy sperm donors.
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5.5 Discussion
The overall aim of this chapter was to investigate the efficiency of sperm 
washing to remove CMV from both in vitro and in vivo infected semen
samples. This has provided evidence to support the role of sperm washing in 
the management of sperm donors with a CMV infection, and has provided 
insight into the interactions between CMV and sperm. This study was novel 
in its design due to the incorporation of the plaque assay in addition to qPCR, 
which acts as a model for transmission in vivo. Incorporating this technique 
showed that virus remaining after washing is able to establish an infection. 
However, overall sperm washing appeared to be mostly effective at removing 
CMV from semen samples, and was more efficient with naturally infected 
samples than those artificially infected.
Despite sperm washing by density gradient centrifugation being broadly 
effective at removing CMV from semen samples infected in vitro, CMV does 
persist after washing at low levels (<17.8%). Furthermore, the plaque assay 
shows that the remaining virus is able to establish an active infection (Figure 
5.1). These findings are similar to those reported for C. trachomatis, where 
sperm washing was found to be ineffective at removing the bacteria from 
both artificially and naturally infected semen samples (Al-Mously et al., 
2009). The average Chlamydial load remaining after washing was 4.02%, a 
slightly lower value than that observed for CMV in this study. The failure of 
sperm washing to completely remove CMV also corresponds with previous 
reports found in vivo. In these studies, CMV DNA is detected in the sperm 
pellet in 89.36% and 92% of semen samples purified by density gradient 
centrifugation (Michou et al., 2012; Naumenko et al., 2014). Unfortunately, 
these papers do not report the viral load remaining after washing, so the 
efficiency of removal of CMV cannot be directly compared to this study. 
The efficiency of sperm washing was not affected by the amount of time the 
sperm were exposed to CMV (Figure 5.1). As little is known about the 
interaction between CMV and sperm, the amount of time needed to establish 
a direct interaction, if one was occurring, was not known. It is known that 
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during a normal replication cycle of CMV in human foreskin fibroblast cells, 
immediate early proteins are detected with 3 hours (Stinski et al., 1981). This 
suggests that binding, entry and initial gene expression would have to occur 
within those first few hours. Most studies allow for an initial attachment period 
of 60 minutes (Griffiths et al., 1984), including studies involving sperm (Pallier 
et al., 2002). However, some studies investigating mechanisms of binding 
use a period of 90 minutes (Compton et al., 1993). Given that any potential 
mechanism of binding to sperm is not known, two incubation periods were 
chosen: one and six hours. If CMV is binding to sperm via a mechanism 
taking longer than one hour to establish, it would be expected that the 
amount of virus remaining after washing would be increased after a six hour 
incubation. This was not observed, showing that the amount of time sperm 
are exposed to CMV does not affect the efficiency of sperm washing. This is 
an important consideration in the fertility clinic with regards to sample 
delivery and preparation. For example, if preparation of the semen sample 
prior to washing took longer than one hour, this would not affect the outcome 
of the procedure. However, after six hours, sperm motility would be 
considerably decreased (Table 5.1), which would affect the quality of sperm 
recovered after washing, and be more problematic for assisted conception 
techniques. 
The efficiency of sperm washing was also not affected by the dose of virus 
the sperm were exposed to (Figure 5.4). As the dose of virus in men with 
natural infection was not known prior to performing the initial experiments, a 
dose of 1 virus particle to 1 sperm was chosen. This ratio follows a pattern 
similar to a multiplicity of infection (MOI) dose used in other studies such as 
Al-Mously et al., (2009). However, in this instance, as the viral load 
(copies/ml) was used to calculate the amount of virus added, rather than the 
PFU, the term MOI cannot be used. When the amount of virus in naturally 
infected men was subsequently found to be much lower (Figure 5.6) than the 
dose of virus used in the initial experiments in this chapter, a dose response 
experiment was carried out (Figure 5.4). At a dose of 1 and 0.1, there was a 
significant reduction in the amount of virus present after washing (Figure 
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5.4), in line with other experiments carried out. However, at the lower doses, 
of 0.01 and 0.001, there is no significant reduction, and importantly, some 
virus still remained. Unfortunately, the ability of virus in these lower doses to 
establish an active infection could not be determined due to detection limits 
of the plaque assay. Whilst the higher doses of virus did not affect the 
efficiency of sperm washing, this experiment does shows that the more virus 
present prior to washing, the more virus will remain after washing (Figure 
5.4). This suggests, that semen samples with a higher dose of virus in vivo
are likely to retain a larger amount of virus after washing. 
From these initial experiments, it was clear that density gradient 
centrifugation was able to remove the majority of CMV in a semen sample, 
regardless of incubation time or dose of virus. However, the retention of 
some virus after washing suggests that CMV could be binding to sperm. 
Conversely, the presence of CMV in the sperm pellet could be due to 
recontamination of the pellet with virus that gets trapped at the interface 
between the two PureSperm layers. Modified methods of sperm washing 
have been adopted to bypass this problem, including the double tube 
gradient method (Politch et al., 2004). The procedure works by having an 
inner tube, through which the pellet is retrieved, without having to pass 
through the interface layer, located in the outer tube (Figure 2.3b). This 
thesis used a commercially available version of this, the ProInsert™ tube, 
which was found to be more effective at removing CMV from semen samples 
in vitro (Figure 5.2). A median percentage of 1.6 (range 0-101)% of CMV 
remained after washing when using the ProInsert™ tube, in comparison to 
15.2 (range 0.6-61)% when density gradient centrifugation was used. 
Interestingly, no infectious virus was detected after washing with the 
ProInsert™ method. 
The average amount of CMV remaining after washing with the ProInsert™ 
method was only ~60,000 copies/ml lower than when density gradient 
centrifugation was used, but infectious virus was still detected with the latter 
method, but not the modified method. It could be argued that the lack of 
plaques observed could be due to detection limits of the plaque assay. 
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However, some of the values of CMV remaining after washing with the 
ProInsert™ method were higher than those found after conventional 
washing, within the same repeat, but plaques were not observed, suggesting 
this finding is not due to the detection limits of the plaque assay.
The presence of DNA without corresponding plaques could be due to DNA 
contamination of the ProInsert™ samples, or ineffective DNA extraction, 
some limitations of the techniques used. Alternatively, it could be due to the 
presence of exogenous viral DNA in the preparation of virus used, a 
limitation discussed in Chapter 4. Exogenous DNA is known to bind directly 
to sperm (Zani et al., 1995), and could therefore be present in the sperm 
pellet, contributing to the presence of viral DNA after washing, as detected by 
qPCR. If only viral DNA were present in the pellet, this would explain the lack 
of plaques observed. It is possible that the ProInsert™ tubes are better at 
separating full virions from the sperm pellet than density gradient 
centrifugation but is not able to filter out exogenous DNA.
Despite these limitations, it is clear that the ProInsert™ method is more 
effective at removing CMV from semen samples. Importantly, viable sperm 
were present in the sperm pellet, which is important if this technique is to be 
used in fertility clinics. Sperm motility was higher after washing compared to 
the density gradient method, although less sperm are recovered (Table 5.2). 
It is important to note that some virus is still detected after washing, though 
this was not determined as infectious. Despite this, the presence of CMV 
after washing with this modified method provides evidence to suggest a small 
proportion of CMV is binding directly to sperm. As re-contamination of the 
pellet is ruled out with this method, the presence of CMV in the sperm pellet 
could be explained through a direct interaction. 
The in vitro experiments outlined so far have shown that sperm washing is 
able to remove over 80% of CMV from semen samples. This is a promising 
finding when considering the role sperm washing might play in the removal of 
CMV in vivo, in the context of donor assisted conception. 
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To investigate this, semen samples were analysed for the presence of a 
natural CMV infection. Out of 79 ejaculates, 13 were found to be positive, 
resulting in a 16.4% prevalence of CMV. This rate of CMV presence in 
semen is slightly higher than what has previously been reported (reviewed in 
Kaspersen & Hollsberg, 2013), which could be due to the use of qPCR to 
detect viral load, rather than other techniques, which are known to be less 
sensitive than qPCR.
CMV DNA was found in the sperm pellet of only 2/13 (15.4%) positive 
samples after washing, with only 6.2% of the virus present before washing 
remaining. This was statistically significant, but directly conflicts with some 
values reported in the literature, which have found up to 92% of naturally 
infected samples remaining positive after washing (Michou et al., 2012; 
Naumenko et al., 2014). However, other studies have reported values similar 
to those found in this study, with only 15% (Witz et al., 1999) and 12.8% 
(Naumenko et al., 2011) of samples remaining positive after washing.
Evidence presented in this chapter suggests sperm washing by density 
gradient centrifugation is more efficient on in vivo infected samples compared 
to experimentally inoculated ones. These findings are encouraging for the 
potential use of sperm washing in fertility clinics as a way of better managing 
sperm donors with a CMV infection. As discussed in Chapter 3, sperm 
donors are currently screened by serum antibody testing, which gives no 
indication of the presence of CMV in their semen. Under these current testing 
conditions, the removal of CMV by sperm washing could not be utilised as a 
tool to improve practice, as the presence of CMV in the individual ejaculate is 
not tested for. The evidence that sperm donors intermittently shed CMV in 
their semen (Figure 5.5), suggests that it may be prudent to screen every 
ejaculate as such rapid changes in the shedding of virus, sometimes as short 
as 3 days, will not be detected by antibody testing. 
The evidence that men intermittently shed CMV in their semen is an 
interesting observation that has been reported before (Kaspersen et al., 
2012). This thesis has built upon these previous reports by showing short 
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bursts of reactivation and clearance of CMV from semen that was not 
reported in the Kaspersen et al., (2012) study. This has previously been 
reported for HSV in oral and anogenital swabs (Mark et al., 2008). Samples 
taken four times a day over a six day period observed approximately 44% of 
HSV reactivation events lasted ≤12 hours. Moreover, in 23% of cases, the 
reactivation event lasted ≤6 hours (Mark et al., 2008). This rapid clearance is 
thought to be due to the persistence of HSV specific CD8+ T lymphocytes in 
genital skin after initial infection (Johnston et al., 2012; Zhu et al., 2007). One 
limitation of this finding is the lack of serological data to accompany the PCR 
data. It would have been ideal to know if the shedding pattern of CMV 
correlated with a donor’s CMV serostatus, as this would have shown if serum 
antibody testing is a valuable tool in determining if a sperm donor is safe to 
use or not. However, this was not done, as when the study was designed, 
the concept of intermittent shedding was not known. The finding that men 
intermittently shed CMV in their semen brings into question how screening 
for CMV in sperm donors is currently being performed and will be discussed 
in more detail in Chapter 7.
The findings outlined in this chapter provide promising prospects for 
alleviating some of the problems with the screening and management of 
CMV positive sperm donors outlined in Chapter 3. However, the limitations of 
the techniques used in this chapter, such as inefficient DNA extraction and 
DNA contamination of samples, need to be acknowledged. The method 
employed for DNA extraction was not optimised for use in sperm. This could 
be problematic, as in comparison to somatic cells sperm have a more 
condensed nucleus. Due to this, it is possible not all of the sperm DNA 
present in a given sample was extracted. This is an inevitable problem when 
working with sperm (Silva et al., 2014; Yuan et al., 2015) but reasonable 
steps were taken to confirm that DNA was extracted by testing for the 
presence of GAPDH, and any negative samples were excluded from analysis 
to eliminate any false negative results. Also, no correlation was observed 
between the sperm concentration and viral load, showing that the amount of 
-197-
sperm DNA present did not influence the amount of viral DNA recovered, 
eliminating the concern of inefficient DNA extraction. 
DNA contamination was a continual problem throughout this study even 
though all obvious potential sources of contamination were eliminated. To 
control for this a negative H2O control was included for each batch of 
samples extracted and if found to be positive, samples were repeated or 
discarded from analysis, ruling out the presence of false positives, where 
possible. Whilst the qPCR assay has limitations, it has been reported that the 
validated assay used is accurate to within one Ct (Atkinson, C., Personal 
Communication). Therefore, with the inclusion of the controls to rule out false 
positives and negatives, it is believed the values reported in this chapter are 
accurate and correct.
Similarly, the plaque assay is not without limitations, as has been discussed 
previously in Chapter 4. A smaller number of repeats for the plaque assay 
were reported in this chapter, in comparison to the qPCR assay, due to these 
limitations. Briefly, these include difficulties in determining the right dilution to 
use, problems with infection and inaccuracies in detecting the true amount of 
infectious virus present in a sample. Despite these problems, the inclusion of 
the plaque assay has presented an interesting and novel finding in that CMV 
remaining after washing is able to establish an infection. Also, it has shown 
that sperm are able to transmit CMV to permissive cells and therefore could 
potentially act as a vector for transmission of CMV in vivo. Given the findings 
that sperm washing is effective at removing CMV in vivo, the findings 
pertaining to the presence of infectious virus in vitro seem unimportant. 
However, this evidence provides support for the theory that CMV is able to 
bind to sperm, resulting in its continued presence in the sperm pellet. 
In summary, the findings outlined in this chapter provide evidence to support 
the fact that sperm washing is generally effective at removing CMV from 
semen samples. It appears to be more effective when used on men 
experiencing a natural infection, as opposed to the in vitro conditions used in 
these experiments. Sperm washing may therefore provide a solution to the 
-198-
problems experienced in relation to the management of CMV positive sperm 
donors in UK clinics. Interestingly, the evidence showing that CMV persists 
after sperm washing in vitro, even with a modified tube aimed to rule out 
contamination, and that virus is able to establish an active infection provides 
evidence to support an interaction between CMV and sperm. The next 
chapter will focus on investigating this in more detail. 
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Chapter 6
Effects of in vitro co-incubation of 
CMV on human spermatozoon 
functional parameters
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6.1 Introduction
The previous chapter in this thesis provided evidence to show that CMV 
might be interacting directly with sperm as some virus remained after 
washing by density gradient centrifugation. This suggests a direct interaction 
between CMV and sperm might be occuring, as has been shown previously 
for C. trachomatis (Al-Mously et al., 2009) and HIV (Politch et al., 2004). To 
investigate this potential interaction further, this chapter will examine if 
exposure to CMV in vitro has any effect on sperm function. 
Many studies have examined if CMV has an effect on male fertility by 
investigating sperm parameters in men with or without a CMV infection 
(Bezold et al., 2001; Bezold et al., 2007; Chen et al., 2013; Eggert-Kruse et 
al., 2009; Kapranos et al., 2003; Michou et al., 2012; Naumenko et al., 2011; 
Neofytou et al., 2009), which provide an insight into how an infection with 
CMV could affect male fertility. However, in vitro studies are able to provide a 
better understanding of the direct mechanism for how CMV might affect 
sperm directly by eliminating other factors that could damage sperm, such as 
the immune system. This has been studied for other pathogens, such as C. 
trachomatis, HIV and HPV and has shown many potential mechanisms by 
which sperm function can be affected by exposure to infectious agents.
C. trachomatis is known to induce apoptosis in sperm (Eley et al., 2005a) 
and increases tyrosine phosphorylation (Hosseinzadeh et al., 2000). This 
provides indirect evidence for a receptor-mediated interaction (Eley et al., 
2005b), which could cause alterations in cell signalling pathways. As of yet, a 
receptor responsible for the interaction between C. trachomatis and sperm 
has not been found. However receptors have been identified for HIV 
(Cardona-Maya et al., 2011) and HPV (Foresta et al., 2010), which explains 
how these pathogens are able to affect sperm motility (Dondero et al., 1996; 
Foresta et al., 2011) through binding directly to spermatozoa.
Some in vitro studies have been conducted for examining the relationship 
between CMV and sperm. A recent study observed a pattern of staining for a 
CMV protein along the equatorial segment of the sperm (Naumenko et al., 
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2014), possibly suggesting a direct interaction, however, this was only 
observed in ~2% of sperm. The authors of this paper claim to have shown 
“successful infection of spermatozoa in vitro” and demonstration of 
intracellular localisation of CMV. However, they provide no explanation of 
why they believe the localisation of the CMV proteins to be intracellular, 
rather than only being present on the outer surface of the sperm head. 
Intracellular localisation of CMV in spermatogonia has been shown 
previously in an in vitro model (Naumenko et al., 2011), resulting in a 
reduction in the number of immature germ cells. If this was occurring in vivo, 
this alteration in immature germ cells might lead to a reduction in sperm 
concentration, as has been documented in CMV positive men (Naumenko et 
al., 2014).
These recent studies provide evidence to suggest that CMV could be 
interacting directly with sperm, possibly through receptor-mediated binding. 
However, what these studies lack is a direct investigation of if an infection 
with CMV affects sperm function parameters, such as motility or viability. 
They also lack any deeper understanding of the molecular basis for any 
effects the virus might be having on the function of the sperm. By gaining an 
understanding of the exact mechanism by which CMV and other pathogens 
are able to affect sperm function, as has been demonstrated with C. 
trachomatis, it will allow for a greater understanding of how CMV infection 
can contribute to male infertility. 
6.2 Experimental rationale
To begin investigating if infection with CMV has an effect on sperm function, 
an in vitro approach was used to examine the effects on certain sperm 
function parameters, such as motility, viability and the acrosome reaction. 
Other parameters that might affect sperm function, such as levels of DNA 
damage and tyrosine phosphorylation were also assessed. By co-incubating 
laboratory grown CMV with sperm in vitro, this controls for the presence of 
other organisms present in an ejaculate, which might also have an effect on 
sperm. Similarly, the use of ejaculated sperm, purified from all seminal 
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components will control for any in vivo biological processes/factors, which 
might have an adverse effect on the spermatozoon. These erroneous factors 
might contribute to inconsistencies observed in in vivo correlation studies. 
Elimination of these factors allows for direct investigation of whether CMV is 
capable of affecting the function of the spermatozoon.  
In order for sperm to successfully deliver the paternal genome to the oocyte, 
they need to be motile in order to reach the egg (Suarez and Pacey, 2006), 
be able to penetrate the zona pellucida, which requires an intact acrosome 
(Yoshinaga & Toshimori, 2003) and be able to hyperactivate (Stauss et al., 
1995). Investigating whether exposure to CMV has an effect on these 
functional parameters will directly assess the fertilisation potential of the 
sperm. Other molecular aspects of sperm function have also been linked to a 
reduction in fertilisation potential, such as the levels of tyrosine 
phosphorylation and DNA damage. Phosphorylation of tyrosine residues on 
the spermatozoon is an essential part of sperm capacitation (Viscont et al., 
1995), hyperactivation (Nassar et al., 1999) and the acrosome reaction 
(Sebkova et al., 2012). The precise activation of these mechanisms at the 
most optimal point in the female reproductive tract is necessary for 
successful fertilisation. Therefore, premature activation of these events might 
lead to a reduction in fertilisation potential. To investigate this, the levels of 
tyrosine phosphorylation and hyperactivation will be assessed. Similarly, 
sperm DNA damage has been linked to an increase in pregnancy loss due to 
the role the sperm genome plays in early embryogenesis (Robinson et al., 
2012). DNA damage that occurs in regions of the sperm genome accessible 
to enzyme modification (i.e regions bound by histones, not protamines) 
(Figure 6.1) is thought to have an impact on the success of fertilisation and 
embryonic development as these areas are thought to be most active during 
the first hours of fertilisation (Hammand et al., 2009; Ward et al., 1999). The 
TUNEL assay is able to measure DNA damage in these areas of the sperm 
genome and will be used in this chapter to assess if exposure to CMV 
compromises the integrity of sperm DNA.
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Figure 6.1: Donut-loop model for sperm chromatin structure. During 
spermiogenesis, histones bound to DNA are replaced by protamines, which fold the 
DNA into tightly packaged toroids. The donut model proposes that a toroid linker 
region, which is composed of chromatin that is more sensitive to DNA damage, 
connects each protamine toroid (Sotolongo et al., 2003). These regions are thought 
to house the remaining histones left over after modification, located at the MAR 
(matrix attachment regions). It is in these regions that is thought most of the sperm 
DNA damage occurs (Shaman and Ward, 2006). The TUNEL assay works by 
detecting DNA damage present in the toroid linker regions. Unlike other DNA 
damage assays, such as the Sperm Chromatin Structure Assay (SCSA), or the 
COMET assay, the TUNEL assay has no salt extraction step, which would remove 
the protamines. Reprinted from Sotolongo et al., (2003) with permission from the Society 
for the Study of Reproduction.
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The aim of this chapter is to determine the fertilisation potential of sperm 
after exposure to CMV by assessing sperm parameters associated with 
reproductive success. By measuring the viability, motility, acrosome status, 
levels of DNA damage and tyrosine phosphorylation, this will be indirectly 
measuring if sperm exposed to CMV are capable of reaching, binding and 
fertilising the oocyte, as well as possessing the genomic integrity to produce 
a viable zygote. Any alteration in these parameters would provide evidence 
for the role in vivo CMV infection might play in male infertility and would 
provide evidence to support a direct interaction between CMV and sperm. 
6.2.1 Specific aim(s):
1. Determine if co-incubation of sperm with CMV affects sperm motility, 
viability and acrosome status over a 6-hour time period.
2. Determine if the dose of CMV has an incremental effect on basic 
sperm function parameters, measured in vitro.
3. Investigate if there are different effects on sperm function between 
laboratory and wild-type strains of CMV.
4. Investigate the effects of CMV exposure on molecular sperm 
responses, such as DNA damage and tyrosine phosphorylation over a 
6-hour time period. 
6.3 Materials and Methods
To achieve the objectives outlined above, washed sperm were co-incubated 
with different strains of CMV at different doses, over a six-hour time period. 
Different parameters of sperm function were assessed in order to determine 
if exposure to CMV was having an effect on sperm function. Sperm motility, 
viability and acrosome status were assessed in the first part of this chapter. 
Following this, molecular markers of sperm function were assessed, in the 
form of DNA damage and tyrosine phosphorylation. Finally, sperm 
kinematics were investigated to analyse if exposure to CMV had any subtle 
effects on sperm movement.
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For all of the experiments outlined in this section, semen samples were 
assessed prior to use for motility and the sperm concentration of each 
sample was measured, as outlined in Section 2.5.1. Samples were washed 
by density gradient centrifugation, as outlined in Section 2.5.3. All samples 
were coded to prevent observer-introduced bias of the results obtained. 
After the initial set up of each experiment all samples were incubated at 37°C 
at 5% CO2 for 6 hours. For time course experiments (Sections 6.3.1.1, 
6.3.1.3, 6.3.1.5, 6.3.2 and 6.3.3), aliquots were removed for analysis at 0, 1, 
3 and 6 hours. However in the dose response experiment (6.3.1.4), aliquots 
were only removed at 6 hours. The aliquots removed for analysis were: 10μl 
to assess sperm motility (see Section 2.5.1); 10μl added to 100μl of HOST 
media for assessment of sperm viability and acrosome status (to reach a 
final sperm concentration of ~1x106/ml) (Section 2.5.4); 35μl diluted in 65μl 
H2O (to reach a final sperm concentration of ~5x10
6/ml) for the TUNEL assay
(Section 2.5.5); and 10μl diluted in 90μl H2O (to reach a final sperm 
concentration of 1.18x106/ml) for tyrosine phosphorylation assessment 
(Section 2.5.6). Statistical differences were examined using the one-way 
ANOVA test on log-transformed data using the Tukey’s test for multiple 
corrections. 
6.3.1 Effects of co-incubation of different strains of CMV on sperm 
motility, viability and acrosome reaction
6.3.1.1 CMV (AD169) time course co-incubation 
Washed sperm from six healthy donors with an initial sperm concentration of 
>60x106/ml were used to prepare 3 x 300μl aliquots of highly motile sperm 
with a concentration of ~18x106/ml and a percent motility >60%. To each 
aliquot, either 100μl of virus-infected supernatant, mock-infected supernatant 
or E. coli lipopolysaccharide (LPS) (026:B6) were added, giving a final sperm 
concentration of ~13.5x106/ml and a total sperm count per incubation of 
~5.4x106. Virus-infected supernatant was added at a viral load of 
5.4x107copies/ml, giving a final number of viral particles of 5.4x106, and a 1:1 
ratio of viral particles to sperm. Mock-infected supernatant was added as a 
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negative control to control for erroneous factors in the growth conditions of 
the virus, such as cell debris and exogenous DNA. This was added at the 
same concentration of virus-infected supernatant (100μl, undiluted). 100μl of 
E.coli LPS was used as a positive control, as this has been shown to effect 
sperm function parameters at a final concentration of 50μg/ml (Hosseinzadeh 
et al., 2003). 
6.3.1.2 LPS control test
Washed sperm from six healthy donors with an initial sperm concentration of 
>60x106/ml were used to prepare 4 x 100μl aliquots of highly motile sperm 
with a concentration of ~10x106/ml and a percent motility of >60%. To each 
aliquot, 20μl of E.coli LPS (055:B5) (Sigma-Aldrich, Dorset, UK), at a final 
concentration of 150μg/ml, 100μg/ml or 50μg/ml was added, along with 20μl 
of H2O as a negative control. The samples were incubated at 37°C in 5% 
CO2 for 6 hours and sperm motility was assessed at the end of the incubation 
period. 
6.3.1.3 CMV Towne VS CMV AD169 time course co-Incubation
Sperm from six healthy donors with an initial sperm concentration of 
>60x106/ml were used to prepare 3 x 300μl aliquots of highly motile sperm 
with a concentration of ~18x106/ml and a percent motility of >60%. To each 
aliquot, either 100μl of CMV (AD169)-infected supernatant (AD169), purified 
CMV (Towne), or serum-free EMEM (negative control) were added, giving a 
final sperm concentration of ~13.5x106/ml and a total sperm count per 
incubation of ~5.4x106. CMV (AD169)-infected supernatant was added at a 
viral load of 5.4x107copies/ml, giving a final number of viral particles of 
5.4x106, and a 1:1 ratio of viral particles to sperm. CMV (Towne) was 
supplied at a titre of 3x106 PFU/ml. As the total viral load was not supplied, 
the viral load in copies/ml was matched with CMV (AD169)-infected 
supernatant by matching the PFU/ml. Therefore, since 100μl of CMV 
(AD169) contains 4300 PFU/ml, the same amount of CMV (Towne) was 
added by diluting 14.5μl of CMV Towne stock in 985.5μl serum-free EMEM, 
to give a final concentration of 4.3x104PFU/ml. By matching the virus 
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preparations based on the PFU titre, a measure of infectious virus, the total 
viral load should be approximately the same. Whilst not exact, due to the 
probability of circulating exogenous DNA in an unpurified preparation of 
virus, the number of live virus particles should be very similar.
6.3.1.4 Dose-response co-incubation
Washed sperm from six healthy donors with an initial sperm concentration of 
>60x106/ml were used to prepare 13 x 100μl aliquots of sperm with a 
concentration of ~20x106/ml and a percent motility >60%. To each aliquot 
different concentrations of either 100μl of CMV (AD169)-infected 
supernatant, mock-infected supernatant, purified CMV (Towne) or serum-free 
EMEM (negative control), were added. A two-fold dilution series of both CMV 
(AD169)-infected supernatant and purified (Towne) was performed to 
achieve final viral loads of 2.0x107, 1.0x107, 0.5x107 and 0.25x107copies/ml, 
giving final virus to sperm ratios of 2:1, 1:1, 0.5:1 and 0.25:1. A two-fold 
dilution series of mock-infected supernatant was also performed to control for 
any erroneous factors in the growth conditions of the virus, such as cellular 
debris and exogenous DNA. The final sperm concentration in each 
experimental incubation was ~10x106/ml with a total sperm count per 
incubation of ~2.0x106. 
6.3.1.5 Wild-type time course co-incubation
In this experiment, different strains of purified CMV were used, all supplied 
by Dr Matthew Reeves (UCL, London). CMV (Towne) and TB40E were used 
as laboratory strains and Merlin as a wild-type strain of CMV. Sperm from six 
healthy donors with an initial sperm concentration of >60x106/ml were used 
to prepare 4 x 300μl aliquots of highly motile sperm with a concentration of 
~18x106/ml and a percent motility >60%. To each aliquot, either 100μl of 
CMV (various strains) or serum-free EMEM (negative control) were added, 
giving a final sperm concentration of ~13.5x106/ml and a total sperm count 
per incubation of ~5.4x106. Once again, the virus preparations were not
supplied with a total viral load value (in copies/ml). Therefore, the 
concentration was matched using the value of 4300 PFU/ml to achieve a final 
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total virus to sperm ratio of 1:1, as outlined in Section 6.3.1.3. To each 
aliquot of sperm, 100μl of each virus preparation, containing 4300 PFU/ml 
was added (which is estimated to be approximately 5.4x106 total virus in 
copies/ml). 
6.3.2 Effects of co-incubation of different strains of CMV on molecular 
markers of sperm function
6.3.2.1 Analysis of DNA damage levels
In the wild-type time course co-incubation experiment detailed in Section 
6.3.1.5, at each time point, 35μl was taken to perform the TUNEL assay (as 
outlined in Section 2.5.5).
6.3.2.2 Tyrosine phosphorylation time course
Sperm from six healthy donors with an initial sperm concentration of 
>66x106/ml were used to prepare 5 x 200μl aliquots of highly motile sperm 
with a concentration of ~16x106/ml and a percent motility >60%. To each 
aliquot, either 100μl of CMV (AD169)-infected supernatant, purified CMV 
(Towne), purified wild-type CMV (Merlin), serum-free EMEM (negative 
control), or E. coli LPS (R515) (Enzo, Exeter, UK) were added, giving a final 
sperm concentration of ~11.6x106/ml and a total sperm count per incubation 
of ~3.6x106. All strains of CMV were diluted prior to addition to the reaction to 
reach a concentration of 3.6x107copies/ml, giving a final number of viral 
particles of 3.6x106 and a 1:1 ratio of viral particles to sperm. As in Section 
6.3.1.3, the viral load of CMV strains Towne and Merlin were estimated 
based on the PFU/ml value provided with the viral preparations. LPS (R515) 
was added at a final concentration of 50mg/ml+2%FCS. 
6.3.3 Effects of co-incubation of different strains of CMV on sperm 
kinematics
In the tyrosine phosphorylation time course experiment outlined in Section 
6.3.2.2, at each time point 10μl of each incubation was taken to assess 
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sperm motility and kinematics on a CASA machine, as outlined in Section 
2.5.2. 
6.4 Results
6.4.1 Co-incubation with CMV has no significant effect on sperm 
parameters in vitro
6.4.1.1 CMV (AD169) time course co-incubation 
The results from this initial co-incubation indicated that at a 1:1 ratio of virus 
particles to sperm, there was a significant effect on sperm motility at 3 hours 
(Figure 6.2a), in comparison to the mock-infected supernatant control 
(P<0.05), but this statistical difference was not seen at 6 hours post-
incubation. However, there was no significant effect on sperm viability 
(Figure 6.2b) or the percentage of acrosome reacted sperm (Figure 6.2c) 
with the preparation of virus-infected supernatant, even after 6 hours.
Further analysis of the individual motility categories (Figure 6.3) shows that 
over the 6-hour co-incubation the percentage of category a spermatozoa (i.e 
those swimming at >25μm/second) decreases. There is a significant 
difference between virus-exposed sperm and both the mock infected sperm 
and LPS control at 1 (P<0.001 and P<0.01, respectively) and 3 hours 
(P<0.01 and P<0.001, respectively). However, this significance was not 
observed after 6-hours co-incubation with the only significant difference 
remaining between the mock-infected control and LPS control (P<0.05) 
(Figure 6.3a). Similarly for category b sperm (those swimming between 25-
5μm/second), there is a slight increase over the 6-hour co-incubation period. 
There are significant differences between sperm co-incubated with virus and 
both mock-infected samples and sperm co-incubated with 50μg/ml LPS at 1-
hour post incubation (P<0.001 and P<0.01, respectively), and a small 
significance of P<0.05 between mock-infected control and LPS control at 3 
hours post-incubation. Once again, this significance was no longer seen at 6 
hours post-incubation (Figure 6.3b). For category c sperm (those swimming 
at <5μm/second) there is a general increase over the 6-hour incubation 
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Figure 6.2: CMV (AD169) time course. Details of percentage: (a) sperm motility; 
(b) viability; and (c) acrosome-reacted sperm over a six-hour co-incubation period 
with 5.4x106 CMV particles, mock-infected supernatant or 50μg/ml LPS positive 
control. Data shown are the mean ± SEM of incubations with sperm preparations 
from six healthy donors. Statistical significance was assessed using a one-way 
ANOVA test on log-transformed data with differences between groups examined 
using Tukey’s multiple comparison test. The symbol (*) indicates a difference 
between the CMV experimental group and the mock-infected control at a
significance level of P<0.05.
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Figure 6.3: Details of individual motility categories over a six-hour co-incubation period with 5.4x106 CMV particles, mock-infected 
supernatant or 50μg/ml LPS positive control. Figures a, b ,c , and d correspond to the four different motility categories, respectively.
Data shown are the mean ± SEM of incubations with sperm preparations from six healthy donors. Statistical significance was assessed
using a one-way ANOVA test on log-transformed data with differences between groups examined using Tukey’s multiple comparison 
test.  The symbol (*) indicates a difference between the CMV experimental group and the mock-infected control. The symbol (+) 
indicates a difference between the CMV experimental group and the LPS control. The symbol (#) indicates a difference between the 
mock-infected control and the LPS control. One symbol indicates a significance level of P = <0.05, two symbols a significance level of 
P<0.01, and three symbols a significance level of P<0.001.
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period. There are significant differences between sperm co-incubated with 
virus and the mock-infected control at both 1 hour (P<0.01) and 3 hour 
(P<0.01) post-incubation, but this significance was not observed at 6 hours 
post-incubation. At 6 hours post incubation, there are significant differences 
between the virus-exposed sperm and LPS control (P<0.001) and LPS 
control and mock-infected control (P =0.05) (Figure 6.3c). Over the 6-hour 
incubation period, there was an increase of category d sperm (immotile), but 
there were no significant differences between any of the conditions (Figure 
6.3d). 
It is clear that the positive control of LPS was not effective in this set of 
experiments as there was only a moderate decline in motility over the 6-hour 
period (Figure 6.2a), despite much higher effects being observed at the same 
concentration by Hosseinzadeh et al., (2003). Similarly, there were no 
obvious effects of LPS on viability and the percentage of acrosome-intact 
sperm (Figure 6.2b,c). Clearly, in order to use LPS as a positive control, the
LPS should be having a more noticeable effect on these sperm function 
parameters. After altering the dose of LPS used (Figure 6.4) from 50μg/ml to
150μg/ml, there was no significant effect on sperm motility, in comparison to 
a negative control. However the dose that seemed to have the most effect on 
decreasing the percentage of progressively motile sperm, and increasing the 
percentage of immotile sperm was 50μg/ml, the same dose as reported to be 
effective in the literature. 
This set of experiments does not clearly identify if exposure to CMV has an 
effect on sperm function, as there is no consistent statistically significant 
difference between sperm co-incubated with virus and those incubated under 
control conditions. This could be due to the dose of the virus, the strain of the 
virus, or factors present in the viral supernatant, which are also present in the 
mock-infected supernatant, such as exogenous DNA. The subsequent 
experiments were designed to address these issues. 
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Figure 6.4: Details of individual motility categories of four healthy donors over a six 
-hour incubation period with an increasing dose of E. coli LPS (055:B5). A H2O 
negative control was used and is shown at a value of zero. Box and whisper plots 
depict the interquartile range, 5th percentile and 95th percentile. The mean is shown 
as a ‘+’. Statistical significance was analysed using a one-way ANOVA test on log-
transformed data with differences between each group examined using Tukey’s 
multiple comparison test. No statistical differences were found.
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6.4.1.2 CMV (AD169) VS TOWNE time course co-incubation 
To determine if the lack of effect on sperm function parameters using CMV 
(AD169) is due to the lack of purification of the AD169 virus preparation, a 
time course was performed using a purified laboratory strain of CMV 
(Towne), supplied from Dr Matthew Reeves (UCL, London). Also, rather than 
a mock-infected supernatant control, a media-only (EMEM) control was used 
as this is a more suitable control for the purified virus. 
The results are shown in Figure 6.5 and in summary there were no significant 
difference between sperm co-incubated with CMV Towne and a media-only 
control on sperm motility (Figure 6.5a), sperm viability (Figure 6.5b) or the 
percentage of acrosome reacted sperm (Figure 6.5c). Similarly, there were 
also no significant differences between CMV Towne and CMV AD169 in the 
percent of viable sperm or the proportion which had undergone the acrosome 
reaction. However there was a significant (P<0.05) reduction in sperm 
motility when exposed to AD169 in comparison to Towne and a media 
control after 6 hours incubation (Figure 6.5a).
Detailed analysis of the individual motility categories (Figure 6.6) shows a 
significant difference in the proportion of grade a sperm co-incubated with 
CMV AD169 and both CMV Towne and a media control after 6 hours 
(P<0.05) (Figure 6.6a). No significant differences were observed between the 
three conditions for either category b or d sperm (Figures 6.6b & 6.6d). 
However there was a significant difference (P<0.01) after 6 hours co-
incubation between sperm incubated with CMV AD169 and CMV Towne 
(Figure 6.6c), for category c sperm. 
This significant decrease in category a sperm and increase in category c 
sperm after co-incubation with AD169 is similar to what is observed in Figure 
6.2c and suggests that whilst CMV AD169 is not causing an increase in the 
percentage of immotile sperm, it is reducing the motility of the sperm. As this 
is not observed with the purified strain of CMV (Towne), this difference could 
be explained by the presence of external factors, such as exogenous DNA, 
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Figure 6.5: CMV (AD169) vs CMV (Towne) co-incubation. Details of percentage: 
(a) sperm motility; (b) viability; and (c) acrosome-reacted sperm over a six-hour co-
incubation period with 5.4x106 CMV AD169 and Towne particles or a serum-free 
EMEM negative control. Data shown are the mean ± SEM of incubations with sperm 
preparations from six healthy donors. Statistical significance was assessed using a 
one-way ANOVA test on log-transformed data with differences between groups 
examined using Tukey’s multiple comparison test. The symbol (*) indicates a 
difference between the CMV AD169 group and CMV Towne group. The symbol (+) 
indicates a difference between the CMV AD169 group and the media control, at a 
significance level of P<0.05.
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Figure 6.6: Details of individual motility categories over a six-hour co-incubation period with 5.4x106 CMV AD169 or Towne particles, 
or a serum-free EMEM negative control. Figures a, b ,c , and d correspond to the four different motility categories, respectively. Data 
shown are the mean ± SEM of incubations with sperm preparations from six healthy donors. Statistical significance was assessed
using a one-way ANOVA test on log-transformed data with differences between groups examined using Tukey’s multiple comparison 
test. The symbol (*) indicates a difference between the CMV AD169 group and CMV Towne group. The symbol (+) indicates a 
difference between the CMV AD169 group and the media control. One symbol indicates a significance level of P<0.05 and two symbols 
a significance level of P<0.01
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present in the un-purified AD169 preparation, which are absent in the purified 
Towne preparation.
6.4.1.3 CMV (AD169) & CMV Towne dose response co-incubation
To investigate if the lack of effects observed in the first two sets of 
experiments is due to the dose of virus used (a 1:1 ratio), a dose response 
was carried out. A range of viral concentrations from 2:1 virus particles to 
sperm down to 0.25:1 were carried out, with a media-only (EMEM) control. 
In summary, there was no significant effect of co-incubation of CMV AD169 
or Towne at any dose on sperm motility (Figure 6.7a), sperm viability (Figure 
6.7b) or the percentage of acrosome reacted sperm (Figure 6.7c), in 
comparison to a mock-infected and negative control. 
This set of experiments shows that the lack of effects observed with CMV 
AD169 and Towne at a ratio of 1 virus: 1 spermatozoon is not due to the 
dose of virus used. When the dose was increased 2-fold, no significant 
effects were observed. 
6.4.1.4 Wild-Type CMV time course co-incubation 
The strains of CMV used in the previous experiments (Section 6.4.1.1-
6.4.1.3) were laboratory strains, characterised by the inability to infect the 
type of cells CMV would infect in vivo. This is caused by mutations in the 
genes responsible for epithelial/endothelial cell tropism. Given this, a further 
set of experiments were performed with a wild-type strain of CMV (Merlin). In 
addition, another high passage strain of CMV (TB40E) was incorporated to 
analyse inter-strain differences.
Briefly, no significant differences were observed in sperm motility (Figure 
6.8a), sperm viability (Figure 6.8b) or the percentage of acrosome reacted 
sperm (Figure 6.8c), between any of the strains of CMV and a negative 
control over a 6-hour co-incubation period. A general trend of decline in 
motility was observed over the 6-hour period for all of the conditions, except 
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Figure 6.7: CMV dose response co-incubation. Details of percentage: (a) sperm 
motility; (b) viability; and (c) acrosome-reacted sperm after a six-hour co-incubation 
with 2.0x107/ml, 1.0x107/ml, 0.5x107/ml, 0.25x107/ml CMV AD169/Towne, or a 
serum-free EMEM negative control. Data shown are the mean ± SEM of incubations 
with sperm preparations from six healthy donors. Statistical significance was 
assessed using a one-way ANOVA test on log-transformed data with differences 
between groups examined using Tukey’s multiple comparison test. No statistically 
significant differences were observed.
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Figure 6.8: Wild-type CMV vs laboratory strain CMV co-incubation. Details of 
percentage: (a) sperm motility; (b) viability; and (c) acrosome-reacted sperm over a 
six-hour co-incubation period with 5.4x106 Towne, Merlin, TB40/E particles or a 
serum-free EMEM negative control. Data shown are the mean ± SEM of incubations 
with sperm preparations from six healthy donors. Statistical significance was 
assessed using a one-way ANOVA test on log-transformed data with differences 
between groups examined using Tukey’s multiple comparison test. No statistically 
significant differences were observed.
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Figure 6.9: Details of individual motility categories over a six-hour co-incubation period with 5.4x106 Towne, Merlin, TB40/E particles, or 
a serum-free EMEM negative control. Figures a, b ,c , and d correspond to the four different motility categories, respectively. Data shown 
are the mean ± SEM of incubations with sperm preparations from six healthy donors. Statistical significance was assessed using a one-
way ANOVA test on log-transformed data with differences between groups examined using Tukey’s multiple comparison test. No 
statistically significant differences were observed.
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TB40E, but this was not statistically significant between the different strains 
of CMV used. 
Similarly, analysis of the individual motility categories (Figure 6.9) revealed 
no significant differences between the virus strains and a media-only control 
for any of the sperm motility categories. There are slightly less category d 
(Figure 6.9d) spermatozoa in the TB40E infected samples, but this was not 
statistically significant. 
From this set of experiments, it can be concluded that different strains of 
CMV, including a wild-type strain, have no effect on functional parameters of 
washed sperm at this concentration. 
6.4.2 Co-incubation with CMV has no effect on molecular markers in 
vitro
As no obvious effects on sperm function, were observed in the experiments 
outlined in Section 6.4.1, further molecular aspects of sperm function were 
considered to investigate if these parameters were affected by exposure to 
CMV. In a similar experimental design, the levels of DNA damage and 
tyrosine phosphorylation were examined after exposure to various strains of 
CMV over a 6-hour co-incubation. 
Briefly, over 6-hours, no changes were observed in the levels of sperm DNA 
damage (Figure 6.10a). There were no significant differences between any of 
the strains of virus used, or the negative control. Similarly, no significant 
differences were observed between the strains of CMV used and either 
control when analysing the levels of tyrosine phosphorylation (Figure 6.10b). 
The levels of tyrosine phosphorylation generally increased over the 6-hour 
incubation, as would be expected, but there was no difference between the 
different incubations. Whilst there was no significant difference between the 
positive control (LPS) and the experimental conditions, incubation with LPS 
did lead to the highest percentage of tyrosine-phosphorylated sperm after 6 
hours incubation. 
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Figure 6.10: Details of percentage: (a) DNA damaged sperm; and (b) tyrosine 
phosphorylated sperm over a six-hour co-incubation period. Samples in (a) were
incubated with 5.4x106 Towne, Merlin, TB40/E particles or a serum-free EMEM 
negative control. Samples in (b) were incubated with 3.6x106 AD169, Towne or 
Merlin particles or a serum-free EMEM negative control. E. coli LPS (R515) was 
added as a positive control at a final concentration of 50mg/ml + 2%FCS. Data 
shown are the mean ± SEM of incubations with sperm preparations from six healthy 
donors. Statistical significance was assessed using a one-way ANOVA test on log-
transformed data with differences between groups examined using Tukey’s multiple 
comparison test. No statistically significant differences were observed
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From these two experiments, it can be concluded that exposure to CMV also 
has no effect on molecular aspects of sperm function at a dose of 1 virus 
particle to 1 sperm.
6.4.3 Co-incubation with CMV has no effect on sperm kinematics in 
vitro
Throughout the experiments outlined in Section 6.4.1, some changes in the 
proportion of sperm swimming in individual motility categories were 
observed, particularly with regard to the percentage of category a and 
category c sperm (Figures 6.3 & 6.6). To investigate these differences 
further, the motility of sperm exposed to CMV were analysed by a CASA 
machine. Briefly, no statistically significant differences were observed 
between any of the strains of CMV used and the two controls for the 
individual sperm motility categories (progressive, non-progressive or 
immotile). Similarly, when analysing the speed of sperm (rapid, medium or 
slow), no differences were observed (Table 6.1).
Upon analysis of the parameters of velocity, including the curvilinear velocity, 
average path velocity and straight-line velocity, no differences were observed 
(Table 6.2). Similarly, the progression ratios of sperm movement, the 
amplitude of lateral head movement (ALH) and beat cross frequency (BCF) 
showed no differences between the groups. Finally, the percentage of 
hyperactive sperm was not affected by co-incubation with CMV, or the 
positive control (Table 6.2). 
In conclusion, co-incubation with various strains of CMV over 6 hours does 
not affect any aspects of sperm motility, progression or movement.
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Table 6.1: Details of sperm motility parameters, measured by a CASA machine, over a 6-hour incubation with 3.6x106 AD169, Towne, or 
Merlin particles or a serum-free EMEM negative control. E. coli LPS (R515) was included as a positive control at a final concentration of 
50mg/ml+2% FCS. Data are shown as mean±SEM. Statistical significance was analysed using a one-way ANOVA test on log-transformed data.
Condition Motility Speed
0hr Progressive (P) Non-Progressive (NP) Immotile (IM) Rapid Medium Slow
All 69.3±8.2 10.7±1.4 19.9±6.8 66.6±8.0 9.6±1.3 3.9±0.9
1hr Progressive (P) Non-Progressive (NP) Immotile (IM) Rapid Medium Slow
LPS 72.4±3.4 11.6±1.9 16.1±1.9 70.9±3.7 9.5±2.6 3.5±0.4
CMV AD169 71.5±1.4 10.0±0.7 18.5±1.6 57.6±12.6 7.7±0.5 3.4±0.4
CMV Towne 63.7±8.4 11.1±1.1 25.2±7.6 62.9±8.4 7.7±0.9 4.2±0.8
CMV Merlin 68.4±7.4   9.0±1.4 22.6±6.7 67.3±7.9 6.8±1.7 4.4±0.8
EMEM 75.0±1.8   9.6±1.6 15.4±1.6 73.7±1.8 7.3±1.8 3.6±0.6
3hr Progressive (P) Non-Progressive (NP) Immotile (IM) Rapid Medium Slow
LPS 76.1±3.7   9.3±1.4 14.6±3.0 75.0±4.2 7.0±1.1 3.3±0.7
CMV AD169 70.2±6.6 10.1±1.6 19.7±5.1 69.6±6.6 6.8±0.6 3.9±1.4
CMV Towne 75.1±2.2   8.9±1.0 16.0±1.9 74.4±2.2 6.3±0.7 3.2±0.5
CMV Merlin 66.0±7.4 11.4±1.5 22.7±6.1 64.4±7.4 9.6±1.6 4.9±1.3
EMEM 68.3±5.2   9.7±1.1 22.0±4.8 67.2±5.3 7.4±0.9 3.6±0.6
6hr Progressive (P) Non-Progressive (NP) Immotile (IM) Rapid Medium Slow
LPS 46.7±9.5 25.4±6.9 27.9±5.2 45.5±9.9 17.4±5.1 9.2±2.2
CMV AD169 57.1±6.8 12.3±1.4 31.8±6.8 56.6±6.8 8.0±1.3 4.8±0.4
CMV Towne 60.1±8.9 14.9±3.4 25.0±8.3 59.1±8.9 10.0±3.0 5.9±1.1
CMV Merlin 56.1±9.9 16.6±3.6 7.3±7.0 55.5±10.0 12.6±3.6 6.8±2.0
EMEM 61.1±10.2 13.6±2.0 23.1±9.4 60.1±10.3 10.6±1.3 4.1±1.3
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Table 6.2: Details of sperm motility parameters, measured by a CASA machine, over a 6-hour incubation with 3.6x106 AD169, Towne, or 
Merlin particles or a serum-free EMEM negative control. E. coli LPS (R515) was included as a positive control at a final concentration of 
50mg/ml+2% FCS. Data are shown as mean±SEM. Statistical significance was analysed using a one-way ANOVA test on log-transformed data.
Condition Velocity Parameters Progression Ratios Motion Vigor Hyperactivity
0hr VCL μm/s VSL μm/s VAP μm/s LIN % STR % WOB% ALH μm BCF Hz %Hyperactive
All 61.2±5.2 23.4±4.5 34.7±4.1 36.6±3.6 65.2±4.3 55.6±1.9 2.3±0.1 9.9±1.0 7.7±3.7
1hr VCL μm/s VSL μm/s VAP μm/s LIN % STR % WOB% ALH μm BCF Hz Hyperactive
LPS 67.6±7.9 23.3±5.7 37.5±5.3 33.4±4.4 55.0±9.0 55.2±2.2 1.9±0.3 10.0±2.1 5.1±4.1
CMV AD169 70.0±5.3 22.3±3.6 38.3±4.1 31.8±3.9 57.5±5.9 54.8±1.5 2.1±0.2 9.8±1.2 4.9±3.9
CMV Towne 65.5±4.7 25.2±6.4 38.3±4.8 36.9±6.6 62.2±7.5 57.7±3.2 2.2±0.2 10.9±1.5 6.1±4.7
CMV Merlin 66.6±3.4 23.5±2.7 37.1±1.8 35.7±3.8 57.4±5.0 56.1±1.8 2.3±0.2 10.7±0.9 7.0±2.9
EMEM 65.9±3.1 24.0±4.5 37.7±2.9 36.1±5.6 62.0±6.8 57.1±2.6 2.1±0.1 10.7±1.4 5.7±4.8
3hr VCL μm/s VSL μm/s VAP μm/s LIN % STR % WOB% ALH μm BCF Hz Hyperactive
LPS 74.4±7.7 25.8±4.3 41.6±4.6 34.2±3.5 56.3±8.3 55.9±1.5 2.3±0.2 11.4±1.2 6.1±3.7
CMV AD169 76.6±6.8 26.3±3.3 42.7±3.5 34.4±3.3 61.0±4.5 56.0±1.2 2.4±0.2 11.1±0.8 5.8±3.3
CMV Towne 79.8±7.0 23.5±2.2 42.3±3.1 29.5±1.4 55.2±2.1 53.2±0.9 2.4±0.1 10.6±0.5 3.7±1.4
CMV Merlin 65.5±2.2 26.1±4.2 38.8±2.5 39.7±5.6 60.8±5.9 59.1±2.7 2.3±0.2 10.5±0.6 9.1±4.5
EMEM 71.4±5.4 26.3±4.4 40.7±3.4 36.0±4.1 57.5±6.4 56.8±1.4 2.3±0.2 9.5±1.7 6.6±3.8
6hr VCL μm/s VSL μm/s VAP μm/s LIN % STR % WOB% ALH μm BCF Hz Hyperactive
LPS 54.1±10.3 18.7±5.4 30.2±6.4 31.2±4,2 52.7±6.7 54.2±2.4 1.9±0.4 7.2±1.8 3.4±2.8
CMV AD169 66.7±7.1 23.9±4.3 33.5±2.2 35.0±2.8 62.7±4.7 55.8±1.0 2.5±0.4 9.9±1.1 5.9±4.2
CMV Towne 65.6±7.4 20.8±2.8 35.9±3.8 31.6±1.7 57.3±2.4 55.0±1.0 2.2±0.1 10.1±0.7 2.4±1.0
CMV Merlin 57.8±5.5 17.8±2.7 30.8±3.5 30.0±2.6 52.2±6.4 51.0±2.3 2.1±0.3 7.8±1.2 3.6±1.2
EMEM 59.3±5.1 19.4±2.0 33.6±2.4 33.2±3.6 53.1±7.2 57.2±2.3 2.1±0.2 8.3±1.8 2.6±1.5
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6.5 Discussion
The aim of this chapter was to investigate if exposure to CMV had any effect 
on sperm function parameters, such as motility and kinematics, viability, 
acrosome status and the levels of DNA damage and tyrosine 
phosphorylation. The results show that CMV does not have any effect on 
these parameters when co-incubated with ejaculated, washed sperm in vitro. 
Different doses of virus, lengths of incubation, and strains of CMV have been 
investigated, none of which exhibit any effect on sperm. Based on findings 
discussed in Chapter 5, which suggested that CMV might be interacting 
directly with sperm, due to it not being washed off by density gradient 
centrifugation, the primary objective of this chapter was to investigate if any 
interaction between CMV and sperm was potentially receptor mediated and 
could therefore affect sperm function. This was not observed but does not 
rule out a potential interaction between CMV and sperm, which does not 
trigger biological effects.
Sperm might encounter CMV in several places throughout the male 
reproductive tract, either pre-ejaculation due to exposure in the testis 
(Naumenko et al., 2011), during ejaculation through contaminated seminal 
components from the prostate gland (Rapp et al., 1975) or the seminal 
vesicle and vas deferens (Decucq and Jegou, 2001), and finally post-
ejaculation exposure can occur in the female reproductive tract. The in vitro
approach taken in this chapter to investigate the effects of exposure to CMV 
on sperm function emulate a post-ejaculation exposure scenario. Other 
factors that could affect sperm, such as the production of ROS due to an 
inflammatory response (Aitken et al., 1992) or the presence of other 
infections, would be occurring in the male reproductive tract in a pre/peri-
ejaculation exposure scenario and therefore a direct investigation of how 
CMV itself is able to affect sperm function can not be performed. In order to 
determine if a direct interaction between CMV and sperm is occurring that 
might affect sperm function, these confounding factors had to be eliminated, 
so an in vitro approach was taken. Despite this, it was not possible to 
determine that donors used for these experiments were not infected with 
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other pathogens, including CMV. However, the use of multiple repeats in 
each experiment would help to mitigate this limitation.
Given that these experiments represent how sperm might be affected by 
exposure to CMV post-ejaculation, extrapolation of the findings of how CMV 
might affect sperm function pre-ejaculation and the consequences this has 
for male fertility is difficult to interpret. It is apparent that CMV does not have 
an effect on sperm that has been ejaculated and separated from seminal 
components. However, given the complex environment in which sperm are 
made and the natural immune response that occurs upon infection, the effect 
of an in vivo infection on sperm function cannot solely be determined from 
this set of experiments. However, the results from these experiments are
able to provide an insight into the relationship between CMV and sperm and 
provide information for consideration when using CMV positive sperm 
donors. 
An aspect of the experimental design throughout this chapter that needs to 
be considered is the amount of virus added to each co-incubation. 
Traditionally when studying viral infection of a cell, the number of plaque 
forming units’ (PFU) would be used in order to maximise the amount of virus 
present that is able to establish an infection. However, this study is only 
concerned with binding events, and potential interactions, not an ability to 
establish an infection. Given this, the total viral load in copies/ml, was used 
as a measure of how much virus to add, rather than the PFU/ml. However, 
as discussed in Chapter 4, the preparation of virus used throughout this 
thesis still contains non-infectious particles, such as dense bodies and 
NIEPs, which are still able to bind to cells, but cannot be quantified by qPCR. 
Given this, for the experiments using the un-purified AD169 strain, the 
number of viral particles added to each experiment is likely to be a significant 
underestimation of the number of particles potentially able to bind to and 
affect the function of a spermatozoon. 
Initial investigation with the AD169 strain of CMV showed there was no effect 
on any parameters analysed. Although there was an initial significant 
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difference in motility after 3 hours co-incubation between the virus infected 
sample and the mock-infected control, this was not apparent after 6-hours 
(Figure 6.2a), due to the mock-infected sample also exhibiting an effect on 
sperm motility. The effect on motility by the mock-infected control is likely 
because of MRC-5 cell debris or exogenous cellular DNA present in the 
inoculum. This is also likely to be present in the virus-infected sample but in 
larger quantities due to the cell death that occurs as a result of viral infection. 
This would explain why a difference is observed after 3 hours co-incubation, 
but not after 6 hours, as the larger quantities of impurities in the virus-
infected samples could affect sperm motility faster than the smaller quantities 
in the mock-infected samples. When analysing sperm motility, the four 
categories recommended in WHO (1999) were used, as opposed to the 
updated recommendation of WHO (2010) to use the three categories of
sperm motility; progressive, non-progressive and immotile. The use of four 
categories in this thesis is consistent with the current Association of 
Biomedical Andrologists (ABA) guidelines (Association of Biomedical 
Andrologists, 2012) and a recent paper outlining a checklist for acceptability 
of studies based on human semen analysis (Björndahl et al., 2016). 
In this set of experiments, an E. coli LPS control was included as a positive 
control, however, it did not exhibit the same marked effect on sperm function 
as has been shown previously (Hosseinzadeh et al., 2003). Initially the 
source of LPS used (Section 6.4.1.1) was from a different strain of E. coli
than that reported in Hosseinzadeh et al., (2003). Further investigation with 
the correct strain showed that the dose at which the maximum effect on 
sperm motility was observed was 50μg/ml (Figure 6.4), as has been 
previously reported, but this was not significant enough to be used as 
positive control. The incorporation of a positive control was considered 
important to show that sperm could be affected by a biological agent within 
the experimental conditions designed for this study. It is known that LPS 
requires FCS to access LPS-binding protein (Tobias et al., 1986) and trigger 
the immune responses that result in damage to the cell. Therefore, a final 
attempt to incorporate LPS as a positive control was conducted in Section 
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6.3.2.2 (Figure 6.10b) and even with the addition of FCS; there were still no 
significant differences on the parameters tested, in comparison to the 
negative control. However, the LPS control did have the most effect on 
increased tyrosine phosphorylation levels, showing sperm can be negatively 
affected within the experimental conditions of this study.
Despite observing some slight differences in sperm motility upon exposure to 
CMV (AD169) in the initial experiment outlined in Section 6.4.1.1, there were 
no sustained differences between samples infected with CMV and the 
negative control samples over the 6-hour co-incubation period. Due to the 
preparation of CMV AD169 not being purified, it cannot be ruled out that the 
slight effects observed are not due to impurities present in the virus 
preparation, such as viral and cellular exogenous DNA. This could contribute 
to the slight differences observed, as sperm are known to bind and uptake 
exogenous DNA (Zani et al., 1995), which has been shown to decrease 
sperm motility and viability in bovine sperm (Canovas et al., 2010). To 
investigate this further, sperm were co-incubated with a purified strain of 
CMV (Towne) (Figure 6.5) and effects on motility, viability and acrosome 
reaction compared to the un-purified strain (AD169). No effect on any of 
these parameters was observed with Towne, although a similar decline in 
sperm motility, and an increase in category c sperm (Figure 6.6c), was 
observed with AD169. The absence of any effect with Towne suggests that 
these effects with AD169 could be due to factors present in the viral 
preparation, as opposed to direct action of the virus itself. 
Further investigation by altering the dose of CMV used in the co-incubation 
experiments also showed no effect on any of the sperm parameters tested 
(Figure 6.7), ruling out the possibility that the lack of effects observed in the 
previous experiments were due to a low dose of virus used (Figure 6.8). 
Similarly, when a wild-type strain of CMV was used, as opposed to the three 
laboratory strains used throughout this chapter, there was also no effect on 
any parameters (Figure 6.9). The differences in cell tropism for laboratory 
and wild-type strains, outlined in Chapter 4, might have explained the lack of 
effect observed when sperm were incubated with laboratory strains of CMV. 
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However, no effect was observed when incubated with a wild-type strain, 
therefore ruling out this explanation. 
From this set of experiments, it is clear that various strains of CMV at 
different doses have no effect on these three basic sperm function 
parameters over a 6-hour incubation period. Currently, there is little in vitro 
work to compare these findings to. One study that investigated the effect of 
both HSV-2 and CMV (Pallier et al., 2002) found no effect on motility upon 
co-incubation of each virus with sperm, despite adding a high concentration 
of virus (104 to 106 PFU for 105 sperm). All of this evidence together suggests 
CMV does not have any effect on sperm function when exposed after 
ejaculation. Interestingly, most in vivo studies do not report any correlation 
between CMV infection and reduced sperm function, including sperm motility, 
concentration and the presence of antisperm antibodies and white blood cells 
(Eggert-Kruse et al., 2009; Kapranos et al., 2003; Michou et al., 2012; 
Naumenko et al., 2011; Neofytou et al., 2009), suggesting pre-ejaculatory 
exposure does not have any effect either. These findings for CMV differ in 
comparison to other Herpesviruses, such as HSV and EBV, which does 
appear to affect sperm function and quality pre-ejaculation (Bezold et al., 
2001; Bezold et al., 2007; Kapranos et al., 2003; Neoftytou et al., 2009). 
However, this in vivo work fails to answer if the effects observed are due to a 
direct interaction between the virus and sperm, which is what this study 
investigated.
Despite CMV not having an effect on basic sperm function parameters, if 
CMV was binding to sperm through receptor mediated events, it is possible 
that molecular signalling pathways would be affected, as has been shown for 
other pathogens, such as HPV and C. trachomatis. Decreased DAPI staining 
of the sperm nucleus after exposure to HPV suggests this exposure might 
have compromised the integrity of the DNA (Kaspersen et al., 2011). 
Increased levels of DNA fragmentation were also observed after in vitro co-
incubation with C. trachomatis (Eley et al., 2005b; Satta et al., 2006), thought 
to be as a result of apoptosis mediated events. However in this chapter, the 
same findings were not found with CMV, as after six-hours co-incubation with 
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multiple strains of CMV, the levels of DNA damage were not significantly 
increased (Figure 6.10a). This suggests that CMV is not able to induce DNA 
damage in washed sperm post-ejaculation, but damage could occur during 
ejaculation or post-ejaculation in the female reproductive tract, due to the 
presence of ROS produced from leukocytes present in semen (Lee et al., 
2014). Likewise, damage could occur pre-ejaculation in the testis through 
CMV infection of spermatogonial cells (Naumenko et al., 2011). Activation of 
CMV immediate early genes has been shown to have a mutagenic effect on 
cellular DNA (Shen et al., 1997), suggesting if damaged sperm survived the 
‘quality control’ abortive apoptotic processes in the testis (Rodriguez et al., 
1997; Aitken and Baker, 2013), mature sperm might be produced with DNA 
damage as a direct result of CMV infection.
The TUNEL assay was used to measure the levels of DNA damage, however 
the use of this assay for sperm has previously been criticised, due to 
problems with accessing DNA breaks because of the condensed nature of 
the sperm chromatin. Others have suggested the addition of a step to fully 
digest the proteins surrounding sperm DNA in order for the TUNEL assay to 
efficiently detect all DNA damage, such as the addition of DTT (Mitchell et 
al., 2011). The assay used in this thesis did not incorporate such a step but 
was still able to detect DNA damage in sperm treated with DNase I, after 
treatment with Proteinase K. It is probable that not all DNA damage was 
detected using this method, but this is a known limitation of this assay and it 
is thought that TUNEL is a better predictor of IVF outcomes (Sun et al., 1997; 
Robinson et al., 2012; Garolla et al., 2015) because it can only detect 
damage in these accessible regions of the genome. 
Another molecular signalling pathway that could be affected by co-incubation 
with CMV is the level of tyrosine phosphorylation, which is affected by co-
incubation with C.trachomatis (Hosseinzadeh et al., 2000), thought to be due 
to a receptor mediated induction of this intracellular signalling pathway. 
However, after a 6-hour co-incubation with multiple different strains of CMV, 
no changes were observed in sperm tyrosine phosphorylation levels (Figure 
6.10). CMV is known to inhibit tyrosine phosphorylation of a major 
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component of the JAK/STAT pathway responsible for the activation of 
Interferon (IFN)-ϒ in somatic cells (Baron & Davignon, 2008). This shows 
CMV is able to alter tyrosine phosphorylation in some cell types, however, 
this chapter did not show any such effect on sperm. 
Despite co-incubation with CMV not affecting any of the parameters 
examined so far, there were some subtle differences in the individual motility 
categories (Figures 6.3 & 6.6) that were not apparent when just reporting the 
percentage of progressive motility. To investigate this further, a CASA 
machine was used to measure subtle differences in sperm movement. It has 
been reported that decreased average path velocity (VAP) and straight-line 
velocity (VSL) correlate with poor reproductive outcomes (Irvine et al., 1994; 
Macleod & Irvine, 1995). In comparison, when samples were analysed with 
the standard WHO guidelines for motility assessment, this did not correlate 
with reproductive success (Macleod & Irvine, 1995). In addition, all 
parameters of sperm movement, except amplitude of lateral head 
displacement (ALH) and beat cross frequency (BCF) correlated with the time 
taken to achieve pregnancy (Irvine et al., 1994). Given this evidence it is 
clear that subtle changes in sperm movement, that are not adequately 
described by the standard four category assessment, might have an impact 
on male fertility. It has previously been reported for HSV-2, that whilst no 
differences in the percentage of motile sperm were observed after co-
incubation, alterations in all sperm kinematic parameters, except the VSL, 
were observed (Pallier et al., 2002). Despite this, analysis of sperm velocity 
and kinematic parameters in this chapter showed no differences in any of the 
kinematic parameters measured by CASA upon exposure to multiple strains 
of CMV (Table 6.1 & 6.2). 
In summary, this chapter has shown that co-incubation with CMV does not 
have any obvious effects on the function of ejaculated, washed sperm, 
however, this does not rule out the possibility that CMV could affect sperm 
function when exposed pre/peri-ejaculation. Similarly, it does not rule out a 
direct interaction between CMV and sperm. Indirect evidence presented in 
Chapter 5 of this thesis provides evidence to suggest CMV could be 
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attaching to sperm. Furthermore, evidence from a study using 
immunofluorescence has shown CMV localises to specific areas of the 
spermatozoon, suggesting a direct interaction (Naumenko et al., 2014). It is 
plausible that CMV might still be binding to sperm without inducing any 
adverse effects. CMV is a complex virus that has co-evolved with its host for 
many years. As such, it has developed extensive mechanisms for evading 
detection by cellular surveillance responses, ensuring its propagation 
amongst the human population. This idea will be explored further in the next 
chapter.
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Chapter 7
Discussion
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7.1 Summary of study aim(s) and main findings
The main aim of this study was to better understand the mechanisms of 
interaction between human Cytomegalovirus and human sperm. Many 
fertility clinics have identified a problem with sperm donor supply and this 
thesis has highlighted that most staff attribute some of this problem to the 
strict CMV screening guidelines (Chapter 3). Whilst it is possible to change 
screening practices to alleviate some of these problems, it is first essential to 
increase the evidence base on which informed decisions can be made. 
Ultimately, a screening procedure that permits the use of seropositive donors 
for all recipients would be the ideal scenario. This would alleviate problems 
with availability and choice for seronegative recipients, in addition to reducing 
waiting times and stress for couples waiting for a sperm donor. However, this 
can only be conducted with a full understanding of the transmission risk a 
seropositive donors poses. To do this, it is essential to better understand the 
relationship between CMV and sperm.
Evidence presented throughout this thesis has shown there is an alternative
way to screen sperm donors for CMV, by screening individual ejaculates, 
rather than each donor and by incorporating sperm washing to increase the 
pool of donors that are safe to use. This alternative approach would not only 
alleviate the problems outlined above, but would also be safer, based on 
what has been learnt about the relationship between CMV and sperm. 
However, there are still questions to be answered, particularly regarding the 
specific molecular interactions between CMV and sperm. Despite this, this 
thesis has provided some clarity on the situation that can prove useful, 
particularly given the apparent problems CMV screening is causing in the 
fertility clinic. 
Throughout this thesis, an in vitro approach was used to investigate the aims. 
By establishing a system in which CMV could be cultured and quantified in 
vitro, it has been possible to examine the relationship between CMV and 
sperm directly, without many of the confounding factors found in in vivo
studies, which can complicate the interpretation of the findings. This has 
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shown that CMV does not affect any of the sperm function parameters 
associated with reproductive success, including motility, viability, acrosome 
status, DNA damage and tyrosine phosphorylation. This is supported by the 
many studies that have been conducted in vivo, which document no damage 
to sperm function in the presence of a CMV infection (Bezold et al., 2001; 
Neofytou et al., 2009; Eggert-Kruse et al., 2009; Naumenko et al., 2011; 
Michou et al., 2012; Chen et al., 2013). This study also showed that neither, 
the concentration of CMV used, the exposure time, nor the strain of virus 
used had any effect on sperm function. However, this does not rule out an 
effect on the male reproductive tract in response to CMV infection. 
Inflammatory responses triggered in response to an infection could 
compromise reproductive potential, a point that will be discussed in more 
detail in Section 7.3.
Whilst this study has shown that CMV infection in men is not an immediate 
concern to the functional capacity of sperm, the shedding pattern of CMV in 
semen should be of concern to fertility clinics. This was not known prior to 
the design of this study but has been reported since, by Kaspersen et al., 
(2012). This thesis was able to build on this by showing the extent of the 
rapid turnaround in viral shedding that has not been previously documented 
for CMV. This finding raises concerns about the current screening practices 
conducted in fertility clinics, as it is unlikely that the recommended test of 
serum antibody testing is able to detect such rapid fluctuations in the 
shedding of CMV in semen. Further complications arise from the apparent 
deviations from the recommended guidelines, reported in Chapter 3. 
Fortunately, this study has shown that sperm washing is mostly effective at 
removing CMV from semen samples infected in vivo and in vitro. As sperm 
washing is routinely conducted in fertility clinics, this is potentially an easy 
solution to the problems many clinics are facing. These findings can be used 
to better inform current screening practices, a point which will be explored in 
detail in this chapter. An alternative approach to the current screening 
process, based on this new scientific evidence, will be proposed. 
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One thing this study has not been able to provide evidence to definitely 
answer, is whether CMV can bind directly to sperm through a receptor 
mediated event, as has been shown for HIV (Cardona-Maya et al., 2011), 
HPV (Foresta et al., 2011a), and C. trachomatis (Hosseinzadeh et al., 2000). 
If an effect on sperm function were observed, this would have opened 
channels for exploration into investigating the type of interaction occurring. 
This was not observed and therefore, this was not investigated directly, but 
some observations were made that could help to increase our understanding 
of this interaction.  
7.2 What do we now know about the interactions between CMV 
and sperm?
Whilst this study has not been able to definitively answer if a direct 
interaction between CMV and sperm is occurring, it is still an important 
question to consider. An understanding of this interaction would help in 
determining the risks of transmission during donor-assisted conception, but 
the true risks can only be fully understood through epidemiological studies. 
However, evidence from this study allows a hypothetical model for how an 
interaction might be occurring. 
Given that CMV does not affect sperm function parameters when co-
incubated in vitro, it could be argued that CMV is not binding to sperm. It 
would be expected that certain intracellular pathways, such as those 
responsible for initiating cell death cascades would be triggered upon binding 
of CMV. As has been shown for C. trachomatis, activation of these apoptotic 
pathways in response to bacterial LPS results in alterations in sperm motility, 
viability and levels of DNA damage (Eley et al., 2005a; Gorga et al., 2001; 
Hosseinzadeh et al., 2000; Hosseinzadeh et al., 2001; Hosseinzadeh et al., 
2003; Jungwirth et al., 2003). This is not observed in sperm exposed to CMV, 
and therefore it could be argued that this is because an interaction is not 
occurring. 
Also, Chapter 5 of this study has shown that sperm washing is mostly 
effective at removing CMV from semen samples, both in vivo (>95% 
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removal) and in vitro (~>90%-98% removal). This evidence does not appear 
to support the theory of a direct interaction occurring between CMV and 
sperm. If this were occurring, it could be argued that a greater number of 
CMV particles would be recovered in the motile sperm pellet. However, other 
studies have not observed the same level of efficiency with sperm washing, 
with Naumenko et al., (2014) observing the majority of CMV remaining after 
washing, providing evidence to support a direct interaction between CMV 
and sperm. This is a plausible scenario given that sperm do possess 
receptors to which CMV is known to bind in somatic cells, such as Heparin 
Sulphate Proteoglycans (HSPGs) (Foresta et al., 2011a). 
One criticism of this theory would be the lack of effect on sperm function 
upon exposure to CMV. This could be explained by the ability of CMV to 
modulate responses by the sperm that could result in cellular damage, such 
as cell death. This thesis has previously discussed in section 1.2.2.3, how 
adept CMV is at manipulating the host cell immune response by overriding 
mechanisms, such as the cell death cascade, in order to support viral growth 
and reproduction. Clearly CMV has the capability to do this in sperm, which 
could explain why no effect on sperm function was observed. However, this 
would rely on the assumption that CMV was able to penetrate the sperm cell 
and modulate genes involved in these inflammatory response-signalling 
pathways. Current evidence from this study does not support this theory. If 
CMV is able to penetrate and reside inside a sperm, this is most likely to 
occur at the spermatogonial cell stage, as shown in vitro in Naumenko et al., 
(2011). At this stage, the cell could be manipulated to reproduce daughter 
viral progeny, which is the main aim of any virus upon infecting a cell. A fully 
differentiated mature spermatozoon could not be manipulated in such a 
manner due to the condensed nature of the genome (Brewer et al., 2002; 
Dadoune, 2003). Also, the chance of exposure to CMV over a sustained 
period of time for spermatogonial cells is greater than for mature sperm, due 
to the nature of swift transit through the reproductive system, once fully 
formed. Finally, as discussed in section 1.2.2.1, multiple receptors are 
required for membrane fusion, in order to allow CMV to penetrate a cell (Kari 
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and Gehrz, 1992; Huber and Compton and Feire, 1997).  It is not sufficient to 
just have one putative receptor, to which an initial interaction is made. 
Currently there is no evidence to support the existence of such a system that 
would allow CMV to penetrate a spermatozoon. This cannot be completely 
ruled out, as it has been shown to occur with other viruses, such as HIV 
(Dussaix et al., 1993; Baccetti et al., 1994). However, at this time there is no 
convincing evidence for CMV being capable of doing this in mature sperm. 
Given this, it is unlikely that the lack of effect on sperm function is due to 
down regulation of immune responses by CMV. 
The simplest explanation for how an interaction might be occurring, without 
the expected measurable corresponding impact on sperm function, is that 
CMV only binds to a small proportion of sperm within a given ejaculate. 
Naumenko et al., (2014) reported that CMV only bound to ~2% of cells, 
despite a high viral load being determined in the individual semen samples. If 
CMV were only binding to a small proportion of sperm, any negative effects 
on sperm at the single cell level would not be observed in the experiments 
performed in this thesis. Given the number of sperm counted per repeat, no 
statistical significance would be observed due to the significant number of 
unaffected sperm present in each experiment. This theory is supported 
further by the small percentage of CMV remaining after washing, which was 
found to be between ~0.7-17.8% of the initial viral load. This is consistent 
with CMV only interacting with a small proportion of the sperm in the 
ejaculate. 
The capability of CMV only binding to a small proportion of the sperm 
population can be explained by considering the role the acrosome might play 
in this interaction. The acrosome has previously been implicated in 
interactions between viruses and sperm, with the direct interaction between 
HHV-6a and sperm being abolished once the acrosome reaction is induced 
(Kaspersen et al., 2012). Similarly, the equatorial segment (ES) has also 
been implicated as a region of the sperm head important in interactions 
between viruses and sperm, particularly HPV (Foresta et al., 2010c; Foresta 
et al., 2011a; Kaspersen et al., 2012). This is interesting as it is known that 
-241-
receptors revealed at the ES, after the acrosome reaction occurs, are 
involved in the binding of sperm to the oocyte membrane (Cho et al., 1998). 
Furthermore, syndecan-1, a HSPG receptor involved in HPV interactions with 
sperm is localised to the ES region (Foresta et al., 2011a). From this study, it 
is not clear if this receptor is only exposed once the acrosome reaction 
occurs, as the authors did not report the percentage of sperm exhibiting 
syndecan-1 expression. However, the authors did report that binding of HPV 
to sperm was only observed for ~25% of sperm cells. This suggests that in 
75% of sperm, HPV was not able to bind, which could be explained by the 
putative receptor not being present because the acrosome was intact. 
With this evidence in mind, there are two possible models for how CMV could 
bind to sperm. The first is that CMV binds to a receptor on the sperm plasma 
membrane situated around the acrosomal region, in a manner similar to 
HHV-6a (Figure 7.1, Model A). The second and more likely model, based on 
the evidence presented in this thesis, is that CMV binds to a receptor 
exposed at the ES once the acrosome reaction occurs (Figure 7.1, Model B). 
Model B is the more likely scenario given that throughout this study, <15% of 
sperm were observed to be acrosome reacted (Chapter 6), giving only a 
small percentage of cells to which CMV could bind. Not all sperm recovered 
after washing are acrosome intact (Brandeis and Manuel, 1993; Matas et al., 
2011), suggesting acrosome reacted sperm are present in the sperm pellet. 
Therefore, this could explain the small amount of CMV remaining after 
washing and would also support the apparent lack of effect on sperm 
function, as a statistically significant difference would not be observed. In 
further support of this model, Naumenko et al., (2014) observed a binding 
pattern of CMV that is similar to the pattern of syndecan-1 binding at the 
sperm ES, observed in Foresta et al., (2011a). This pattern of fluorescence is 
a hallmark of acrosome reacted sperm and supports the theory that CMV is 
only able to bind to acrosome reacted sperm. 
The consequence of this is that sperm could act as a vector for viral 
transmission. This could result in sperm carrying CMV into the cervix of a 
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Figure 7.1: Two hypothetical models of how CMV may be interacting with sperm. Morphological images presenting the biological process of 
the acrosome reaction are included to demonstrate the actual process, depicted in the theoretical model. Model A depicts a scenario, in which 
CMV binds to a receptor on the surface of the plasma membrane (PM) that surrounds the acrosome. During the process of the acrosome 
reaction, this portion of the PM is lost, exposing receptors at the equatorial segment (ES) on the surface of the inner acrosomal membrane. 
Model B depicts a scenario where CMV is able to bind to receptors exposed at this surface. Morphological images reprinted with permission 
from Michaut et al., 2000, with permission from PNAS. Figure Key: PM = Plasma Membrane, OAM = Outer acrosomal membrane, IAM = Inner 
acrosomal membrane, ES = Equatorial Segment. 
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female, or at the very least the vagina, which could lead to the virus 
ascending to the uterus (Coonrod et al., 1998). This would result in a genital 
tract infection, potentially leading to health complications and transmission of 
CMV to the fetus. The likelihood of this and the potential outcomes will be 
discussed in more depth in the next section. Another concern would be the 
ability of sperm to deliver CMV to the egg, potentially creating a fetus with 
systemic CMV infection. 
However, both models for CMV-sperm interaction presented in this 
discussion rule out this possibility. During the acrosome reaction, the plasma 
membrane and the outer acrosomal membrane fuse together in an exocytotic 
process, which culminates in the release of the acrosomal contents (Michaut 
et al., 2000). As a result of this, the plasma membrane in this region of the 
sperm head is lost (Figure 7.1b). Therefore, if CMV were binding to a 
receptor in this region, as is proposed in Model A, this interaction would be 
lost prior to penetration of the ZP, ruling out its passage into the egg, but not 
ruling out infection of the mother and subsequent vertical transmission to the 
fetus. Similarly, with Model B, sperm carrying CMV would no longer be able 
to penetrate the ZP, due to having already undergone the acrosome reaction. 
Once again, this model of interaction would not allow sperm to deliver CMV 
directly to the oocyte. Finally, given the theory that CMV only binds to a small 
percentage of sperm cells, it is likely that a sperm carrying CMV would not 
reach the oocyte, as most sperm are lost during the transit through the 
female reproductive tract (Suarez and Pacey, 2006). Therefore, it is unlikely 
that sperm are able to deliver CMV directly to the oocyte. The only scenarios 
by which transmission straight to the oocyte would be of concern, is if CMV 
was internalised into the sperm head, for which there is no current evidence 
to support. Also, it is possible that sperm carrying CMV might be chosen for 
ICSI, which could lead to the transmission of CMV directly to the egg, as has 
been shown for HBV (Ali et al., 2005). Whilst the presence of CMV in semen 
and any potential interaction does not appear to pose a risk directly to the 
oocyte, this does not rule out effects on the male reproductive tract and the 
female reproductive tract, which may affect fertility. Also, the consequences 
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of transmission of CMV to a fetus via infection of the uterus and placenta 
need to be considered. The consequences of this for male reproductive 
potential and assisted conception will be discussed further in the next two 
sections.
7.3 Is CMV infection a concern for male reproductive potential?
Whether CMV interacts directly with sperm or not, it is clear that this does not 
effect sperm function when exposed post-ejaculation, an observation found 
in this study, and others (Pallier et al., 2002; Naumenko et al., 2011). 
However, this does not give an accurate picture of the effect on sperm 
through pre/peri-ejaculation exposure due to the secondary responses that 
occur in the male reproductive tract in response to infection, and the 
possibility that CMV could infect spermatogonial cells in the testis 
(Naumenko et al., 2011). Viruses are able to cause inflammatory disorders of 
the male reproductive tract, as they are able to infect the epithelial cells lining 
the reproductive system through the blood stream (Keck et al., 1998). This is 
important, as the role inflammation of the male genital tract plays in 
contributing to male infertility cannot be ruled out.
Inflammation of the reproductive tract often results in increased production of 
leukocytes (Comhaire et al., 1999), which correlates with a history of infertility
(Wolff and Anderson, 1988). In turn, the levels of IL-8, a pro-inflammatory 
cytokine activated by NF-κB are increased, in line with a rise in the levels of 
leukocytes present in semen (Eggert-Kruse et al., 2001). IL-8 has been 
implicated as playing a key role in male genital tract inflammation (reviewed 
in Lotti and Maggi, 2013). CMV is known to significantly up-regulate the 
expression of IL-8 in fibroblasts (Craigen et al., 1997) and monocytes 
(Muruyama et al., 1997; Murayama et al., 1998), which serves to promote 
viral replication and modulate antiviral activity of host cells through inhibiting 
interferon (Muruyama et al., 1994; Murayama et al., 1998). The link between 
IL-8 playing a role in male genital tract infection and CMV being able to up
regulate IL-8 expression supports a role of CMV in causing inflammation, a 
correlation that has been observed in vitro (Naumenko et al., 2014).
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Inflammation in the male genital tract is detrimental to reproductive health 
due to the secondary effects on sperm and spermatogenesis. The presence
of monocytes, in response to infection, activates cytokines such as IL-8, 
leading to the recruitment of B-lymphocytes (Seshadri et al., 2012). This 
results in the production of anti-sperm antibodies, which are detrimental to 
sperm function (Eggert-Kruse et al., 2002). Furthermore, the presence of 
granulocytes results in the production of ROS, which induces DNA damage
(Kodama et al., 1997; Twigg et al., 1998) and lipid peroxidation on the 
spermatozoon (Aitken et al., 1993; Aitken et al., 1995).
CMV infection mostly presents as an asymptomatic infection, which is likely 
to mean that inflammation of the genital tract will remain sub-clinical. 
Consequently, CMV infection will remain undiagnosed and untreated. 
Intermittent shedding of CMV over a sustained period of time (Kaspersen et 
al., 2012), will likely lead to multiple instances of inflammation, resulting in 
repeated episodes of damage to sperm. Despite this, most in vivo studies did 
not observe any correlation between semen quality and the presence of 
CMV. Also, this study did not observe any significant differences in the 
semen volume, sperm concentration or sperm motility between the 13 CMV 
positive samples and the CMV negative samples (Table 5.4). Effects of 
inflammation on sperm function are only likely to occur during active 
shedding of CMV. As this study has shown, men intermittently shed CMV, 
with a rapid rate of clearance. This would have an effect on studies 
investigating the role CMV plays in infertility, and likely contributes to the 
negative findings. Similarly, these studies do not consider the length of time 
of CMV infection. This would be difficult to determine, but prolonged infection 
with multiple bouts of reactivation might have a more permanent effect on 
male infertility and could also be a compounding effect in in vivo studies. 
When considering the role CMV infection of the male reproductive tract might 
play in male infertility, it is important to consider the effects of transmitting 
CMV to the female and any consequences this might have on reproduction. If 
CMV is binding directly to sperm, it will be transmitted to the female 
reproductive tract. Given that this does not appear to affect sperm function, 
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sperm would be able to travel through the cervix into the uterus. Even if CMV 
is not binding to sperm, it could still be transmitted to the female reproductive 
tract via carriage in the seminal fluid. This would allow the virus to establish 
an infection in the genital tract, which might affect the outcomes of 
pregnancy. 
One argument against this is that the immune system present in the female 
reproductive tract would combat the virus and prevent an infection 
establishing. The mucosal immune system of the female reproductive tract 
mediates this immune response, acting through TLR’s on the surface of cells, 
which form the innate immunity. This results in the production of 
cytokines/chemokines, necessary to mount a full immune response against 
an infectious agent (reviewed in Wira et al., 2005). Whilst these mechanisms 
exist, this thesis has already discussed how well CMV is adapted to evade 
the host immune response. Therefore it is possible that CMV could establish 
an infection throughout the female reproductive tract, despite the immune 
system present. This is supported by evidence that CMV can be detected
throughout the entire female reproductive tract in women with pelvic 
inflammatory disease, including the cervix, endometrium, Fallopian tubes and 
ovaries (Clarke et al., 1997b). 
Transmission of CMV via semen could be one cause of infection in the 
female reproductive tract, either through sperm directly carrying CMV into the 
upper genital tract, or through ascension of the virus from the cervix. It has 
been shown in mice that viral infection of the cervix during pregnancy can 
result in the ascension of bacteria into the uterus, compromising pregnancy 
(Racicot et al., 2013). The authors hypothesised that a down-regulation of 
TLR ligands in the murine cervix when infected with virus might be 
responsible. Interestingly, this study also suggested that the sex hormones 
that regulate changes to the cervix throughout the menstrual cycle might also 
make the cervix more susceptible to viral infection (Racicot et al., 2013). All 
of this evidence points to the fact that transmission of CMV through semen
could establish an infection throughout the female reproductive tract, and 
affect fertilisation and pregnancy outcomes. This is supported by in vitro
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evidence that shows shedding of CMV in the reproductive tract correlates 
with increased miscarriage rates (Tanaka et al., 2006). 
Whilst the immune system in the female reproductive tract is there to protect 
from infection, it is a fine balance between doing this and sustaining the life 
of the allogenic fetus. Unfortunately, when challenged with an infectious 
agent, this can often result in ‘rejection’ of the developing embryo/fetus. TLR-
2 is thought to play a key role in the immune response against pathogens in 
the cervix (Lashkari et al., 2015). It has been shown in vitro that activation of 
the TLR-2 ligand during pregnancy can result in a failure for the developing 
embryo to implant (Sanchez-Lopez et al., 2014), therefore negatively 
effecting pregnancy outcome. 
This evidence clearly shows CMV is able to establish an infection in the 
reproductive tract of both males and females, which can have negative 
outcomes on reproductive potential. When considering the role CMV plays in 
donor assisted conception, it is important to consider how this translates to 
the risk of transmission of CMV to a fetus. Evidence shows that the presence 
of CMV in the genital tract correlates with women giving birth to babies born 
with congenital CMV infection, in comparison to mothers positive for CMV in 
their saliva, blood or urine (Kaye et al., 2008). Infection of the endothelial 
cells that line the uterus is thought to be the cause of transmission to the 
fetus, through direct contact with the placental cytotrophoblasts (Maidji et al., 
2002). Therefore, this evidence shows that infection in the female genital 
tract can lead to transmission of CMV and this could be mediated by 
transmission of the virus via semen. 
It is clear that whilst CMV might not have any direct effects on the function of 
a spermatozoon, its presence in the male reproductive tract can have 
consequences for the reproductive potential of a man. This can be due to the 
effect on the male genital tract or through transmission to the female 
reproductive tract, which has a myriad of consequences on the success of 
fertilisation and pregnancy in itself. Clearly, these concerns do not only apply 
to natural conception, but also to assisted conception. Therefore the next 
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section will consider if these potential negative outcomes on fertility and 
pregnancy should be of concern to fertility clinics. 
7.4 Should CMV infection in men be a concern for fertility clinics?
Whether a direct interaction between CMV and sperm is occurring, or not, it 
is clear from this study that sperm washing is mostly effective at removing 
CMV from semen samples. Of the initial viral load, the majority of CMV is 
removed (>93%) from samples infected in vivo (Section 5.4.3), with a similar 
rate of removal observed for samples infected in vitro (Sections 5.4.1, 5.4.2 
and 5.4.4). Given this evidence, it appears that this technique is more 
effective than has been previously reported in the literature (Michou et al., 
2012; Naumenko et al., 2014). Given that fertility clinics routinely carry out 
sperm washing during the process of preparing a sample for assisted 
conception, it is likely that CMV is removed from most semen samples, 
regardless of the inadequacies of current screening methods. 
Despite the current guidelines stating that only seronegative donors should 
be recruited whenever possible, Chapter 3 of this thesis shows that the 
majority of clinics report to actively recruiting seropositive donors. This is 
concerning due to evidence suggesting that the current methods for 
screening sperm donors might be ineffective. This is based on the evidence 
that men intermittently shed CMV, which is likely to be left undetected using 
the current diagnostic test, serum antibody testing. Therefore, if clinics do 
deviate from guidelines and use seropositive donors, it is probable that 
semen samples from donors actively shedding CMV are being used for 
therapeutic use. Furthermore, evidence from the survey conducted shows 
that some clinics are using seropositive donors for seronegative women. In 
this scenario, there is the potential that a semen sample, which contains 
CMV, would be given to a woman with no pre-existing immunity, which could 
result in substantial health consequences to any resulting fetus. However, 
this study has shown that for 84.6% of ejaculates, sperm washing was able 
to remove CMV from these samples. Therefore, it is likely that if CMV were 
present in any semen samples from seropositive men used for donor 
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insemination, the virus would have been removed during the routine sperm-
washing step.
However, it must be noted that sperm washing is not 100% efficient. In 
15.4% of ejaculates, CMV remained after washing and there was an overall 
6.4 (range 2.2-10.2)% of CMV viral particles remaining after washing. As has 
been discussed, this could be due to a direct interaction between CMV and 
sperm, or due to internalisation of the virus into the sperm head. Therefore, 
in the 15.4% of cases where CMV is not removed by sperm washing, there is 
the potential for horizontal transmission to the female recipient. Given the 
complications associated with CMV infection of the female reproductive tract 
outlined in the previous section, this is something fertility clinics should 
continue to be concerned about. 
The aim of this thesis was to develop the understanding around CMV and 
sperm in order to alleviate some of the problems the requirement to screen 
for CMV causes. Whilst it has been documented in this thesis, in Section 
3.4.3, that the use of seropositive donors for all recipients, regardless of 
serostatus, is being performed in some clinics, the risks of doing this are 
currently not known. Fortunately, evidence showing sperm washing is mostly 
effective at removing CMV supports a scenario in which this practice could 
be routinely used in the process of screening and managing CMV positive 
sperm donors. However, this technique is not 100% effective, therefore, 
before this can be considered as a routine alternative to only using 
seropositive donors for seropositive women, other factors need to be 
considered, in order to ensure the safety of this approach. 
7.5 How can screening for CMV and the management of CMV 
positive donors be improved? 
It is clear that the current screening process and management of CMV 
positive donors can be improved. Rather than seromatching donors and 
recipients based on their CMV serostatus, this thesis has suggested that the 
use of sperm washing might be an effective way of rendering samples from 
seropositive donors safe to use for seronegative recipients. However, to do 
-250-
this, the method of screening donors needs to be changed. A test that is 
better suited to detecting fluctuations in the seminal viral load, such as qPCR 
could be incorporated. Also, in order to incorporate sperm washing into the 
CMV screening and management process, the testing of individual semen 
samples needs to be conducted, rather than testing the individual. Currently, 
testing donors for CMV infection via serology only gives an indication of a 
past infection. Likewise, using qPCR on any sample other than semen will 
not give an accurate indication of the viral load in semen due to the 
phenomenon of compartmentalisation.
Sperm washing is not 100% effective; therefore it is essential to ensure a 
sample is negative for CMV after washing, as this study has shown CMV 
remaining after washing is able to establish an infection in vitro. Therefore, if 
CMV is present in the motile sperm pellet, it could cause an infection in the 
recipient. Given this, it is essential that each sample be tested before and 
after washing for the presence of CMV to avoid horizontal transmission. This 
can only be carried out with a method of testing which would detect CMV in 
the individual semen sample, such as qPCR. However, it might not be 
practical to test the sperm pellet after washing due to the turn around time on 
obtaining the qPCR results.  Given this, it would make more sense to screen 
all ejaculates at the point of freezing and to discard all the positive samples. 
However, as DNA technologies become more advanced, it might be possible 
to develop a rapid ‘on the spot’ test for CMV detection that would bypass this 
problem. 
Currently, the incorporation of this process into sperm donor screening is 
hindered by the lack of a validated qPCR test for the detection of CMV in 
semen, but this could easily be resolved. There are a number of benefits for 
fertility clinics in altering the screening process to incorporate these 
suggested changes, which will be presented in a new model for screening in 
the next section. 
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7.6 How could changing screening methods impact sperm donor 
recruitment?
Evidence from this study clearly supports a change in the way current 
screening for CMV in sperm donors and management of those donors is 
conducted. This section will propose a new model for screening donors. The 
feasibility of this approach, in terms of cost will be discussed, alongside the 
benefits of this approach and how it might help alleviate some of the 
problems currently facing fertility clinics. 
7.6.1 Model assumptions
In order to fully explain this model, it is necessary to explain a number of 
assumptions, rules and sources of data.
1. The numbers of donors used throughout is based upon the number 
of new donor registrants in 2013, as per the HFEA donation 
statistics 2012-2013 (HFEA, 2013a). Currently, there are no official 
statistics on the total number of sperm donors available in any given 
year, so the availability of donors has been calculated based on the 
number of new donor registrants in one year.
2. Based on statistics from the HFEA, (2013a), the average number of 
IVF/DI cycles each woman has is 1.6. This value is based on the 
number of heterosexual couples, same sex couples and single 
women undergoing IVF with donor sperm, or donor insemination. 
This comes to a total of 4,461 women having 7,138 cycles of IVF/DI 
(HFEA, 2013a), equating to 1.6 cycles per woman. 
3. Using the figures outlined in assumption 2, it is estimated that each 
donor is able to donate to 16 cycles, based on the criteria that each 
donor can donate to a maximum of 10 families, and that each family 
undergoes, on average, 1.6 cycles. The actual number of donations
per donor might be as high as 45, as reported in Paul et al., 2003, 
but only the samples to be used for therapeutic use will be 
considered in this model. This model will look at the number of 
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cycles and the number of available donors in one year to calculate 
the total cost of the different screening approaches in one year 
alone.
4. The number of available donors for the number of cycles conducted 
is based upon the number of new registrants. Clearly, there are 
other donors available from previous years, but this is off-set by the 
assumption that not every single donor will donate to ten families.
5. The number of available overseas donors is not taken into 
consideration, as these donors are not screened for CMV by UK 
clinics. 
6. This model will only consider the use of CMV seronegative sperm 
donors for use in donor-assisted conception. Despite evidence in 
this thesis showing clinics are using seropositive donors, it is not 
something that can be measured for the purpose of this model. 
Therefore, this model will consider the recommended approach and 
assume that only seronegative donors are being used on a routine 
basis.
7. The only costing taken into consideration for this model is the 
costing for serum antibody testing and qPCR. This is because all 
factors that can be assigned a monetary value will stay the same (i.e 
costs for quarantine). It does not take into consideration the cost of 
administrative duties to the respective screening protocols, or any 
other similar costs. Costs for qPCR are estimated at £50 per sample
via personal communication with Claire Atkinson at the Virology Unit 
of Royal Free Hospital, London [Atkinson, C, Personal 
Communication]. Serum antibody testing costs are estimated at £35
per sample (one at the beginning of quarantine and one at the end)
from information available on the Bristol Centre for Reproductive 
Medicine (BCRM) website regarding charges for patients (BCRM, 
2016).
-253-
7.6.2 The model
In the UK, there were 391 new UK sperm donor registrants in 2013. As per 
the findings of this study (Section 3.4.1), only 97.1% of clinics screened their 
donors for CMV. Assuming an equal distribution of donors across all clinics in 
the UK, this would amount to 380 donors being screened via serology, at a 
total cost of £13,300 (i.e £35x380). As can be seen in Figure 7.2, assuming 
clinics are following the current recommendation of excluding all seropositive 
donors (Assumption 6) this would immediately result in approximately 60% of 
donors being excluded on the basis of being seropositive for CMV as this is 
the prevalence of CMV in the general population. This would leave 163 
seronegative donors available for use, in addition to the 11 donors that were 
never screened for CMV, as only 97.1% of clinics screen for CMV. In 
addition, 26.5% of UK clinics reported carrying out PCR in conjunction with 
serum antibody testing. Of the 380 donors that would actually be screened, 
this suggests 100.7 would be further screened using PCR. Assuming the 
same cost of £50, this equates to a total extra cost of £5,035.
The semen samples then go through a quarantine period, which is subject to 
various practical and administrative costs. After this, the donors are screened 
once again to ensure they have not seroconverted to being CMV seropositive 
during the quarantine period, equating to a total cost of £5,705. There is no 
current estimate as to how many donors seroconvert and how many samples 
are discarded due to this, so for the purpose of this model, it is assumed all 
donors are viable for use. 
In addition to screening the sperm donor, the female recipient is also 
screened. In 2013, an estimated 4,461 women had treatment with donor 
sperm (HFEA, 2013a). Results from this study showed that 88.6% of clinics 
screened the female recipient. Once again, assuming an equal distribution of 
donor cycles across the clinics, this would equate to 3,952 women having 
CMV serology testing conducted. Also, 20.4% of clinics reported to screen 
the male partner of the female recipient, if there was one. 
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Figure 7.2: A flowchart depicting the current process (Model A) for CMV screening 
of sperm donors in UK fertility clinics. The number of donors available at each step 
in the process is included, along with the cost associated with any screening steps. 
In addition, the number of women receiving donor sperm and the number of cycles 
of IVF/DI are included. The numbers used throughout are from the HFEA Donation 
and Fertility Treatment Statistics from 2013.
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In 2013, approximately two thirds of women accessing fertility treatment with 
donor gametes had a male partner (although no distinction was made 
between donor sperm, eggs or embryos, the majority of cycles using donor 
gametes used donor sperm) (HFEA, 2013b). This equates to 600 male 
partners also being screened for CMV antibody status. Conducting this 
screening activity is for the sole purpose of being able to seromatch donor 
and recipient and equates to a total cost of £159,328. 
For a model that incorporates qPCR into the screening process, the key 
distinction is the requirement to screen the individual ejaculate. This would 
increase the practical and administrative workload, as rather than processing 
one sample from one donor, this model estimates that on average, a 
minimum of 16 samples would need to be processed (see assumption 4) 
(Figure 7.3). Any extra administrative costs associated with this are not 
quantified in this model. It is also important to consider that screening in this 
way might produce extra wastage costs, due to the turnaround time in qPCR 
results. This would result in a total screening cost of £312,800. 
However, based on evidence from this study, it is estimated that 83.5% of 
semen samples will be negative for CMV, leaving 327 donors available for 
use for any recipient, regardless of their CMV serostatus. It is important to 
note here that this completely eliminates the need for: (a) screening for CMV 
in the female recipient: (b) quarantine for CMV seroconversion (although this
would still be conducted for the detection of other infectious agents); and (c) 
no further screening after the quarantine period. For the remaining 64 donors 
that test positive for CMV, there is an option to wash these samples and re-
test for the presence of CMV after washing. This would be at a total cost of 
£51,600, but would yield a further a further 54 donors available for use, 
based on a 15.4% rate of positivity after washing (as per the findings in 
Chapter 5 of this thesis). One advantage of screening samples in this 
manner would be that samples could be stored in separate locations based 
upon their CMV positivity. This would eliminate any risks or concerns 
regarding cross-contamination of samples during storage in liquid nitrogen 
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Figure 7.3: A flowchart depicting a proposed new model (Model B) for CMV 
screening of sperm donors. This includes an alternative method of testing, using 
qPCR, instead of serum antibody testing. The number of donors available at each 
step in the process is included, along with the cost associated with any screening 
steps. In addition, the number of women receiving donor sperm and the number of 
cycles of IVF/DI are included. The section outlined in a red box is an optional 
section of the flowchart. The numbers used throughout are from the HFEA Donation 
and Fertility Treatment Statistics from 2013.
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Table 7.1: The total cost of screening sperm donors using the current screening process 
(Model A), in comparison to a new proposed model (Model B).
Step in Screening 
Process
Model A Cost (£) Model B Cost (£)
Initial screening sperm 
of donor/ejaculate
18,335 312,800
Screening female 
recipient (and male 
partner)
159,320 Nil
Screening after 
quarantine/sperm 
washing
5,705 51,600
Cost of importing 
overseas donors to fulfil 
short fall in demand
2,455,260 1,037,930
Total Cost 2,638,620 1,402,330
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(Foresta et al., 2010a). However, given the increase in number of CMV 
negative donors that could be used (327 vs 163), in comparison to the 
current model, this step could be considered as optional. However, this 
model will include the extra cost of this step in order to showcase the full 
extent to which findings from this study can be implemented in the CMV 
screening process.
For clinics following the guidelines and only recruiting seronegative donors, 
there would be twice the number of available donors to use, which would be 
a huge benefit. However, for clinics already recruiting and using seropositive 
donors, the major saving point is the lack of requirement to screen the female 
recipient, as seromatching is no longer required, at a total cost of £159,328 
(Table 7.1). To compare the benefits of the increase in available donors to 
clinics recruiting only seronegative donors, in relation to the cost, it is 
necessary to consider the number of cycles of IVF/DI these donors would be 
able to donate too. A total of 7,138 cycles of IVF/DI were conducted with 
donor sperm in 2013 (HFEA, 2013b). Assuming each donor donates to 16
cycles, the current model would allow for 2,608 cycles of IVF/DI to be 
conducted. This leaves a short fall of 4,530 cycles, which would need to be 
fulfilled with sperm from overseas donors. The estimated cost of this based 
on the current European Sperm Bank charges would be £542 per semen 
sample (European Sperm Bank, 2016), equating to a total cost of 
£2,455,260. In comparison, with the new model, there would only be 1,915
cycles short of an available sperm donor, which would equate to a cost of 
£1,037,930. This leaves a total cost for the current model of £2,638,620, in 
comparison to £1,402,330 for the new model (Table 7.1). Potentially, if all 
ejaculates from each donor were screened, estimated to be 45 (Paul et al., 
2003), there could be an extra cost of £728,808 (cost of screening an 
additional 12,512 samples, in addition to an additional 2,064 after washing) 
on top of the current estimate in for the new model. This would still be 
~£500,000 less than the current model based on the assumptions made and 
the estimates calculated. 
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To determine the full benefits of each model, it would be beneficial to conduct 
a cost effective analysis, which includes all of the costs associated with each 
approach. Due to limitations of access to such information, it was not 
possible to conduct such an analysis in this thesis. However, it is clear to see 
from Figures 7.2 and 7.3 that the proposed model is simpler than the current 
approach, as there is no requirement to seromatch donor and recipient, and 
significantly increases the number of available donors. This would ultimately 
translate to needing to recruit fewer donors from overseas, saving a 
significant amount of money. What this model is not able to estimate is 
whether the administrative costs of recruiting, screening and storing donors 
in the UK outweighs the cost of buying semen samples from overseas sperm 
banks. This could be worked into a cost effective analysis to fully evaluate 
the feasibility of screening for donors via the proposed model. One clear 
advantage of the proposed model of screening is that it removes the added 
complication of seromatching donors and recipients. By determining that 
each individual sample is negative for CMV, and therefore safe to use, the 
serostatus of the recipient is irrelevant. This therefore removes the need for 
the costly screening process of all recipients undergoing assisted conception 
with donor sperm. 
Another factor to consider is the number of babies born every year as a 
result of IVF with donor sperm, or donor insemination and whether this 
constitutes a big enough risk to warrant a change in screening. In 2012, a 
total of 1215 babies were born from 6846 cycles of IVF/DI using donor sperm 
(HFEA, 2013b) (654 births from 2372 cycles of IVF using donor sperm, and 
561 births from 4474 cycles of DI). The overall incidence of CMV infection in 
neonates on a population level is 0.7% (Dollard et al., 2007), resulting in 8.5 
babies being at risk of infection. Furthermore 25.5% of these babies will 
exhibit symptoms of CMV infection (Dollard et al., 2007), resulting in the 
possibility of ~2 babies every year being born with symptoms associated with 
CMV infection. Whilst any infection in this group of infants could not be 
directly attributed to a risk from using donor sperm, due to other 
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environmental factors, there are still enough babies being born using donor 
sperm every year to warrant the risk being taken seriously.
Whilst the model presented in this section has its limitations based on the 
assumptions made, it is clear that there may be a number of benefits to 
incorporating a screening process that screens each ejaculate, as opposed 
to the individual donor. These include:
1. A two-fold increase in the number of available donors.
2. The option to segregate positive samples from negative, ruling out 
cross-contamination risks.
3. Removal of the costly requirement to seromatch donors and 
recipients.
4. Reducing the need for overseas donors.
5. Increased safety, as samples can be definitively determined as safe 
(within the limits of the qPCR test performed).
6. Overall reduced cost (£1,402,330 vs £2,638,620).
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7.7 The future & further research
Overall, the evidence presented in this thesis and the model discussed in this 
chapter, supports a change in the way sperm donors are screened for CMV 
in the UK. Screening each individual ejaculate for CMV via qPCR would 
significantly increase the number of available sperm donors, as has been 
shown in Section 7.6. This approach would also increase safety, as there 
would be a higher-level confidence that an individual sample from a CMV 
positive donor was negative for CMV and therefore safe to use with a CMV 
negative recipient. Ideally, the serostatus of each donor used throughout this 
study would have been determined. If this information had been gathered, it 
would have been possible to determine if a CMV positive sample came from 
an IgG or IgM seropositive donor. Therefore it would have been possible to 
investigate the effectiveness of the current method of screening over the 
proposed model, at accurately quantifying the risk a donor poses. Similarly, 
paired serology and semen results would have highlighted if serum antibody 
testing was able to detect the rapid fluctuations in seminal shedding of CMV. 
This was not conducted, as the phenomenon of intermittent shedding of CMV 
in semen was not known prior to the design of this study. A robust study 
investigating this in sperm donors would add significant weight to the 
argument that the model proposed in this thesis should be used for screening 
of CMV in sperm donors. 
Whilst qPCR could be incorporated into screening practices, it is not without 
limitations. Due to its detection limits, it is often not possible to definitely 
determine if a sample is negative or not. Often virology clinics will report a 
negative value as less than a certain number of viral copies (for this thesis, 
the detection limit was 200 copies/ml). This is likely to change in the future 
due to more sensitive techniques being developed for the detection of DNA, 
such as digital droplet PCR (Sedlak et al., 2014). However, it would be ideal 
if no screening needed to be performed for CMV, as it is likely that the cost of 
screening for CMV will always outweigh the risks. Unfortunately, without 
epidemiological studies to determine the actual risk of transmission involved 
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with using CMV positive sperm donors, it is not likely the risks will ever be 
fully understood. 
One way this could be avoided, is if it were possible to completely eliminate 
CMV from semen samples. This thesis has shown that sperm washing is 
mostly effective at removing CMV, but that it is not 100% efficient. It has also 
been argued that whilst CMV does not affect sperm function, this does not 
rule out a direct interaction between CMV and sperm. If the mechanism of 
interaction between CMV and sperm could be fully understood, it may be 
possible to develop a mechanism to completely remove CMV from semen 
samples, by interfering with the receptors involved with the interaction, as 
has been shown for HPV (Garolla et al., 2012).  Further research into the site 
of binding, as discussed in Section 7.2, might shed some light on the 
situation. A similar experiment to that of Kaspersen et al., (2012) could be 
conducted to determine the role the acrosome plays in this interaction. By 
inducing the acrosome reaction and examining the effects on sperm function, 
or by using immunofluorescence to determine binding, it would be possible to 
determine on which membrane surface the putative CMV receptor was 
present. This would allow candidate receptors to be proposed and systematic 
investigation of their involvement in the interaction with CMV. Robust 
elimination of CMV from semen samples might remove the need to test for 
CMV at all, completely removing all concerns over donor supply problems, 
problems with seromatching, and the expense of conducting such tests. 
It is clear that the current method for screening sperm donors is causing 
problems in fertility clinics and this study has provided evidence to explore 
alternative screening strategies, which could significantly decrease the 
current burden on them. Furthermore, it has provided additional avenues for 
exploration to completely eliminate these problems and change the future 
landscape of sperm donor screening in the UK. Without epidemiological 
studies that rule out transmission to a fetus via a sperm donor, CMV should 
always be a concern to fertility clinics. This does not mean it always needs to 
be a burden. This thesis has shown that with a better understanding of the 
relationship between CMV and sperm, methods can be proposed to alleviate 
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the problems clinics are currently facing. With further research, these 
problems could be eliminated all together, whilst still ensuring no donor 
conceived child is ever born with congenital CMV as a result of infection 
through a sperm donor. 
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Appendix I: Biosafety approval letter
Health 
& Safety.
Dr Allan Pacey
Department of Human Metabolism
Academic Unit of Reproductive and 
Developmental Medicine
WT2013_05
Biological Safety Officer
Cliona Boyle
Level 7
The Arts Tower
Western Bank
Sheffield, S10 2TN
United Kingdom
09 May 2013 Telephone: +44 (0)114 2227469
Fax: +44 (0)114 2768741
Email: Safety@sheffield.ac.uk
Dear Dr Pacey
AUTHORISATION TO COMMENCE HAZARD GROUP 2 WORK
Your Hazard Group 2 Project entitled:
Investigating interactions between Cytomegalovirus and human 
spermatozoa
: - has been assessed project and approved by the Biosafety Committee.
The above project is now authorised to commence subject to the following 
conditions being met in advance of the project commencing:
a) That all workers involved in the project have been assessed as 
“medically fit” by the Staff Occupational Health Service prior to 
commencing their involvement on the project.  
b) That the laboratory (or laboratories) to be used for the project [JW4 
64, JW4 74] has been assessed as suitable for work with Genetically 
Modified Organisms. 
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c) That the Principal Investigator updates relevant databases with 
changes to personnel or laboratories involved in the above project as 
soon as practicable following changes;
d) That the Principal Investigator inform Health & Safety in the event of a 
change, or planned change, to the Project  Proposer; 
e) That the Principal Investigator submit a new or revised project to 
Biosafety Committee in the event of any changes to the experimental 
details (e.g. changes to the organisms involved, etc), or to the Hazard 
Classification of the Project;
f) That the project is carried out in full compliance with the requirements 
of the Control of Substances Hazardous to Health: Schedule 3 and
Hazardous Wastes Regulations 2005;
g) That the project has been notified to the HSE and a letter of approval 
received from HSE for the project to commence; (strike through if 
Class 2 project).
Yours sincerely
Cliona Boyle
Health & Safety                 Date:…09 May 2013
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Appendix III: Poster used for sperm donor recruitment 
I f you ar e inter ested in
par t icipat ing please email
spermresearch@sheffield.ac.uk
for mor e infor mat ion.
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Appendix IV: Survey evaluating CMV screening in fertility 
clinics 
CYTOMEGALOVIRUS (CMV) SCREENING QUESTIONNAIRE
This questionnaire has been designed by researchers at the 
University of Sheffield to try and understand the approaches 
currently used in UK fertility clinics for diagnosing 
Cytomegalovirus (CMV) in sperm donors and the provision of 
fertility treatment using donor sperm. We would be grateful if you 
could take the time to fill out this questionnaire and return it to the 
address below. Thank you in advance for your help.
Kind Regards,
Allan Pacey and Katrina Williams
Please return completed questionnaire to: Allan Pacey, Academic Unit of 
Reproductive and Developmental Medicine, Level 4. The Jessop Wing, Tree 
Root Walk, Sheffield, S10 2SF, United Kingdom. (A.pacey@sheffield.ac.uk)
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CYTOMEGALOVIRUS (CMV) SCREENING QUESTIONNAIRE
Contact details Please give the name and contact details of the person filling out this 
form so that we can contact you to clarify any of your responses if required (please note any 
responses will be anonymous and without attribution to named individuals)
Title:
Name:
Address:
Postcode:
Telephone:
E-mail: 
Role: Doctor Nurse Embryologist Andrologist
Other
Section 1: About your clinic.
1.1 Do you offer fertility treatment with donor sperm?
YES NO
1.2 Do you recruit sperm donors?
YES NO
1.3 Do you obtain donor sperm from other centres?
YES NO
1.4 Do you supply donor sperm to treatment centres?
YES NO
-314-
If you answered no to all of these questions then please go straight to section 
8, but if you answered yes to any please tell us more in the relevant sections 
below.
1.5 How many cycles of treatment using donor sperm did your centre 
perform in 2012?
……. cycles                     N/A 
1.6 If you recruited donors, how many donors did you screen in 2012 
(regardless of whether they were finally accepted)?
……. donors                    N/A
Section 2: About your clinic’s approach to CMV screening.
2.1 Do you screen for CMV in female patients receiving fertility 
procedures with donor sperm?
YES NO N/A (Don’t treat patients)
2.2 Do you screen for CMV in the male partner of the woman receiving 
fertility treatment (if she has a male partner)?
YES NO   N/A (Don’t treat patients)
2.3 Do you screen sperm donors you recruit for CMV?
YES NO N/A (Don’t recruit donors)
2.4 If you recruit your own donors, do you always quarantine sperm 
samples for >180 days as advised by the ABA, ACE, BAS, BFS, RCOG 
(2008) guidelines?
YES          NO Don’t know        N/A
If answered no, please explain why not:
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2.5 If you screen your own donors for CMV, do you screen them:
Before quarantine begins   After the quarantine    Both         
Don’t know
N/A
2.6 In the space below please tell us your views about CMV screening 
at your centre:
Section 3: CMV screening via serum antibody testing.
3.1 Do you screen donors/patients for CMV by serum antibody testing?
YES          NO (Go to section 4)
3.2 Do you carry out serum antibody testing for: 
IgG levels IgM levels Both Other      Don’t 
know
3.3 Do you exclude ALL seropositive donors (IgG or IgM)?
YES NO Don’t know
3.4 Do you exclude sperm donors with positive IgG at the start of the 
quarantine period?
YES NO Don’t know
3.5 Do you exclude sperm donors with positive IgG at the end of the 
quarantine period, if;
a) previously negative?      YES    NO Don’t 
know
b) the IgG antibody titre has increased? YES   NO                  Don’t 
know
3.6 Do you exclude sperm donors with positive IgM at the start of the 
quarantine period?
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YES NO Don’t know
3.7 Do you exclude sperm donors with positive IgM at the end of the 
quarantine period, if previously negative?
YES NO Don’t know
3.8 Please use the space below to tell us your views about CMV 
screening using serum antibody testing:
Section 4: CMV screening via PCR.
4.1 Do you screen donors/patients for CMV via PCR?
YES          NO (Go to section 5)
4.2 Which biological specimen do you carry out PCR analysis on?
Blood Urine Semen Saliva
4.3 Do you carry out qualitative PCR?
YES NO Don’t know
4.4 Do you exclude sperm donors with the presence of CMV DNA?
YES NO Don’t know
4.5 Do you carry out quantitative PCR?
YES NO Don’t know
4.6 If yes, do you determine the viral load of CMV?
YES NO Don’t know
4.7 Do you have a threshold value of viral load for excluding CMV 
positive donors / samples?
YES NO Don’t know
If yes, what is the threshold value?.........................
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4.8 Please use the space below to tell us your views about the use of 
PCR to screen for CMV:
Section 5: CMV screening via viral culture.
5.1 Do you screen donors/patients for CMV via viral culture?
YES          NO (Go to section 6)
5.2 Which biological specimen do you carry out viral culture on?
Blood Urine Semen Saliva
5.3 Do you exclude samples presenting CMV cytopathic effect after 2-3 
days?
YES NO Don’t know
5.4 In the case of an initially negative result, do you continue the 
culture to confirm negativity?
YES NO Don’t know
5.5 Please use the space below to tell us your views about the use of 
viral culture to screen for CMV:
Section 6: About buying donor sperm from other centres.
6.1 When obtaining donor sperm from other centres, do you check that 
they have been screened for CMV?
YES              NO       N/A (don’t buy from other centres-Go to 
section 7)
6.2 If you obtain donor sperm from other centres, do you check HOW
the donors have been screened for CMV?
YES                     NO
6.3 Do you know how the recruitment centres screens for CMV (i.e. 
Serology, PCR or culture)?
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YES                    NO
6.4 If you obtain donors from other centres, do you check that they 
have been quarantined for >180 days as advised by the ABA, ACE, 
BAS, BFS, RCOG (2008) guidelines?
YES                   NO
6.5 Do you always request the official copy of the screening results for 
each donor? 
YES NO Don’t know
6.6 Please use the space below to tell us your views about buying in 
sperm from other centres with regard to CMV testing:
Section 7: CMV Matching.
7.1 Where applicable, do you match donors with recipients with regards 
to their CMV status?
YES NO  N/A (Don’t treat patients-Go to section 8)
7.2 If yes can you please describe in the space below how you do this?
7.3 Does matching for CMV status cause supply problems with regard 
to the availability of donors?
YES NO  Don’t know
7.4 If yes, can you please describe this in more detail in the space 
below?
7.5 When providing treatment to women with a CMV positive donor, do 
you inform her of the theoretical risk of CMV transmission to the fetus?
YES             NO
7.6 If yes, what is your experience of women’s response to this 
information? Is this a major concern to them?
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Section 8: Your views about CMV and donor sperm treatments.
Please use the space below to tell us your views about the 
requirements for CMV testing and seromatching that are not covered 
elsewhere in this questionnaire: 
Thank you for taking your time to complete this questionnaire. If you would 
like to see a copy of the summary results then please tick this box 
-320-
Appendix V: Example calculation of infectious load (PFU/ml)
1. Volume of virus-supernatant added to plate= 100μl
2. Number of plaques counted= 20
3. Dilution of virus in well= 10-3
4. 20 x 103= 20,000 plaques in undiluted sample
5. 20,000 x 10= 200,000 plaques in 1ml undiluted sample
6. Infectious load = 2x105 PFU/ml
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Appendix VI: MRC-5 Mycoplasma test results
Figure: PCR results showing a negative result for Mycoplasma detection in MRC-
5 cell supernatant. Lane 1 shows 1μl of Positive Template Control, used to test the 
efficiency of the PCR reaction and Lane 2 shows 5μl of MRC-5 cell culture 
supernatant amplified with 10μl of reaction mix. In comparison to the positive 
control, the cell culture supernatant reaction does not display a band at ~270bp, 
confirming that this cell line is not contaminated with Mycoplasma.
 M    1      2    M
200bp
100bp
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Appendix VII: DNA concentration and OD ratios of DNA 
samples extracted from semen samples in Chapter 5 
Pre-Wash Post-Wash
Experiment/Conditions DNA 
(ng/μl)
OD 
260/280
OD 
260/230
DNA 
(ng/μl)
OD 
260/280
OD 
260/230
Time (Section 5.4.1)
1-hour Infected 9.9±5.0 1.8±0.07 0.9±0.4 2.8±1.5 2.2±0.1 0.2±0.1
1-hour Control 8.0±2.5 1.6±0.11 0.7±0.3 2.0±0.7 1.7±0.1 0.5±0.3
6-hour Infected 11.4±6.5 1.9±0.2 0.8±0.3 1.4±0.2 1.8±0.3 0.2±0.1
6-hour Control 14.7±9.4 1.9±0.04 0.8±0.2 3.0±0.5 2.9±0.5 0.4±0.2
ProInsert™ (Section 
5.4.2)
ProInsert™ Infected 9.6±3.9 2.0±0.3 1.4±0.6 6.9±3.7 3.2±1.0 0.3±0.1
ProInsert™ Control 7.1±3.3 1.9±0.1 0.9±0.4 3.6±0.9 2.8±0.4 0.3±0.1
Density Gradient Infected 9.6±3.9 2.0±0.3 1.4±0.6 1.6±0.4 2.0±0.1 0.2±0.1
Density Gradient Control 7.1±3.3 1.9±0.1 0.9±0.4 1.6±0.2 2.3±0.3 0.1±0.0
Naturally Infected
(Sections 5.4.3 & 5)
102 semen samples* 9.3±1.1 1.8±0.05 1.0±0.2 3.0±1.4 1.9±0.2 0.3±0.04
Dose (Section 5.4.4)
1:1 4.6±0.1 1.9±0.2 0.4±0.1 1.0±0.5 3.0±0.0 0.1±0.1
0.1 5.6±1.7 2.0±0.1 1.6±0.8 3.3±1.9 4.0±1.0 0.2±0.0
0.01 6.0±2.0 1.7±0.1 0.6±0.2 3.6±1.3 2.2±0.6 0.4±0.2
0.001 3.4±0.5 2.0±0.2 0.4±0.2 0.8±0.3 3.0±1.0 0.1±0.1
Control 5.4±1.6 1.6±0.1 0.7±0.2 1.8±0.3 1.8±0.3 0.4±0.3
Data are shown as mean±SEM
*For samples from naturally infected men, 102 samples were included pre-  
wash and 13 samples post-wash
